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• OSA   Ovine serum albumin 
• PAA    Poly(acrylic acid) 
• PAEMA  Poly(aminoethyl methacrylate) 
• PAEMA-co-SA Poly(aminoethyl methacrylate)-co-succinic   
anhydride 
• PEG    Poly(ethylene glycol) 
• PBS    Phosphate buffered saline 
• PMEDS  Poly([2-(methacryloyloxy) ethyl]dimethyl-(3-    
sulfopropyl) ammonium hydroxide) 
• PMPC   Poly(2-methacryloyloxyethyl phosphorylcholine) 
• PMVEMA  Poly(methyl vinyl ether-alt-maleic anhydride) 
• PVA    Poly(vinyl alcohol) 
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• PVP   Polyvinylpyrolidone 
• RAFT   Reversible addition- fragmentation chain transfer  
• RBCs   Red blood cells 
• RCA120  Ricinus communis agglutinin 120 
• ROCK   Rho-associated kinase 
• ROS   Reactive oxygen species 
• SA   Succinic anhydride 
• SBA   Soybean agglutinin 
• SEC   Size exclusion chromatography  
• Taq   Taq polymerase 
• TEA   Triethylamine 
• TMS   Tetramethylsilane 
• TH    Thermal Hysteresis 
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Abstract 
Antifreeze proteins (AFPs) and antifreeze glycoproteins (AFGPs) are proteins found 
in a wide variety of organisms adapted to survive in freezing temperatures. These 
proteins are powerful ice recrystallization inhibitors (IRI), slowing or even stopping 
ice crystal growth. This property is of significant interest in the area of 
cryopreservation due to ice recrystallization upon thawing being the limiting factor in 
the recovery of many biological materials. The need for reliable cryopreservation is 
becoming more and more necessary in many clinical areas, including regenerative and 
transplant medicine, and protein based therapeutics. 
 
The identification of new protein structures and sequences is crucially to 
understanding this ability. To this end l-type lectins, which show sequential homology 
to type 2 AFPs were explored and found to possess calcium dependant IRI activity. In 
addition, a secondary motif, amphipathicity was investigated. As many AFPs possess 
separate well defined hydrophilic/ hydrophobic domains this was thought to be a 
property of high importance. The antimicrobial peptide nisin A, which is amphipathic, 
was found to also possess cation dependant IRI activity.  This identification 
demonstrates a new approach to identifying IRI active molecules and may further 
enhance our understanding of the mechanisms involved.   As current “gold standard” 
methods for identification of IRI activity are relatively slow and time consuming 
signifying that the discovery of new IRI molecules is a slow process. In order to 
increase throughput of the discovery of novel IRI active molecules a gold 
	 xxvi	
nanoparticle assay was developed.  Using this method serum proteins were discovered 
to possess weak but definite activity at higher concentrations. This is of particular 
interest as serum proteins such as fetal calf serum are commonly used in 
cryopreservation applications.  
 
The isolation of these remarkable proteins from primary sources in significant 
quantities is difficult and not financially viable, while recombinant expression is 
complicated by glycosylation of AFGPs. Furthermore non-native proteins may cause 
immunogenic problems. Therefore synthetic mimetic such as polymers and small 
molecules are highly appealing. Using a biomimetic approach, amphipathic 
metallohelicies with alpha helical character similar to that of a type 1 AFP were 
evaluated for ice recrystallization inhibition. It was found that these metallohelices 
could be optimized to completely inhibit ice recrystallization, demonstrating that by 
creating materials which mimic AFPs similar properties can be engineered 
successfully. In addition, polyampholyte polymers (polymers possessing both positive 
and negative side chains) were synthesized, and demonstrated to possess IRI activity 
when the ratio of positive to negative side chains was roughly 1:1. These were then 
used to significantly enhance post-thaw recovery rates of red blood cells (RBCs). 
Polymers are appealing as they are highly tunable and can be used to mimic proteins 
in a wide variety of biological areas. Polyampholyte polymers and previously 
identified IRI polymer; polyvinyl alcohol (PVA), added to polyethylene glycol were 
found to be a highly efficient way of preserving proteins and antibodies under 
freezing conditions. The application of polyampholytes and other IRI active 
molecules are therefore highly attractive in the cryopreservation of a whole range of 
biological materials, potentially yielding widespread clinical benefits.     
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Chapter 1 	
1. Introduction 
1.1.   The frozen world 	
Ice plays an important role in a wide variety of areas, from evolutionary biology to 
geological weathering, to modern medicine,[1-3] due to its unique properties. Under 
terrestrial freezing conditions it forms a hexagonal crystal structure (ice 1h), but with 
up to 15 other crystalline structures are possible at higher pressures, more than any 
other known material.[4] There is also the phenomenon, that solid ice is less dense 
than liquid water unlike almost all other liquids. These unusual properties make the 
understanding of ice and particularly the ice-water interface extremely challenging, 
but vital for us to be able to explain for biotechnology, industry and fundamental 
science. 
  
The prevalence of ice in many areas of the globe has lead to a wide variety of 
organisms evolved to thrive in areas where ice is present. As ice formation is a 
complex process, there is a lot we can learn from studying these life forms adapted to 
live in freezing conditions. The biological effect and methods by which living 
organisms can survive in cold temperatures have been of interest for scientific 
investigation for hundreds of years. Recently this interest has led to research into 
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areas including cryopreservation of cells and tissues,[3] treatment and prevention of 
cold induced injury such as frostbite[5] and protection of crops.[6] As the effect of 
cooling is to reduce biological degradation and extend storage time, cryopreservation 
has many potential applications. However, a significant challenge to storing human 
tissue, is that humans, and many other organisms have evolved to function at higher 
temperatures, with lower temperatures leading to cell damage and meaning that ice 
modulating materials could have a huge impact. 
 
Many organisms including fish, beetles, plants and bacteria have been found to be 
able to survive temperatures below the freezing point of water, without the damaging 
effects caused by uncontrolled ice growth, using a variety of techniques.[7-9] The 
challenge is to fully understand these mechanisms and develop them for use in a 
variety of applications. 
 
1.2 .   Cold survival methods in nature 	
1.2.1. Antifreeze glycoproteins 	
Average surface ocean temperatures at polar latitudes can drop as low as -1.9 °C 
presenting a stern challenge for life, yet many fish species thrive in such conditions 
using freeze-avoidance methods. This interesting ability was first investigated in 
Antarctic notothenioid fish species by DeVries and Schoolander over 45 years ago, 
and was found to be due to their unusual serum composition.[10-11] The fish possess 
higher concentrations of salts and sugars than fish found in warmer waters, but this 
only accounts for around 70 % of the observed freezing point depression. The other 
30% was found to be due to the presence of a mixture of glycoproteins.[10, 12]  
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Furthermore, it was discovered that these glycoproteins depress the freezing point 
significantly more than would be expected from a concentration dependent colligative 
effect. To account for this non-colligative ability there must be some active, ice 
binding property associated with these glycoproteins and hence they were termed 
antifreeze glycoproteins (AFGPs). 
 
Figure 1.1. Notothenioid Antarctic fish species and associated thermal hysteresis 
properties. A.) Example notothenioid fish, Trematomus hansoni;[13] B.) Thermal 
hysteresis diagram of ice in the presence of an AFGP showing depressed freezing 
point with respect to melting point (Endothermic heat flow is shown as positive). 
 
Additional investigation quickly uncovered the presence of several different AFGPs 
with differing molecular weights, all possessing a remarkably conserved primary 
sequence.[14-15] Each AFGP consists of varying numbers of repeating alanine-alanine- 
threonine  (AAT) tripeptide units.[16] A complex disaccharide moiety, β-D- 
galactosyl(1→ 3)-α-N-acetyl-galactosamine was found to be joined as a glycoside to 
the hydroxyl group of the threonine residue, Figure 1.2.[17] To date, β-D- 
galactosyl(1→ 3)-α-N-acetyl-galactosamine is the only known disaccharide found in 
naturally occurring AFGPs, highlighting the importance of this specific sugar.  
Interestingly, this sugar is highly unusual in nature, the only other place where this 
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disaccharide is common is on a T-antigen associated with many human carcinoma 
cancers.[18] Further research has found that AFGPs are also found in evolutionary 
different Arctic cod species, despite being unrelated. This is a rare example of 
convergent evolution where two species evolve the same gene independently, 
probably driven by past climate fluctuations in both north and south polar areas.[19-20] 
More recently, AFGPs with very similar structures have also been discovered in 
several insect species.[21] 
 
 
 
 
 
 
 
Figure 1.2. Chemical structure of an Antifreeze glycoprotein AFGP. The 
glycoprotein consists of a repeat unit of AAT peptide with complex disaccharide β- 
D-galactosyl(1→ 3)-α-N-acetyl-galactosamine connected to the threonine residue. 
AFGPs contain between 4 and 55 repeat units. 
 
A large number of different sized AFGPs have been identified and categorised 
according to their molecular weight. These range from 2.6 kDa (4 repeat units) to 33.7 
kDa (55 repeat units), classes 1-5 are usually sub-classified as large, while 6-8 are 
classified as small. While the large majority have the AAT repeat unit, there can be 
minor differences in the amino acid sequence, most commonly in classes 6-8 where 
the first alanine in a small number of the repeat units is replaced by a proline. In 
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addition, the recent isolation of an AFGP from the Antarctic fish Pleuragramma 
antarcticum suggests that further amino acid substitutions could be tolerated. In this 
case the AFGP consisted of the amino acids aspartic acid, glutamic acid, glycine, 
alanine with small amounts of arginine, threonine, valine and leucine and the sugar N-
acetylglucosamine.[22] 
In notothenioid fish species AFGPs have been found to present in virtually all body 
fluids, with the highest being present in the blood plasma.[23] Their regulation and 
expression is highly temperature specific, with day length having no effect on 
expression levels. At temperatures above 1 °C very little AFGP was observed in the 
blood plasma.[24] The process of AFGP production is both a product of evolutionary 
and environmental factors, with young Arctic cod, Gadus morhua caught in warmer 
areas found to be able to produce the same amounts of AFGP as those caught further 
north when kept in the same conditions. This is despite those cod caught further south 
never having experienced temperatures cold enough for AFGP expression.[25]  
A range of techniques have been utilized to elucidate the primary, secondary and 
tertiary structure of AFGPs. Genetic analysis and various amino acid determination 
methods were used to ascertain the primary sequence discussed above.[15, 19] Structural 
information has been investigated using a variety of techniques including circular 
dichroism (CD), Raman spectroscopy, light scattering and NMR spectroscopy. The 
first CD study concluded that AFGPs have a random coil conformation,[15] and this 
was further re-enforced by independent studies using proton and carbon NMR 
spectroscopy and Raman spectroscopy.[26-27] This was followed by more detailed 
NMR analysis which suggested that AFGPs contain some turn structure.[28]  
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The most detailed insight has come more recently using a combination of high field 
NMR (500 MHz) and Fourier transform infra-red (FTIR) spectroscopies and 
molecular dynamics (MD) simulation. AFGP 8, a short chain length AFGP with small 
amounts of proline in its amino acid sequence, was found to display no significant 
long range order, but possesses a high amount of short chain ordering inducing a type 
2 polyproline helical conformation. Using MD techniques to further probe AFGP 8 
supported the NMR findings that a polyproline helix is the most probable 
conformation, although it was also discovered that several other conformations are 
equally as energetically favorable. Using the same methodology on a mixture of 
longer chain AFGP 1-5 it was reported that these particular proteins were unordered 
showing no long or short range ordering.[29-30] This suggests that AFGPs can adopt 
more than one structural conformation dependent on external conditions. Hydrogen 
bonding between the protein backbone and the N-acetyl groups were also found to 
play a role in the AFGP’s stability.[31] Finally, separate 13C NMR and FTIR analysis 
of an AFGP from Arctogadus glacialis probing its conformation in both solution and 
freeze-dried states, have further enforced the conclusion that AFGPs are highly 
flexible being able to access several conformational states.[32] 
 
Despite the range of techniques described above, a three-dimensional structure of an 
AFGP has yet to be published.[33] The many structural conformations available, the 
high carbohydrate content and relative flexibility of the peptide backbone make it 
extremely difficult to produce a definitive structure. 
 
 
	 6	
1.2.2. Antifreeze proteins 		
In addition to the AFGPs described above, a second group of proteins with similar 
abilities, known as antifreeze proteins (AFPs) were first discovered in the fish species 
Winter flounder (Pseudopleuronectes americanus).[34] Unlike AFGPs they lack any 
carbohydrate content. From this initial discovery AFPs have been found in a wide 
variety of different organisms, including insects, spiders, plants, bacteria and yeast.[35-
38] Unlike AFGPs which have a highly conserved primary structure, AFPs have been 
found that exhibit a wide variety of differing amino acid sequences and defined 
tertiary structures.  
 
To date, eleven different AFPs have been identified,[39] with four different types 
discovered in fish species alone (type 1 -4 AFPs).[40] Some species such as Winter 
flounder, Pseudopleuronectes americanus have even been found to express more than 
one AFP.[41] By investigating the evolutionary origins of these proteins it has been 
found that they have a very recent evolutionary history and multiple origins. For 
example type 2 AFPs are evolutionary similar to l-type lectins (sugar binding 
proteins),[42] while type 4 AFPs are highly similar to plasma apolipoproteins.[43]  
 
Type 1 AFPs are the simplest AFP characterised, and consequently the most widely 
investigated. In contrast to AFGPs a high resolution crystal structure has been 
obtained, showing that it exists as a single alpha helical protein (Figure 1.3A).[44] 
Analysis of the protein sequence revealed that AFP type 1 consists of 37 amino acids, 
with a high percentage of alanine, and a repeat sequence of 11 amino acids with 
highly arranged polar and non polar residues.[45] This helical structure results in all the 
	 7	
hydrophobic residues being on one face of the helices, and recent MD simulations 
investigating this surface suggests that it is these that are involved in ice binding.[46] 
Type 2 AFPs are also extremely well studied. They are large globular proteins rich in 
cysteine and lacking and repetitive amino acid sequences. The structure was solved by 
NMR spectroscopy and was found to be rich in alpha helices (18 %), beta sheets (38 
%) and random coils (44 %),[47] while the cysteine residues play a large role in tertiary 
structure through disulphide bonding (figure 1.3B). As mentioned above they show 
similarity to l-type lectins including a binding pocket which appears to bind to ice 
rather than sugar molecules.[48]  
 
Similarly, type 3 AFPs also possess a globular structure, although lack the cysteine 
residues characteristic of their type 2 homologues. They characteristically show high 
amounts of beta sheet, while the ice-binding surface is thought to be a flat 
amphipathic region (Figure 1.3C).[49] Type 4 AFPs are different yet again, containing 
high amounts of glutamate and glutamine, and a high helical content as discovered by 
CD spectroscopy. The tertiary structure was found to consist of a 4 helix bundle 
orientated with the more hydrophobic surfaces pointing inwards.[50] No one has yet 
completely solved the three-dimensional structure of a type 4 AFP. 
 
Insects can live in terrestrial environments with lower temperatures (-30 °C) 
compared to fish (-1.9 °C), so the AFPs need to be significantly more efficient and are 
often termed hyperactive AFPs. One of the most widely studied of these is found in 
the moth Tanebrio molitor, the crystal structure indicates the presence of 7 different 
coils, most of which contain β-strands (Figure 1.3D).[51] Furthermore, it has a high 
amount of disulphide bonding and a regular array of threonine- cysteine- threonine 
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motifs on one side. This motif is thought to allow the threonine residues to align with 
both basal and pyramidal planes of an ice crystal, inhibiting growth in both directions, 
where as fish AFPs only seem to bind to the pyramidal plane.[52]  
 
Figure 1.3. Structural representation of various AFPs. (A) Type 1 AFP from 
shorthorn sculpin, (Kwan et al. 2005);[53] (B) Type 2 AFP from herring (Liu et al. 
2007);[54] (C) Type 3 AFP from ocean pout (Antson et al. 2001);[55] (D) Insect AFP 
from Tanebrio molitor (Liou et al 2000);[51] (E) Plant AFP from grass Lolium perenne 
(Middleton et al. 2012);[56] (F) Insect AFP from spruce budworm (Graether et al. 
2000).[57] 
 
The final group of AFPs discussed here is those produced by plant species. These 
have been found to contain high amounts of beta sheet, and recent crystallography 
A C 
D E F 
B 
	 9	
data of an AFP from ryegrass Lolium perenne suggests that they have the ability to 
bind to both basal and pyramidal planes (Figure 1.3E).[58] However the irregular 
spacing of ice binding sites containing serine, threonine and valine means that it has 
relatively weak activity compared to hyperactive insect AFPs.  
 
To date only one plant AFP has a solved crystal structure, conversely many insect 
AFPs have been identified, including those recently found from spruce budworm 
(Choristoneura fumiferana) (Figure 1.3F) and snow flea Hypogastrura nivicola.[59] It 
is highly probable that a wide range of highly different plant and insect AFPs similar 
to those found in fish will be observed in future research. Overall, the wide variety of 
different AFPs described above highlights the many methods that nature has evolved 
to overcome the problem of freezing, while also demonstrating that identifying why 
something has “antifreeze” activity is not trivial. 
 
1.2.3. Other cryo-survival methods 	
Several non-protein based strategies have also discovered, mainly in amphibians and 
insects. These strategies involve a mixture of freeze tolerance and freeze avoidance, 
in contrast to AFGPs and AFPs, which are exclusively the latter.[60] One protein free 
strategy is the synthesis of large volumes of carbohydrates to prevent freezing; a drop 
in temperature such as that experienced at the start of winter leads to a metabolic 
change, resulting in the production of large amounts of one or more small molecules. 
For example, in many frog species large amounts of glycogen is stored in the liver 
prior to hibernation and is redistributed around the body as glucose in the event of the 
skin experiencing freezing temperatures.[61] These cryo-protectant molecules are 
found in a range of organisms and are commonly polyols and sugars such as 
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trehalose, glucose, glycerol and sorbitol (Figure 1.4) and are often produced in 
conjunction with ice nucleation agents such as ice nucleating proteins (INPs), 
allowing ice to form in a controlled manner.[62] 
 
Figure 1.4. Polyols commonly used in cryo-survival.  (A) trehalose; (B) glucose; 
(C) glycerol; (D) sorbitol. 
 
The synthesis of large quantities of polyols can also result in vitrification, a phase 
transition in which water freezes into a glassy state, rather than a crystalline one. 
Unlike freezing, vitrified ice is not destructive towards biological material. This is 
very common in many sub-arctic plants where vitrification of seeds and twigs are key 
to survival over winter.[63]  
 
While vitrification is highly desirable for many animals, some organisms can survive 
relatively high amounts of freezing  (up to 65 % of total body water).[64] The onset of 
freezing is highly controlled resulting in a very gradual ice formation occurring over a 
period of several hours or even days, resulting in dehydration of the intracellular 
space making ice formation largely extracellular, although studies have shown that 
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intracellular ice formation can be tolerated in certain larger cell types.[65] Large 
amounts of carbohydrates are also produced, stabilizing cellular macromolecules and 
limiting intra-cellular freezing.  
 
A further survival method is that of anhydrobiosis; avoiding the damaging effect of 
freezing by reducing the amount of water present to miniscule amounts. This is most 
common in microorganisms, although is also used as a protection method in seeds and 
spores.[66] Similar to the methods discussed above, several carbohydrates are routinely 
expressed in order to stabilize cellular and sub-cellular material.[67] While these 
carbohydrates are widely used to enable life to exist in freezing conditions, the 
concentrations required are significantly higher than those found for AFPs and 
AFGPs, meaning the latter are highly appealing for scientific investigation as low 
concentration inhibitors. 
 
Finally, several sugar molecules containing little or no protein have recently been 
found to exhibit similar antifreeze activity to an AFP or AFGP. This includes the 
isolation of a xylomannan carbohydrate macromolecule from the Alaskan beetle, Upis 
ceramboides, figure 1.5.[68] The recognition of the ability of this xylomannan to act as 
an antifreeze molecule was further enforced by its more recent discovery in several 
other species including 6 insect, one plant, and one frog species.[69]						
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Figure	 1.5.	 Xylomannan	 disaccharide	 core	 strucutre	 from	 Alaskan	 beetle	
Upis	ceramboides.[68]		
A further polysacharide from the marine bacteria species Colwellia psychrerythraea 
has also been recently discovered. Interestingly, through NMR studies and MD 
simulation, this polysaccharide exhibits a structure very similar to an AFGP.[70] This 
vast range of methods and molecules used by organisms to survive in freezing 
conditions, highlights the importance of this phenomenon and has inspired a range of 
potential applications. The following sections will expand on the unique antifreeze 
properties of AFPs and AFGPs rather than polyols since they possess the ability 
protect an organisms at remarkably low concentrations, making them incredibly 
appealing for a range of applications. 
 
1.3.    Interactions of AFGPs with ice 	
As described above, AFPs and AFGPs have been discovered to depress the freezing 
point of water by a much greater amount than would be expected due to colligative 
effects. This interesting ability signifies that another, active process must be occurring 
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to account for this. After much investigation, three separate properties have been 
identified that explain the interactions observed,[71] all of which are described in detail 
below. 
 
1.3.1. Thermal hysteresis 	
Thermal Hysteresis (TH) is the depression of a liquid’s freezing point relative to that 
of its melting point. Upon the addition of any solute to a solvent a freezing point 
depression is observed due to a colligative effect (i.e. a thermodynamic effect similar 
to that of osmotic pressure or boiling point elevation) whereby the equilibrium point 
of freezing and thawing is lowered proportionally to the concentration of solute (point 
at which Gibb’s free energy of freezing and thawing are equal.).[71] However, in 
solutions containing AFGPs, the freezing point can actually be observed to be lower 
than the melting temperature, Figure 1.6. In some cases this can be up to 1000 times 
that of the predicted colligative effect. This effect is asymptotically concentration 
dependent, so after a certain concentration there is no further TH increase.[72] This can 
be observed experimentally using a nanolitre osmometer to hold an ice crystal in this 
hysteresis gap. The ice crystal will not grow or melt as long as it is in this range, 
allowing the precise TH gap to be found. It should be noted that the observation of 
this property requires high concentrations, typically > 20 mg.mL-1. 
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Figure 1.6. Example of concentration dependant thermal hysteresis of AFGP 
from Dissostichus mawsoni. Black data points are TH activity in water, green 
data points in citrate buffer, adapted from Meister et al. 2013.[73] 
	
1.3.2. Dynamic ice shaping 	
Dynamic ice shaping (DIS) refers to an AFP or AFGP’s ability to shape the 
morphology of a single ice crystal. This is due to the commonly observed preferential 
binding to the pyramidal faces of the ice crystal as oppose to the basal faces, and 
results in a spicular shape developing, Figure 1.7. 
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Figure 1.7. Dynamic ice shaping of antifreeze proteins. Growth of the ice crystal is 
preferentially along the c-axis, due to binding on the pyramidal face. Adapted from 
Capicciotti et al. 2013.[74] 
 
DIS can generally be observed using a nanolitre osmometer holding the crystal as 
close to freezing point as possible, or in the TH gap between freezing and melting if 
there is one. Other methods for observing this phenomenon include hemisphere 
etching and wide-angle x-ray diffraction.  
   
1.3.3. Recrystallization inhibition 	
The third property that AFGPs possess is recrystallization inhibition (RI), the ability 
to slow the rate of ice crystal growth. Ice recrystallization can be considered an 
Ostwald ripening process, whereby small crystals dissolve and larger crystals grow, 
resulting in a smaller number of bigger crystals, minimizing surface energy. This is 
usually measured using a “splat assay” developed by Knight et al.[75] Briefly, this 
involves dropping a small droplet of solution from a height of  > 1 m onto a surfaced 
cooled sufficiently that the droplet freezes instantly (< -50 °C). This produces a thin 
wafer of small crystals typically less than 10 µm diameter, which are annealed on a 
temperature controlled microscope stage at a desired temperature for a desired amount 
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of time (typically – 8 °C for 30 minutes), Figure 1.8. The value frequently reported in 
the literature is usually the mean of the largest dimension for the 10 largest crystals in 
any wafer.  The above method also eliminates the ice nucleation process as a variable, 
making it highly repeatable and is therefore the method most often used when 
determining ice recrystallization inhibition (IRI) activity.    
 
 
Figure 1.8. Example wafers from splat test method for determining IRI activity. 
(A) PBS buffer control; (B) PBS with the addition of an IRI inhibitor. Both samples 
are at the same magnification, images were taken after 30 minutes at -8 °C. 
 
Despite the “splat assay” method being highly repeatable, it is not very high-
throughput and consequently several other methods have been introduced, including 
use of capillary tubes,[76] the addition of high concentrations of solutes such as 
sucrose,[36, 77] and even the use of microfluidic systems.[78] In a further attempt to 
increase throughput time of IRI asaays, domain recognition software was recently 
introduced by Jackman et al.,[79] but there remains no truly high throughput system for 
the identification of IRI activity. As ice crystal growth is a major problem in cellular 
	 17	
cryopreservation, the inhibition demonstrated by AFGPs is of high interest 
commercially.[80-81] 
	
1.3.4. Structure binding relationships of AFGPs 	
The exact interaction between an AFGP and ice is not currently totally understood, 
although several hypotheses have been proposed. To determine the ice-binding point 
mutations of AFPS and the synthesis of synthetic mimics have been produced to 
assess the effect of the substitution of amino acid residues and modification to 
glycans. Initial models assumed that hydrogen bonding was responsible for this 
interaction based on the facts that threonine and other polar residues can hydrogen 
bond with water and that the peptide sequence was a repeat unit. Two contrasting 
models were developed, one in which functional groups tightly bind in a zipper like 
fashion to the ice surface,[82] and the other which postulates that the functional groups 
could be incorporated into the ice lattice.[83]  
 
However, more recent studies have cast doubt on this hydrogen bonding mechanism. 
This includes the substitution of Thr for Val, preserving the methyl group but not the 
hydroxyl moiety, reducing the ability of the protein to hydrogen bond. The protein 
containing Val amino acid still retained its activity, thus suggesting that the binding is 
due more to Van der Waals interactions.[84] This is reinforced by modelling 
undertaken by Wen and Laursen, which also suggests an active role for Van der 
Waals interactions possibly in combination with hydrophobic forces.[85]More recently, 
several investigations involving both experimental and theoretical study, have 
demonstrated the importance of hydrophobic interactions between the AFGP and ice 
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and implies that this method of interaction could be most significant in the antifreeze 
activity of an AFGP or AFP.[46, 86-88]   
 
The first model describing the method of action of an antifreeze molecule was that of 
Raymond and DeVris, who proposed a mechanism of adsorption and inhibition after 
observing ice crystals with a distinct hexagonal bipyramid shape, suggesting that 
growth on the prism faces was being inhibited.[89] It is believed that crystal growth 
proceeds by propagation of a step across a crystal face. When an AFP or AFGP binds 
to the crystal surface in the path of a growing step it will only be able to grow in the 
gaps between the bound molecules in curved fronts, Figure 1.9. The growth of these 
curved fronts leads to a higher surface energy than that of a flat surface causing the 
transformation of water into ice to be less favourable therefore reducing the freezing 
temperature and growth rate of AFP bound crystals. This is known as the Kelvin or 
Gibbs-Thompson effect.[90-91] 
 
 
 
Figure 1.9. Ice growth in curved fronts. Growth of Curved fronts increasing surface 
energy and therefore decreasing growth rate. Adapted from Gibson, 2010.[71] 
 
Several groups have further developed the adsorption-inhibition model. These 
include, most notably, the button mattress model of Knight and co-workers and the 
step- pinning model proposed by Raymond et al.[89, 92] The button mattress model 
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hypothesises that a bound AFP inhibits growth of the ice lattice around it, therefore 
creating a button-mattress like surface, where as the step-pinning model postulates 
that the bound antifreeze molecules inhibit growth on the surface by preventing 
propagation of the step. Both of these models assume that the antifreeze binds 
irreversibly to the ice surface since desorption would results in rapid crystal growth in 
the areas where the AFP desorbed.   
 
 Although studies by Celik et al. and Knight and DeVries investigating the super 
heating of ice in the presence of an AFP, with support from recent experimentation 
using microfluidics, strongly suggest that at least some AFPs can bind irreversibly to 
the ice surface, there has been some criticism of this theory.[78, 93-94] This includes the 
assumption that the water- ice interface is sharp, despite evidence that the transition 
from the solid phase to the liquid at the interfaces are gradual and occur over several 
layers of water molecules, known as the quasi-liquid layer.[88]   
 
In 1999, Hall and Lips proposed an alternative model suggesting that AFPs are 
adsorbing reversibly to a rough surface, based on the observation that the free energy 
of adsorption is almost zero. They envisage a layer of AFPs on the crystal surface 
with a dynamic exchange of molecules at the ice water interface. The AFP would 
increase the step energy associated with the formation of a 2D nucleus thereby 
leading to a reduction in freezing point.[95] Despite this model having some success in 
mathematically describing experimental findings, there are limitations. Recent 
findings by Celik et al., that surface bound AFPs still inhibit ice crystal growth in a 
solution depleted of AFPs, showing that a dynamic exchange between free and 
adsorbed AFPs is unlikely.[78] Overall, there is still currently some disagreement as to 
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the exact mechanism of binding and inhibition, which remains to be determined by 
further investigation. 
 
In addition, the molecular mass is also found to play a role in the level of antifreeze 
activity. In a study by Wu et al. it was found that AFGPs could be separated into two 
distinct classes, those above 13 kDa and those below. Those above showed 3-4 times 
greater TH activity than those which were smaller.[96] 
 
A further recent hypothesis for the strength of certain hyperactive AFGPs is that the 
short range binding mechanisms are supplemented by long range interactions. 
Ebbinghaus et al. postulate that this could be due to a large hydration shell formed 
around the AFGP, as hydration water has a lower freezing point compared to bulk 
water.[97] In addition, from computer simulation and terahertz absorption spectroscopy 
of an AFP isolated from the beetle Dendroides canadensis, it has been found that 
protein-water interactions are present up to a distance of 20Å and play an essential 
role in the strong thermal hysteresis (TH) activity observed.[73]  
 
1.4.   Synthetic mimics 	
AFPs and AFGPs are of much interest in a range of different areas, including 
cryopreservation, cryosurgery and food technology due to their interesting 
properties.[98-100] However, there are significant challenges associated with isolating 
these proteins from their host species and expressing useful amounts using 
recombinant methods, while there are also potential immunogenic problems with in 
vivo uses. In addition to this, there is still the challenge of identifying which structural 
motifs provide “antifreeze” activity. 
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To overcome these challenges several attempts at modifying AFGPs have been 
reported. A detailed structure-property relationship study on AFGPs was undertaken 
by Nishimura and co-workers, although it should be noted that only TH and DIS were 
investigated, Figure 1.10.[101] An important observation was that a single tripeptide 
motif could influence ice growth while possessing no measureable TH, and that 
structural changes could be made while still maintaining antifreeze activity. For 
example, changing the linkage between the sugar and peptide backbone from the 
native α to its β analogue resulted in no TH activity while maintaining DIS activity. 
Overall the N-acetyl group at the C-2 position on the sugar was found to be essential 
for TH activity while ice shaping was maintained without it. From circular dichroism 
it was found that the presence of the N-acetyl group was important for forming a 
polyproline secondary structure. Furthermore the addition of charged moieties 
resulted in loss of both TH and DIS activity. This suggests that TH requires a certain 
secondary structure while DIS does not, allowing these properties to be effectively de-
coupled.  
 
In 2003, Enaide et al. observed that highly simplified glycoproteins retained IRI 
activity while possessing no TH or DIS activity, suggesting that there could be 
multiple molecular mechanisms that can lead to the same macroscopic properties, and 
that it is possible to design molecules that specifically display IRI activity.[102]  
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Figure 1.10. Selection of synthetic AFGPs synthesized by Nishimura and co-
workers, demonstrating necessary moieties for TH activity.  
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Ben and co-workers have shown that it is possible to make reasonably large structural 
modifications, creating glycopeptides that maintain IRI activity but display no 
measurable TH activity.[103-104] To explain this phenomenon, they proposed the use of 
hydration number as a predictive tool.[105] This was defined as the number of tightly 
bound water molecules divided by the carbohydrate’s molar concentration, and was 
found to correlate well with IRI activity.  None of these AFGP mimics possessed the 
ability to shape ice, which suggests that they are not binding and affecting the growth 
of the ice crystal itself, leading to the hypothesis that these glycopeptides act at the 
quasi-liquid layer instead.[104] As the glycopeptide would be excluded from the ice 
crystal lattice during freezing the concentration in this layer would increase, and 
consequently the number of hydrated water molecules would also increase. It is 
postulated that only the free water molecules can add to ice crystals meaning that 
crystal growth is inhibited.   
 
Several other groups have also investigated the production of synthetic antifreeze 
mimics, including Heggemann et al. who used microwave assisted solid phase peptide 
synthesis to vary the protein backbone sequence of AFGPs including the insertion of 
glycine and serine, not normally found in nature.[106] Finally Nishmura and co-
workers synthesized cyclic AFGPs which possess strong DIS and TH activity, 
although IRI activity wasn’t investigated. 
 
With recent advances in controlled radical polymerisation and post-
polymerisation,[107-108] synthetic polymers have become more appealing as 
biomimetics for a range of different areas including antimicrobial peptides, cell 
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signalling and mussel adhesion proteins.[109-111] Despite this, there has been relatively 
little study into the area of polymers displaying similar properties as AFGPs and 
AFPs. However there has been some, limited work into polymers that display IRI 
activity. The first observations that polymers could inhibit ice recrystallization were 
made by Knight et al., who investigated four polypeptides and 3 vinyl polymers.[112] 
Specifically they found that poly vinyl alcohol (PVA) (figure 1.11A) was an 
extremely potent IRI macromolecule, while poly(L-Histidine) (figure 1.11B) and 
poly(hydroxyproline) (figure 1.11C) also acted as inhibitors at relatively low 
concentrations ( < 1 mg.mL-1). This is remarkable, given that there is significant 
differences in structure, both between polymers and to native AFGPs. Poly(L-
Histidine) is also the first case of any IRI active molecule that does not have large 
amounts of alcohol units.  
 
Figure 1.11. Synthetic polymers found to possess IRI activity. (A) Poly vinyl 
alcohol (PVA); (B) poly(L- Histidine); (C) poly(hydroxyproline). 
 
This was followed by a study from Börner and co-workers who synthesized 
poly(tarter amides), suggesting that some limited TH and IRI  activity was present, 
although in the case of IRI no quantitative measurement was taken.[113] Importantly, 
they found that the length of backbone spacer played an important role on the 
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properties of the polymer, demonstrating that the spacing between groups interacting 
with the ice is important. 
 
Although many polymers were investigated, PVA was the only one found to display 
IRI activity similar to that of an AFGP or AFP. Inada and co-workers have 
extensively investigated PVA with respect to it’s IRI activity, finding that there is a 
strong correlation between molecular weight and ice recrystallization inhibition.[114] 
Likewise the degree of hydrolysis also correlated well with increasing activity, the 
same group followed this analysis with further investigation demonstrating that PVA 
exhibits small but measureable DIS and TH activity.[115-116] The above findings were 
supported by more recent findings by Congdon et al. showing that IRI activity is 
“turned on” when the polymer size increases from 10 to 20 repeat units, Figure 
1.12.[117] Furthermore, it was also found that the substitution of the polymer side 
chains was not well tolerated, although hydrophobic modifications were slightly less 
inhibitory than hydrophilic, implying that an unbroken chain of hydroxyl groups is 
important for activity. 
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Figure 1.12. IRI activity of PVA with varying repeat units. MLGS (mean largest 
grain size) is expressed as a percentage relative to PBS buffer. IRI activity is turned 
on when increasing from 10 to 20 repeat units. Adapted from Congdon et al. 2013.[117] 
 
Several further attempts have been made at determining the reason for PVA’s 
remarkable IRI activity despite it bearing little similarity to an AFGP or AFP. Deller 
et al. tested an extensive range of polyols finding that from a large library of 
saccharides, polymers and small molecules, PVA is the only one to exhibit IRI 
activity, further suggesting that the spacing of hydroxyl groups and structure of the 
polymer plays an important role.[118] In addition, polyethylene glycol (PEG) and 
poly(acrylic acid) (PAA) two other commonly used polymers no activity. Budke and 
Koop postulated that the hydroxyl groups have very similar spacing to the prism 
planes of hexagonal ice, suggesting that spacing is critical.[119] However this does not 
agree with the AFP model, where a hydrophobic face binds to ice raising the 
possibility of multiple mechanisms for IRI activity. 
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The use of PVA in cryoprotective applications is highly appealing as, unlike AFGPs 
and AFPs, it can be synthesized on a large basis for relatively low cost. It is also 
biocompatible and biodegradable and has the advantage of already being FDA 
approved.[120-121] However it should be mentioned that a type 3 AFP (named ice 
shaping protein (ISP) 3) has been found to be non toxic in oral studies, and is 
currently used by Unilever PLC in ice cream to improve quality and storage 
lifetime.[122-123] Despite this promise no IRI active molecule is currently used in a 
clinical setting. 
 
Complexes of zirconium acetate (Figure 1.13A) and zirconium acetate hydroxide 
(Figure 1.13B) were identified to posses ice shaping properties, similar to those 
reported for AFGPs and AFPs although only at specific pH values (pH 3-5).[124] The 
low molecular weight (327 g.mol-1) make this particularly interesting as previous 
studies have observed a positive correlation between size and activity.[33, 117] This was 
expanded in a study by Mizrahy et al. who investigated both TH and IRI activity in 
addition to ice shaping behaviour, finding that these complexes have negligible TH 
behaviour, but possess IRI activity in addition to ice shaping ability already found.[125] 
The authors also surmise that the complexes undergo a relative degree of 
oligomerization giving activity at certain pH values, and that the functional groups 
involved in ice binding are acetate and hydroxyl moieties. Although this compound is 
relatively cheap, making it commercially attractive, it may be undesirable as a 
cryoprotectant due to the potential toxicity effects associated with high concentrations 
of metals and would be of more use in material science applications.  
	 28	
 
Figure 1.13. Zirconium acetate IRI complexes; (A) Zirconium acetate; (B) 
Zirconium acetate hydroxide. 
 
Overall the synthetic AFGP/ AFP analogues described above demonstrate the wide 
variety of different structures that can interact with ice, and there are still significant 
challenges in understanding the rules of rationally designing an antifreeze molecule, 
making this an important area for further research. Furthermore with the exception of 
PVA there is a current lack of potentially commercially viable molecules with 
antifreeze activity that could be of use as a cryoprotectant.  
 
1.5.    Challenges in cryopreservation 	
While the AFGPs, AFPs and synthetic mimics have numerous potential applications, 
the focus here will be on cryopreservation due to the huge need for innovative storage 
methods of biomaterials produced by recent medical advances that currently suffer 
from longevity issues. This storage can be categorized into four different areas, non-
vitrifying (ice crystals present) cryopreservation, vitrifying (ice in glass-like state) 
cryopreservation, hypothermic storage (> 0 °C) and lyophilisation. Methods of 
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cryopreservation are described in detail below, together with biological materials of 
interest that would benefit enormously from reliable cryopreservation. 
 
1.5.1.  Overview of current cryopreservation methods 	
It is clear that there is a wide variety of different biological materials that require 
cryopreservation to be fully utilized. Cryostorage of these materials requires both 
optimization of the cryoprotective solution for specific cell types, and the rates at 
which freezing and thawing is undertaken, and this is discussed in detail below.  
 
1.5.1.1.   Cryoprotective compounds  	
In general there are two types of cryoprotectants, those that penetrate the cell 
membrane and those that don’t. Both types form hydrogen bonds with water and act 
by regulating the amount of liquid water and solute concentrations. Penetrating 
cryoprotectants include dimethyl sulfoxide (DMSO), ethylene glycol and glycerol. 
These are small enough to penetrate the cell membrane and act via a colligative 
mechanism, replacing water inside the cell. In the 1950s Lovelock  developed a 
theory to explain this cryoprotective mechanism, postulating that due to the molar 
depression of the freezing point due to the solutes in solution, at any temperature 
below the ice transition during cooling, increase in salt concentration would be 
slowed due to the presence of the cryoprotectant (in this case glycerol).[126-127] This 
effect would prevent toxic concentrations of salts forming and subsequent damage. 
Likewise the increasingly high viscosity of the cryoprotectant during cooling helps 
maintain cell shape and slow intracellular ice formation.  
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Although these cryoprotectants have been used to preserve a variety of cell types such 
as red blood cells and bacteria, they require relatively high concentrations and show 
toxicity. Using DMSO as an example to show toxic effects, it has been found that 
DMSO can cause denaturing of proteins,[128] membrane proliferation[129] and increase 
the concentration of Ca2+ ions in the cytoplasm, which has been linked to 
depolymerisation and changes within the cytoskeleton.[130] Furthermore it has also 
been proposed that DMSO can effect RNA splicing.[129] Other penetrating 
cryoprotectants have also been observed to cause similar toxic effects.[131]  
 
Non-penetrating cryoprotectants include polymers such as polyethylene glycol (PEG) 
and polyvinylpyrolidone (PVP) and also certain sugars that are too large to enter the 
cell. They are thought to act by dehydrating the cell before freezing due to high 
osmotic coefficients, reducing the amount of water the cell has to lose to regain 
osmotic balance under cooling.[80] Therefore intracellular ice formation becomes less 
likely, and so provides protection. However, they provide little protection against 
injuries caused by slow freezing and display significantly weaker activity than 
penetrating cryoprotectants. Although non-penetrating cryoprotectants show relatively 
weak activity, they can be added to their penetrating counterparts, reducing the 
concentrations required and consequently the toxicity effects.[132]  
 
The use of saccharide molecules as cryoprotectants is also appealing as they are 
highly biocompatible in comparison with DMSO.  A selection of sugars have been 
used in cryopreservation studies, both as a replacement and in addition to traditionally 
used protectants such as DMSO.[133] These include mono and disaccharides such as 
glucose, sucrose, fructose and particularly trehalose. In a study of the 
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cryopreservation and viability of mouse oocytes and zygotes, trehalose was found to 
substantially increase viability levels,[134] while it has also been shown that a trehalose 
solution can be used to preserve carrot and tobacco cells.[135] Likewise, the addition of 
a selection of sugars to an ethylene glycol solution have been found to improve the 
vitrification properties, shifting the glass transition temperature and improving 
cryopreservation potential, while also demonstrating low toxicity, Figure 1.14.[136] 
The optimal concentration and type of different sugars (and cryoprotectants in 
general) varies between different cell types. Therefore, careful testing and 
optimization is required for the highest cell survival possible under cryopreservation.  
  
 
Figure 1.14. Phase diagram of ice showing vitrification as a function of solute 
concentration.  
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In addition to a colligative effect, which helps minimize changes in volume as the cell 
undergoes freezing and rewarming, sugars have also been found to interact with the 
cell membrane, increasing stability. For example, in a study by Strauss et al. it was 
found that sucrose, trehalose and glucose all stabilize and prevent membrane fusion of 
simple lipid bilayers under freezing and thawing.[137] The mechanism by which this 
occurs is thought to be due to hydrogen bonding to the polar phospholipid head 
groups displacing the water.[138] Furthermore, it has also been suggested that a 
saccharide can interact with, and stabilize acyl chains present in phospholipids.[139] 
Finally, sugars may also stabilize proteins, with the hydroxyl groups mimicking 
hydration, preventing denaturation further improving cryopreservation properties.  
Despite the remarkable abilities of AFGPs, AFPs and synthetic analogues discussed 
above there have been relatively few reported attempts to use these within 
cryopreservation. Addition of AFGPs to red blood cells (RBCs) provided some 
cryoprotective effect, although above a certain concentration recovery actually 
decreased. This is thought to be due to needle like crystals forming due to the DIS 
activity possessed by the glycoprotein, Figure 1.15.[140] Furthermore, a study that 
investigated the effect of two AFPs and an AFGP on the viability of mouse 
spermatozoa, found that survival was decreased upon the addition of an AFP or 
AFGP, again the authors surmised that this was due to DIS.[141] Several other studies 
have been undertaken showing conflicting reports on the viability of these proteins as 
cryprotectants.[142-144]  
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Figure 1.15. AFP concentration dependent hemolysis of red blood cells (RBCs). 
Percent hemolysis is after freeze, storage at -196 °C and thaw. Adapted from 
Carpenter and Hansen, 1992.[145] 
 
Interestingly AFPs and AFGPs have been found to effect the cell membrane during 
hypothermic and cryo-storage. Tomczak et al. investigated a type 1 antifreeze protein 
in the hypothermic storage of chloroplast membranes finding that there is binding of 
the AFP to the lipid bilayer. This binding was found to inhibit leakage across the 
membrane and improved cell viability.[146] In a follow up paper the same authors also 
assessed the role of various AFPs and AFGPs on membrane permeability under 
freezing. Finding that some proteins such as type 1 AFP described above caused 
increased membrane leakage while others such as small AFGPs have an inhibitory 
effect.[147] This membrane binding is thought to be due to the hydrophobic face 
exhibited by all AFGPs and AFPs and demonstrates an unexpected property that 
would be highly interesting for cryopreservation applications. 
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In addition, cryopreservation using synthetic analogues has been attempted on several 
occasions. This includes the use of a synthetic AFGP with DMSO to preserve islet 
cells and the use of PVA to enhance the survival of RCBs.[98, 148] Poly(ε-L-lysine) 
modified with between 0 and 100 % hydroxyl groups (Figure 1.16) has also been 
investigated as a cryoprotectant although no quantitative analysis of IRI activity exists 
for this polymer.[149] The authors found that between 50 and 70 % carboxylation gave 
a significant improvement on the recovery of L929 cells when frozen and thawed 
compared to a DMSO control. Interestingly these polymers could be added at high 
concentrations (up to 20 wt%), meaning that the addition of other cryoprotectants, 
such as DMSO could be avoided. 
 
 
Figure 1.16. Carboxylated Poly(ε-L-lysine), functionalized with between 0-90 % 
carboxyl groups. 
 
Reactive oxygen species (ROS) including hydroxyl radicals (OH) and hydrogen 
peroxide (H2O2) are formed naturally during metabolism within a cell. These can 
react with cellular constituents such as proteins and lipids to become stable and are 
required for various cellular processes such as cell signaling. Under normal conditions 
molecules called antioxidants convert ROS to safe products preventing cell damage, 
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however, in excess these can cause irreparable damage and lead to cell death,[150] 
known as oxidative stress. The disruption caused by cryopreservation and subsequent 
thawing has been found to lead to imbalances of ROS and antioxidants, so there has 
been a significant amount of investigation into the addition of antioxidants into 
cryopreservation solutions.[151] 
 
There are two different types of antioxidants, enzymatic and non-enzymatic and both 
types can prevent harmful build-up of ROS species.[150] Among these antioxidants, 
several have shown promise for cryopreservation, these include glutathione (GSH) a 
tripeptide found ubiquitously in living cells, its precursors L-glutamine (L-Glu) and 
L-cysteine (L-Cys), ascorbic acid and superoxide dismutase and/ or catalase.[152]  
 
The cell type plays a huge role in the optimization of cryopreservation, for example 
Câmara et al. found that the addition of GSH has little effect on the viability of ram 
spermatozoa, while Gadea and coworkers found that it has a protective effect in the 
cryopreservation of boar spermatozoa.[151, 153] Furthermore a study into the growth 
rates of cryopreserved Rubus (blackberry) shoots discovered that the addition of GSH 
improved regrowth by approximately 25 %,[154] demonstrating the challenge in the 
cryopreservation of a wide variety of cell types. 
 
Finally there has been significant recent investigation into the effect of ice nucleation 
on cryopreservation and whether the addition of certain additives controlling this 
process lead to increased cell recovery.[155] As the sample is cooled, supercooling 
occurs, leading to uncontrollable nucleation, including intracellular nucleation and 
subsequent damage to the cells. Controlled nucleation has been found to improve 
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post-thaw viability in numerous cell types including, stem cells, pulmonary 
endothelial cells and bacteria.[156-158] The production of commercially viable, 
biocompatible ice nucleating agents are the subject of significant current research,[159] 
and will be high importance when designing future cryoprotectant mixtures.  
	
1.5.1.2.   The effect of freezing and thawing rates on cryopreservation 	
The survival for a certain cell during cryopreservation can depend on the cooling rate, 
with all cells exhibiting an optimal cooling rate. If the cooling is too fast or too slow 
then the level of cell survival will be low. The optimal cooling rate of a particular cell 
will be different to that of another cell, and so must be determined either through 
simulation or by experimentation for best cryopreservation.[160-161] While both slow 
and fast cooling lead to cell death, the mechanisms are different. Generally, slow 
freezing results in a prolonged exposure to extracellular ice, increasing solute content 
and causing osmotic problems, while fast freezing causes intracellular ice formation, 
both causing the death of a cell. The rate of thawing can also lead to decreased cell 
survival rates if it is not optimised. Overall, it appears that faster warming is 
preferential to a slower rate. It has found that slower warming can lead to intracellular 
ice formation, leading to ice recrystallization and cell damage.[162]  
 
Although a faster thawing rate is generally preferred over a slower rate, for cells, 
which have undergone slow cooling this becomes disputable. Some studies have 
found that slowly cooled cells show increased survival rates at slower warming 
speeds, for example Whittingham et al. found this to be the case when investigating 
mouse embryos[163] and Towill and Mazur reported similar findings in plant cells.[164] 
The reason for this is hypothesised to be due to osmotic shock, since under fast 
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thawing there is no time to equilibrate.[165] However studies of other types of cell such 
as mammalian sperm have discovered that slow warming for cells, which have 
previously been cooled slowly, leads to a lower survival rate than faster warming 
rates.[166] 
 
After discussion of the various factors involved cryopreservation, several areas of 
importance are discussed below in greater detail, highlighting where cryostorage is 
currently viable and the challenges to be overcome if we are to fully to be able to take 
advantage of recent medical breakthroughs.   
  
1.5.2. Cryopreservation of red blood cells 	
An area where reliable cryopreservation could be of enormous benefit is the storage 
of blood. The majority of blood products required in a clinical setting are the red 
blood cells (RBCs), although platelets and blood plasma are also required. In the 
United Kingdom approximately 6,000 units of blood (1 unit = 470 mL) are required 
on a daily basis, with the largest uses being for treatment of anaemia (30%) and in 
surgery (30%).[167]  
 
Although the demand is relatively constant, the supply is not. During adverse weather, 
or periods where a large number of people are on holiday, such as around Christmas 
and New Year the stocks can drop dramatically. This is summarized in figure 1.13, 
detailing the fluctuations over a 14-week period (figure 1.17A) and showing how 
different blood groups have differing stocks (figure 1.17B). During adverse weather 
in February, and at Easter the stocks can be observed to be significantly lower than 
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normal, while rarer blood groups such as AB negative have worrying low stock levels 
at the time of writing. 
 
 
Figure 1.17. Fluctuations of bloodstocks. (A) Overall bloodstocks over a 14-week 
period in 2015; (B) Differing levels of stocks for various blood types. Figures adapted 
from NHS blood and transplant.[167]   
 
The fundamental problem is that RBCs can only be stored for 35 days in hypothermic 
conditions, with platelets having a shelf-life of just 7 days at room temperature.[167] 
Several storage solutions have been developed, all containing anticoagulants, 
nutrients and solutes to maintain osmotic pressure. Commonly this involves the 
addition of compounds such as citrate (anticoagulant), nutrients phosphate and 
adenine and dextrose.[168] The loss of red blood cells is associated with various 
factors, collectively known as the “RBC storage lesion”, including decrease in pH, 
decrease in ATP and 2,3-DPG levels and a build up of lactic acid.[169-170] 2,3-DPG is a 
key regulator in haemoglobin oxygen affinity.[171] This RBC storage lesion is 
potentially harmful, with the transfusion of older blood resulting in an increased risk 
of death in certain cases.[172] Other problems associated with hypothermic storage 
	 39	
include the build up of bioreactive substance such as cytokines,[173] and changes to the 
membrane composition.[174]  
 
In addition to RBCs platelets are of significant importance in the clinical setting. 
Platelets require storage at 22 °C in contrast to RBCs. As mention above they can 
only be stored for up to 7 days due to structural lesions, reduced aggregation 
efficiency and risk of bacterial infection. Hypothermic storage can trigger activation, 
while also causing modifications in shape and activity.[175]  
 
Current cryopreservation of RCBs requires an array of cryoprotectants, at high 
concentration and a way of storing samples, usually below -130 °C. The predominant 
additive in standard cryopreservation is glycerol at concentrations of up to 40 %, 
which must be removed after thawing as it can induce heamolysis.[176] Despite two 
methods being developed for the routine storage of RCBs in glycerol,[177] 
cryopreservation is limited to specific applications where donations are typically 
limited such as rare blood groups. Addition and removal of glycerol must be highly 
controlled, requiring specialist equipment and training, while post-thaw cell viability 
is limited.[178]  
 
In addition to glycerol several cryopreservation techniques using cryoprotectants that 
are non cell penetrating have been investigated. These include hydroxyethyl starch 
(HES) and dextran.[179-180] HES has been widely studied as a cryoprotectant and acts 
to alter solution viscosity, while also acting as an osmolyte reducing intracellular 
water and helping to reduce potentially damaging ice formation on thawing.[181] 
Although post-thaw cell viability is generally high, there has been recent concern 
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about renal toxicity of HES,[182] and this has led to it being recently withdrawn from 
use in the UK and strictly limited in the USA pending further investigation.[183]   
 
RBCs require optimised cooling and thawing techniques. Focusing on cooling; a 
range of rates and techniques have been investigated, with the vast majority 
recommending the immediate immersion in liquid nitrogen cooling the sample 
rapidly.[180, 184] Although cooling rate has been studied, the critical process for RBC 
cryopreservation is thawing. Ideally, the thawing process should be fast to prevent ice 
recrystallization, however RBCs are stored in volumes of 470 mL meaning that 
differential warming would occur. The cells in the centre would still experience 
harmful ice growth, while those on the outside may be exposed to high temperature 
for a relatively long period of time.  
 
Furthermore there has been some limited investigation using AFGPs, AFPs and other 
IRI active molecules in the cryopreservation of RBCs. Carpenter and Hansen 
demonstrated that the addition of a type 1 AFP from Winter flounder 
(Pseudopleuronectes americanus) to a HES solution enhanced survival of RBCs,[140] 
and Chao et al. expanded on this, demonstrating that this is an ability of a range of 
AFGPs and AFPs.[185] More recently Deller et al. found that the addition of 1 mg.mL-1 
PVA to HES provided a similar benefit.[98] In all cases high concentrations of IRI 
molecule resulted in increased hemolysis, thought to be due to DIS. 
 
1.5.3. Stem cell cryopreservation 	
Recent advances in stem cell technology has lead to a wide variety of potential uses 
including bone regeneration, wound treatment and treatment for central nervous 
	 41	
system problems.[186-188] Preservation of these cells enables them to be transported 
from specialist facilities to elsewhere, and means that they can become more viable as 
a treatment option. Furthermore, histocompatibility between donor and recipient is a 
major issue. For example, hematopoietic stem cells, Figure 1.18, used to treat 
leukaemia are often hard to match, meaning that a large library of different genotypes 
is required and therefore requiring the highly efficient cryopreservation methods.[189]  
   
 
Figure 1.18. Hematopoietic stem cells and associated differentiation. Adapted 
from Mateos et al. 2015.[190] 
 
Stem cell cryopreservation has had some success and current therapeutic strategies 
rely on good cryostorage. One stem cell line that is successfully stored and used to 
treat hematologic malignancies such as leukaemia is hematopoietic stem cells.[191] The 
current best practice for the storage of this cell line involves the use of 10 % DMSO 
in conjunction with serum albumin and saline.[3] As discussed in section 1.5.1.1, 
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DMSO has some toxicity issues, so a post-thaw washing stage must be undertaken. 
Standard cooling procedure involves cooling at a rate of 1-2 °C.min-1 to – 40 °C then 
slightly faster at 5 °C.min-1 to -120 °C and then stored in liquid nitrogen. Although 
fast freezing of hematopoietic stem cells by placing directly in liquid nitrogen, has 
also been investigated and found to have little detrimental effect.[192] Thawing rates 
are fast by submerging the samples within a water bath at 37 °C. However, the use of 
a water bath can lead to problems with sterility and is often not compatible with a 
clean room or a operating theatre,[193] highlighting the need for an IRI active 
compound allowing the samples to be thawed at a slower rate without the fear of 
detrimental ice crystal growth. 
 
Embryonic stem cells and induced pluripotent stem cells have much promise as 
treatment for a range of genetic diseases, however their extremely fragile nature 
makes them highly challenging to cryopreserve. Current cryostorage procedure results 
in recovery of only around 1% and can also induce differentiation.[194] Due to this low 
yield, several more complex procedures have been introduced, including the addition 
of Rho-associated kinase (ROCK) inhibitor Y-27632 (protein that inhibits actin 
depolymerisation and consequently cell death),[195] and the use of very high 
concentrations of glucose to produce a vitrified solution.[196] Despite these innovative 
methods no high-yielding method is currently available and therefore 
cryopreservation of these particular cell lines is highly challenging.   
 
1.5.4. Reproductive medicine 	
In addition those described above, another area of major importance for 
cryopreservation is that of reproductive medicine. Relatively recent advances in this 
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field have lead to the widespread use of in-vitro fertilization (IVF) and artificial 
insemination of domestic species in farming and endangered species.[197] Of all cell 
types frog and fowl spermatozoa were the first to be successfully cryopreserved and 
some of the greatest successes to date in cellular cryopreservation have been reported 
in the field of reproductive medicine.[198] 
 
Reproductive medicine can be split into three cell types, spermatozoa, oocytes and 
embryos. Spermatozoa arguably the most commonly frozen cell type, typically 
involving the use of glycerol as the main cryoprotectant instead of DMSO. Although 
both have been found to have some toxic effect including loss of motility, possibly 
due to the high osmotic stress so must be removed post-thaw. The optimal freezing 
and thawing rates are generally thought to be fast, with freezing carried out by placing 
samples in liquid nitrogen vapour, while thawing is undertaken at 37 °C in a water 
bath.[199] Typically only low numbers of sperm survive thawing, which can be 
problematic when cryopreserving samples with low sperm numbers. To improve 
viability several studies have assessed the addition of AFPs to the cryomixture with 
mixed results; both enhancement and toxicity were observed.[141, 200] 
 
The cryopreservation of oocytes presents a difficult challenge, due to the unique 
nature of the cell type. They have a large cellular volume making intracellular ice 
formation problematic, while also possessing a very complicated microtubule 
structure due to being locked into the metaphase of meiosis. Furthermore 
cryopreservation can induce changes in the glycoprotein coat surrounding the oocyte 
which is critical for fertilization.[201] These challenges mean that typical success rates 
of live births from cryopreserved embryos remains very low.  
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Two different approaches are commonly used to cryopreserve oocytes, a slow 
freezing strategy, whereby samples were frozen to -8 °C at 2 °C.min-1 and held at a 
constant temperature to insure controlled ice nucleation. The temperature was then 
decreased to -30 °C at 0.3 °C.min-1 and finally rapidly cooled at 50 °C.min-1 to -150 
°C and placed in liquid nitrogen for storage. The cryoprotectants used were 1,2 
propanediol (membrane permeable) and sucrose (membrane impermeable).[202] The 
second method involves fast freezing to produce a vitrified state using either an 
ethylene glycol, sucrose and human serum albumin mixture,[203] or a solution 
containing DMSO and PEG.[204] Both fast and slow freezing methods use fast 
thawing, Figure 1.19. 
 
 
Figure 1.19. Cryopreservation of mouse and bovine oocytes using various 
freezing rates.  Survival	based	on	development	into	expanded	blastocysts,	mouse	oocytes	 cryopreservated	 in	 DMSO	 and	 PEG,	 bovine	 oocytes	 in	 1,2	 propanediol	and	sucrose.	Adapted	from	Leibo	2008.[205]	
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A significant portion of cell damage to oocyte cells during cryopreservation is caused 
by ice recrystallization, so AFGPs and AFPs or synthetic mimics would be a useful 
addition to the cryoprotective solution. O’Neil et al. prepared a solution of DMSO 
with the addition of 1 mg.mL-1 AFGP and analysed its effect compared to DMSO 
alone, finding significant improvement in viability although only when added at 4 
°C.[206] Likewise, Kim and co-workers reported increased viability upon the addition 
of a type 3 AFP.[207] 
  
The final area of reproductive medicine involves the cryopreservation of fertilized 
embryos. As discussed above for oocytes, there is much discrepancy as to whether 
slow or fast cooling (vitrification) is the optimal method and what the optimal 
composition of the cryosolution is. Slow cooling methods involve the use of 1,2 
propanediol or glycerol with sucrose and requires holding at -7 °C to insure controlled 
ice nucleation,[208] while fast cooling methods favour glycerol at higher 
concentrations.[209] Several studies have investigated the effect of IRI active 
molecules on cryopreservation of embryos in a range of species including zebra 
fish,[210] rabbit[211] and mice.[212] Despite this initial promise, no current study has 
investigated the effect of AFPs or AFGPs on the freezing of human embryos, 
presumably due to ethical concerns.  
 
1.5.5. Transplantation medicine 	
Cryopreservation techniques have huge potential in the area of transplantation 
medicine. For example in the USA there are currently over 120,000 people waiting 
for organ transplants,[213] Table 1.1, and with an aging population this will only 
increase over time. A wide variety of different cell types are covered under transplant 
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medicine and the level of complexity can vary from material of one cell type to a 
whole organ with a variety of different cells present. In addition, unlike RBCs the 
cells undergoing transplantation must be able to proliferate in the recipient in order to 
be of benefit. Thus the challenges associated are demanding and require optimization 
for a particular cell type. 
 
Table  1.1. Transplant waiting list for the USA by organ. Data correct as of August 
28th  2015.[213] 
Organ Candidates 
Kidney 101,055 
Liver 15,159 
Pancreas 1,050 
Kidney/ Pancreas 1,962 
Heart 4,183 
Lung 1,537 
Heart/ Lung 47 
Intestine 256 
Total 122,352 
 
 
Although the cryostorage of whole organs has yet to be achieved, there has been some 
success in the preservation of individual cells lines. One of these is hepatocytes, the 
primary cell type within the liver. This cell type is used to treat metabolic liver 
diseases and acute liver failure, while also being useful for toxicology testing.[214] The 
standard cryopreservation mixture used is known as University of Wisconsin solution 
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(also known as viaspan). It consists of osmolytes such as lactobionate and raffinose, 
glutathione and adenosine to maintain cell function, and salts such as potassium 
phosphate and HES. Usually up to 10 % DMSO is added depending on the 
cryopreservation procedure used.[215]  
 
In order to achieve successful cryopreservation the cells must be frozen as soon as 
possible after harvesting, followed by a slow freezing regime of around 1 °C.min-1 
and then storage in liquid nitrogen. Thawing rate is generally rapid, although after 
thawing the hepatocytes are cooled down to 4 °C to minimize the toxic effects of 
DMSO.[216] While this is reasonably successful, hepatocyte function is generally 
compromised on thawing, for example albumin production is generally only 50 % of 
that observed in fresh cells. Likewise, a significant percentage of cells fail to attach to 
the culture substrate.[216] Despite these problems, transplanted hepatocytes have been 
found to be highly beneficial in clinical trials.[217]  
 
 A further primary cell type that is of interest for transplantation given the recent 
dramatic increase in type 2 diabetes, are islet cells which control insulin levels. 
Several studies have now shown that islet transplantation can reduce or even 
eliminate the need for insulin supplementation signifying that a reliable supply would 
be of enormous therapeutic benefit.[218] General cryopreservation procedure is similar 
to that of hepatocytes employing slow cooling and fast thawing rates with DMSO as 
the cryoprotectant. However, a recent study by Stiegler et al. found that encapsulation 
of hepatocytes in sodium cellulose sulphate and frozen with the addition of glycerol 
resulted in a similar recovery level to DMSO,[219] while further investigations have 
focused on the use of vitrifying solutions with the addition of polyols such as 
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propanediol.[220] Furthermore a synthetic AFGP described by Matsumoto et al. was 
found to enhance survival rates of islets cells in comparison to standard the 
cryosolution by as much as 20 %, which the authors attributed to its IRI activity, thus 
demonstrating the enormous potential for IRI active molecules in 
cryopreservation.[221] 
 
AFGPs and AFPs also have the potential to increase the storage lifetime of organs 
ready for transplantation due to their TH ability. Amir et al. showed that rat hearts 
stored at sub zero temperatures without freezing due to the addition of a type 3 AFP 
had an extended storage time compared to standard protocols. Although this is not a 
long term storage method, this limited increase could be crucial in transporting the 
donor organ to its recipient.[222]  
 
1.5.6. Protein storage 	
Proteins as therapeutics have also increased dramatically since insulin became the 
first therapeutic around 30 years ago. Now these materials have the potential as 
treatments across a whole spectrum of different medical fields, with more than 130 
currently in use.[223] The majority of these are unstable for longer periods of time at 
room temperature, meaning that lyophilisation or cryopreservation is critical. Several 
problems need to be overcome in order to successfully preserve protein material, 
including adverse pH shifts and high localized salt concentrations on the removal of 
water.[224] Membrane proteins are particularly difficult to store successfully.   
 
A variety of different molecules have been used in order to improve the storage of 
protein materials, including sugars, glycerol, amino acids, polymers and inorganic 
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salts. A common characteristic of these preservatives is that they seem to be 
preferentially excluded from contact with the protein in solution.[225] Various physical 
factors also affect recovery rates, including freezing and thawing rates and protein 
concentration.[226]  
 
The most common method of cryopreservation is lyophilization in the presence of the 
disaccharide trehalose (figure 1.3A), which acts to stabilize the protein. Numerous 
studies have shown the benefit of this particular sugar over a range of proteins.[227-228] 
In addition, Maynard and co-workers have explored the synthesis of several trehalose 
glycopolymers as a way of enhancing their protective effect, finding that recovery 
could be improved by up to 50 % compared to trehalose alone.[229] Despite the success 
of trehalose in the storage of a range of proteins, there still remains a wide range of 
other possible therapeutic proteins that are not currently able to be stored long-term, 
therefore significant further research needs to be undertaken in order to realize the 
enormous potential in this field of medicine.  
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1.6.    Thesis aims and summary 	
From considering the above research, this thesis aims to investigate the application of 
new AFP/AFGP molecules and apply these to cryopreservation. This includes 
studying the attributes that a molecule must possess in order to possess IRI activity, 
and whether synthetic, commercially viable AFGP/AFP biomimetics can be made. In 
addition cryopreservation of several biological materials will be investigated. 
 
Chapter 2 describes how other proteins, not thought of as AFPs although 
evolutionarily similar can also posses IRI activity in the right conditions, due to 
various similar structural motifs. Calcium dependant L-type lectins are investigated 
due to their similarity to type 2 AFPs, while the antimicrobial peptide nisin is 
considered as it has structural similarity to type 1 AFPs. The identification of these 
structural similarities is of benefit when designing synthetic mimetics.  
 
After exploring structural features of peptides that possess IRI activity, synthetic 
mimetics were explored. Chapter 3 examines polyampholytes as novel IRI 
molecules, finding that poly(aminoethyl methacrylate) (PAEMA) functionalized with 
succinic anhydride (SA) forming a polymer with both positive and negative charges 
(PAEMA-co-SA) possessed IRI activity when the ratio of positive to negative charges 
is around 50 %. The systematic investigation of further polyampholytes including 
polybetaines and carbohydrate centred oligomers and IRI activity was also 
considered. 
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The “splat test” method of identifying IRI activity is robust, but not very high 
throughput, meaning that the identification of new IRI molecules such as those 
described in chapters 2 and 3 is a time consuming process. Chapter 4 details a novel 
gold nanoparticle based method for quickly and efficiently screening a wide range of 
materials, while also identifying that serum albumins such as bovine serum albumin 
(BSA) possess limited IRI activity at concentrations of around 20 mg.mL-1. 
 
Chapter 5 investigates the use of amphipathic metallohelicies as potent IRI active 
molecules. These molecules are intrinsically hydrophobic, demonstrating that 
hydrophobicity is a desirable property for inhibiting ice crystal growth, while also 
having a similar helical structure to a type 1 AFP and the benefit over polymeric 
inhibitors of having a defined molecular weight.  
 
Chapter 6 uses the knowledge that polyampholytes have IRI activity, discovered in 
chapter 3, in order to create a cheap, non-toxic, commercially viable polyampholyte 
based on poly(methyl vinyl ether-co-maleic anhydride). This is then used in 
conjunction with HES as a cryopreservative of RBCs, proving that even under sub-
optimal slow thawing conditions the addition of an IRI active molecule can have 
enormous benefit to recovery. 
 
Finally, Chapter 7 considers the problem of therapeutic protein storage, through the 
use of IRI active molecules. Using a mixture of PVA and PEG or PAEMA-co-SA and 
PEG, recovery of several proteins was found to be significantly enhanced when 
frozen at -20 °C and -80 °C. In addition the same mixture was used to successfully 
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cryo-store antibody IgG, thus demonstrating this mixture as a viable solution to the 
problem of storing therapeutics. 
  
	 53	
1.7.    References    
  
[1] G. M. Hewitt, Biol. J. Linn. Soc. 1996, 58, 247-276. 
[2] S. Prestrud Anderson, J. I. Drever, N. F. Humphrey, Geology 1997, 25, 399-
402. 
[3] D. Berz, E. M. McCormack, E. S. Winer, G. A. Colvin, P. J. Quesenberry, Am. 
J. Hematol. 2007, 82, 463-472. 
[4] T. Bartels-Rausch, V. Bergeron, J. H. E. Cartwright, R. Escribano, J. L. 
Finney, H. Grothe, P. J. Gutiérrez, J. Haapala, W. F. Kuhs, J. B. C. Pettersson, 
S. D. Price, C. I. Sainz-Díaz, D. J. Stokes, G. Strazzulla, E. S. Thomson, H. 
Trinks, N. Uras-Aytemiz, Rev. Mod. Phys. 2012, 84, 885-944. 
[5] M. Heisig, S. Mattessich, A. Rembisz, A. Acar, M. Shapiro, C. J. Booth, G. 
Neelakanta, E. Fikrig, PLoS ONE 2015, 10, e0116562. 
[6] J. G. Duman, M. J. Wisniewski, Environ. Exp. Bot. 2014, 106, 60-69. 
[7] M.-L. Sutinen, R. Arora, M. Wisniewski, E. Ashworth, R. Strimbeck, J. Palta, 
in Conifer Cold Hardiness, Vol. 1 (Eds.: F. Bigras, S. Colombo), Springer 
Netherlands, 2001, pp. 89-120. 
[8] P. L. Davies, B. D. Sykes, Cur. Opin. Struct. Biol. 1997, 7, 828-834. 
[9] P. Prestrud, Arctic 1991, 44, 132-138. 
[10] A. L. DeVries, D. E. Wohlschlag, Science 1969, 163, 1073-1075. 
[11] P. F. Scholander, L. van Dam, J. W. Kanwisher, H. T. Hammel, M. S. Gordon, 
J. Cell. Comp. Physiol. 1957, 49, 5-24. 
[12] S. K. K. DeVries A.L., and R.E. Feeney, J. Biol. Chem. 1970, 245, 2901–
2908. 
[13] B. Hathaway, Vol. 2015, Yale News, 2012. 
[14] A. L. DeVries, Science 1971, 172, 1152-1155. 
	 54	
[15] A. L. DeVries, Komatsu, S. K., and Feeney, R. E., J. Biol. Chem. 1970, 245, 
2909–2913. 
[16] Y. Lin, J. G. Duman, A. L. DeVries, Biochem. Biophys. Res. Comm. 1972, 46, 
87-92. 
[17] M. M. Harding, P. I. Anderberg, A. D. J. Haymet, Eur. J. Biochem. 2003, 270, 
1381-1392. 
[18] F. V. D. Akker, E. Steensma, W. G. J. Hol, Protein Sci. 1996, 5, 1184-1188. 
[19] L. Chen, A. L. DeVries, C.-H. C. Cheng, Proc. Nat. Acad. Sci. U. S. A. 1997, 
94, 3817-3822. 
[20] F. Franks, E. R. Morris, Biochim. Biophys. Acta 1978, 540, 346-356. 
[21] G. Neelakanta, H. Sultana, D. Fish, J. F. Anderson, E. Fikrig, J. Clin. Invest. 
2010, 120, 3179-3190. 
[22] A. P. A. Wohrmann, Mar. Ecol. Prog. Ser. 1996, 130, 47-59. 
[23] J. A. Ahlgren, C.C. Cheng, J.D. Schrag, and A.L Devries, Comp. Biochem. 
Physiol. B 2006, 144, 290–300  
[24] G. L. Fletcher, M. J. King, M. H. Kao, Can. J. Zoo. 1987, 65, 227-233. 
[25] C. F. Purchase, S. V. Goddard, J. A. Brown, Can. J. Zoo. 2001, 79, 610-615. 
[26] Y. Tomimatsu, J.R. Scherer., Y. Yeh, and R.E  Feeney, J. Biol. Chem. 1976, 
251, 2290–2298. 
[27] E. Berman, A. Allerhand, and A.L.  DeVries, J. Biol. Chem. 1980, 255, 4407–
4410. 
[28] J. A. Drewes, K. L. Rowlen, Biophys. J. 1993, 65, 985-991. 
[29] A. N. Lane, L. M. Hays, R. E. Feeney, L. M. Crowe, J. H. Crowe, Prot. Sci. 
1998, 7, 1555-1563. 
	 55	
[30] A. N. Lane, L. M. Hays, N. Tsvetkova, R. E. Feeney, L. M. Crowe, J. H. 
Crowe, Biophys. J. 2000, 78, 3195-3207. 
[31] D. H. Nguyen, M. E. Colvin, Y. Yeh, R. E. Feeney, W. H. Fink, Biophys. J. 
2002, 82, 2892-2905. 
[32] N. M. Tsvetkova, B. Phillips, V.V. Krishnan, and R.E. Feeney, Biophys. J. 
2002, 82, 464–473. 
[33] M. M. Harding, P. I. Anderberg, A. D. J. Haymet, Eur. J. Biochem. 2003, 270, 
1381-1392. 
[34] J. G. Duman, A. L. Devries, Nature 1974, 247, 237-238. 
[35] N. Hashim, I. Bharudin, D. Nguong, S. Higa, F. Bakar, S. Nathan, A. Rabu, H. 
Kawahara, R. Illias, N. Najimudin, N. Mahadi, A. Murad, Extremophiles 
2013, 17, 63-73. 
[36] M. Smallwood, D. Worrall, L. Byass, L. Elias, D. Ashford, C. J. Doucet, C. 
Holt, J. Telford, P. Lillford, D. J. Bowles, Biochem. J. 1999, 340, 385-391. 
[37] J. G. Duman, V. Bennett, T. Sformo, R. Hochstrasser, B. M. Barnes, J. Insect 
Physiol. 2004, 50, 259-266. 
[38] A. Hakim, J. B. Nguyen, K. Basu, D. F. Zhu, D. Thakral, P. L. Davies, F. J. 
Isaacs, Y. Modis, W. Meng, J. Biol. Chem. 2013, 288, 12295-12304. 
[39] V. Haridas, and S. Naik RSC Adv. 2013, 3, 14199-14219. 
[40] R. S. H. L.A. Graham, G.L. Fletcher, and P.L. Davies PLoS ONE 2013, 8, 
81285-81297. 
[41] C. B. Marshall, A. Chakrabartty, P. L. Davies, J. Biol. Chem. 2005, 280, 
17920-17929. 
[42] L. A. Graham, S. C. Lougheed, K. V. Ewart, P. L. Davies, PLoS ONE 2008, 3, 
e2616. 
	 56	
[43] G. Deng, D. W. Andrews, R. A. Laursen, FEBS Lett. 1997, 402, 17-20. 
[44] D. S. C. Yang, M. Sax, A. Chakrabartty, C. L. Hew, Nature 1988, 333, 232-
237. 
[45] R. S. Hobbs, M.A. Shears, L.A. Graham, P.L. Davies, and G.L. Fletcher, 
FEBS J. 2013, 278, 3699-3711. 
[46] A. Jorov, B. S. Zhorov, D. S. C. Yang, Prot. Sci. 2004, 13, 1524-1537. 
[47] W. Gronwald, M. C. Loewen, B. Lix, A. J. Daugulis, F. D. Sönnichsen, P. L. 
Davies, B. D. Sykes, Biochemistry 1998, 37, 4712-4721. 
[48] Y. Nishimiya, H. Kondo, M. Takamichi, H. Sugimoto, M. Suzuki, A. Miura, 
S. Tsuda, J. Mol. Biol. 2008, 382, 734-746. 
[49] A. A. Antson, D. J. Smith, D. I. Roper, S. Lewis, L. S. D. Caves, C. S. Verma, 
S. L. Buckley, P. J. Lillford, R. E. Hubbard, J. Mol. Biol. 2001, 305, 875-889. 
[50] G. Deng, R. A. Laursen, BBA - Prot. Struct. Mol. 1998, 1388, 305-314. 
[51] Y.-C. Liou, A. Tocilj, P. L. Davies, Z. Jia, Nature 2000, 406, 322-324. 
[52] M. Bar-Dolev, Y. Celik, J. S. Wettlaufer, P. L. Davies, I. Braslavsky, J. R. 
Soc. Interface 2012, 9, 3249-3259. 
[53] A. H. Kwan, K. Fairley, P. I. Anderberg, C. W. Liew, M. M. Harding, J. P. 
Mackay, Biochemistry 2005, 44, 1980-1988. 
[54] Y. Liu, Z. Li, Q. Lin, J. Kosinski, J. Seetharaman, J. M. Bujnicki, J. 
Sivaraman, C. L. Hew, PLoS One 2007, 2, e548. 
[55] A. A. Antson, D. J. Smith, D. I. Roper, S. Lewis, L. S. Caves, C. S. Verma, S. 
L. Buckley, P. J. Lillford, R. E. Hubbard, J. Mol. Biol. 2001, 305, 875-889. 
[56] A. J. Middleton, C. B. Marshall, F. Faucher, M. Bar-Dolev, I. Braslavsky, R. 
L. Campbell, V. K. Walker, P. L. Davies, J. Mol. Biol. 2012, 416, 713-724. 
	 57	
[57] S. P. Graether, M. J. Kuiper, S. M. Gagne, V. K. Walker, Z. Jia, B. D. Sykes, 
P. L. Davies, Nature 2000, 406, 325-328. 
[58] A. J. Middleton, C. B. Marshall, F. Faucher, M. Bar-Dolev, I. Braslavsky, R. 
L. Campbell, V. K. Walker, P. L. Davies, J. Mol. Biol. 2012, 416, 713-724. 
[59] R. Gupta, and R. Deswal, J. Biosci. 2014, 39, 931-935. 
[60] K. B. Storey, and J.M. Storey, in Extremophiles, Vol. 2 (Ed.: C. a. G. Gerday, 
N.), Eolss Publishers, Oxford, UK, 2005, pp. 184-215. 
[61] T. P. Mommsen, and K.B. Storey, Gen. Compo. Endocrinol. 1992, 87, 44-53. 
[62] K. B. Storey, and J.M. Storey, Annu. Rev. Physiol. Rev. 1992, 54, 619-637. 
[63] A. G. Hirsh, Cryobiology 1987, 24, 214-228. 
[64] D. A. Wharton, W. Block, Cryobiology 1997, 34, 114-121. 
[65] B. J. Sinclair, D. Renault, Comp. Biochem. Physiol. A: Mol. Int. Physiol. 2010, 
155, 14-18. 
[66] J. H. Crowe, A. E. Oliver, F. Tablin, Integr. Comp. Biol. 2002, 42, 497-503. 
[67] J. H. Crowe, F. A. Hoekstra, L. M. Crowe, An. Rev. Physiol. 1992, 54, 579-
599. 
[68] K. R. Walters, A. S. Serianni, T. Sformo, B. M. Barnes, J. G. Duman, Proc. 
Nat. Acad. Sci. U. S. A. 2009, 106, 20210-20215. 
[69] K. Walters, Jr., A. Serianni, Y. Voituron, T. Sformo, B. Barnes, J. Duman, J. 
Comp. Physiol. B 2011, 181, 631-640. 
[70] S. Carillo, A. Casillo, G. Pieretti, E. Parrilli, F. Sannino, M. Bayer-Giraldi, S. 
Cosconati, E. Novellino, M. Ewert, J. W. Deming, R. Lanzetta, G. Marino, M. 
Parrilli, A. Randazzo, M. L. Tutino, M. M. Corsaro, J. Am. Chem. Soc. 2015, 
137, 179-189. 
[71] M. I. Gibson, Polym. Chem. 2010, 1, 1141-1152. 
	 58	
[72] J. Barrett, Int. J.  Biochem.  Cell Bio. 2001, 33, 105–117. 
[73] K. Meister, S. Ebbinghaus, Y. Xu, J. G. Duman, A. DeVries, M. Gruebele, D. 
M. Leitner, M. Havenith, Proc. Nat. Acad. Sci. U. S. A. 2013, 110, 1617-1622. 
[74] C. J. Capicciotti, M. Doshi, and R.N. Ben, in Recent Developments in the 
Study of Recrystallization (Ed.: P. Wilson), InTech, 2013, pp. 252-279. 
[75] C. A. Knight, J. Hallett, A. L. DeVries, Cryobiology 1988, 25, 55-60. 
[76] M. M. Tomczak, C. B. Marshall, J. A. Gilbert, P. L. Davies, Biochem. 
Biophys. Res. Comm. 2003, 311, 1041-1046. 
[77] C. Budke, C. Heggemann, M. Koch, N. Sewald, T. Koop, J. Phys. Chem. B 
2009, 113, 2865-2873. 
[78] Y. Celik, R. Drori, N. Pertaya-Braun, A. Altan, T. Barton, M. Bar-Dolev, A. 
Groisman, P. L. Davies, I. Braslavsky, Proc. Natl. Acad. Sci. U. S. A. 2013, 
110, 1309-1314. 
[79] J. Jackman, M. Noestheden, D. Moffat, J. P. Pezacki, S. Findlay, R. N. Ben, 
Biochem. Biophys. Res. Commun. 2007, 354, 340-344. 
[80] A. Fowler, M. Toner, Ann. N. Y. Acad. Sci. 2006, 1066, 119-135. 
[81] C. J. Capicciotti, J.S. Poisson, C.N Boddy, and R.N. Ben., Cryobiology 2015, 
15, 79–89. 
[82] K.-C. Chou, J. Mol. Biol. 1992, 223, 509-517. 
[83] C. A. Knight, E. Driggers, A. L. DeVries, Biophys. J. 1993, 64, 252-259. 
[84] A. D. J. Haymet, L. G. Ward, M. M. Harding, C. A. Knight, FEBS Lett., 430, 
301-306. 
[85] D. Wen, R. A. Laursen, Biophys. J 1992, 63, 1659-1662. 
[86] F. D. Sönnichsen, C. I. DeLuca, P. L. Davies, B. D. Sykes, Structure 1996, 4, 
1325-1337. 
	 59	
[87] N. Hashim, S. Sulaiman, F. Abu Bakar, R. Illias, H. Kawahara, N. Najimudin, 
N. Mahadi, A. Murad, Polar Biol. 2014, 37, 1495-1505. 
[88] A. Wierzbicki, P. Dalal, T. E. Cheatham Iii, J. E. Knickelbein, A. D. J. 
Haymet, J. D. Madura, Biophys. J 2007, 93, 1442-1451. 
[89] J. A. Raymond, A. L. DeVries, Proc. Nat. Acad. Sci. U. S. A. 1977, 74, 2589-
2593. 
[90] J. J. De Yoreo, P. G. Vekilov, Rev. Mineral. Geochem. 2003, 54, 57-93. 
[91] Y. Yeh, R. E. Feeney, Chem. Rev. 1996, 96, 601-618. 
[92] C. A. Knight, C. C. Cheng, A. L. DeVries, Biophys. J. 1991, 59, 409-418. 
[93] Y. Celik, L. A. Graham, Y. F. Mok, M. Bar, P. L. Davies, I. Braslavsky, Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107, 5423-5428. 
[94] C. A. Knight, and A.L DeVries, Science 1989, 245, 505-507. 
[95] D. G. Hall, A. Lips, Langmuir 1999, 15, 1905-1912. 
[96] Y. Wu, J. Banoub, S. V. Goddard, M. H. Kao, G. L. Fletcher, Comp. Biochem. 
Physiol. B: Biochem. Mol. Biol. 2001, 128, 265-273. 
[97] S. Ebbinghaus, K. Meister, B. Born, A. L. DeVries, M. Gruebele, M. 
Havenith, J. Am. Chem. Soc. 2010, 132, 12210-12211. 
[98] R. C. Deller, M. Vatish, D. A. Mitchell, M. I. Gibson, Nat. Commun. 2014, 5, 
3244-3251. 
[99] K. Muldrew, J. Rewcastle, B. J. Donnelly, J. C. Saliken, S. Liang, S. Goldie, 
M. Olson, R. Baissalov, G. Sandison, Cryobiology 2001, 42, 182-189. 
[100] M. Griffith, K. V. Ewart, Biotechnol. Adv. 1995, 13, 375-402. 
[101] Y. Tachibana, G. L. Fletcher, N. Fujitani, S. Tsuda, K. Monde, S.-I. 
Nishimura, Angew. Chem. Int. Ed. 2004, 116, 874-880. 
	 60	
[102] A. Eniade, A. V. Murphy, G. Landreau, R. N. Ben, Bioconjugate Chem. 2001, 
12, 817-823. 
[103] S. Liu, R. N. Ben, Org. Lett. 2005, 7, 2385-2388. 
[104] R. Y. Tam, C. N. Rowley, I. Petrov, T. Zhang, N. A. Afagh, T. K. Woo, R. N. 
Ben, J. Am. Chem. Soc. 2009, 131, 15745-15753. 
[105] R. Y. Tam, S. S. Ferreira, P. Czechura, J. L. Chaytor, R. N. Ben, J. Am. Chem. 
Soc. 2008, 130, 17494-17501. 
[106] C. Heggemann, C. Budke, B. Schomburg, Z. Majer, M. Wißbrock, T. Koop, 
N. Sewald, Amino Acids 2010, 38, 213-222. 
[107] C. Boyer, V. Bulmus, T. P. Davis, V. Ladmiral, J. Liu, S. Perrier, Chem. Rev. 
2009, 109, 5402-5436. 
[108] G. Moad, E. Rizzardo, and S.H. Thang., Aust. J. Chem. 2006, 59, 669–692. 
[109] S. Drotleff, U. Lungwitz, M. Breunig, A. Dennis, T. Blunk, J. Tessmar, A. 
Göpferich, Eur. J. Pharm. Biopharm. 2004, 58, 385-407. 
[110] B. Lee, J. Dalsin, P. Messersmith, in Biol. Adhes. (Eds.: A. Smith, J. Callow), 
Springer Berlin Heidelberg, 2006, pp. 257-278. 
[111] A. Muñoz-Bonilla, M. Fernández-García, Prog. Polym. Sci. 2012, 37, 281-
339. 
[112] C. A. Knight, D. Wen, R. A. Laursen, Cryobiology 1995, 32, 23-34. 
[113] Y. E. Yagci, M. Antonietti, H. G. Börner, Macromol. Rapid Comm. 2006, 27, 
1660-1664. 
[114] T. Inada, S.-S. Lu, Cryst. Growth Des. 2003, 3, 747-752. 
[115] T. Inada, S.-S. Lu, Chem. Phys. Lett. 2004, 394, 361-365. 
[116] T. Inada, P. R. Modak, Chem. Eng. Sci. 2006, 61, 3149-3158. 
	 61	
[117] T. Congdon, R. Notman, M. I. Gibson, Biomacromolecules 2013, 14, 1578-
1586. 
[118] R. C. Deller, T. Congdon, M. A. Sahid, M. Morgan, M. Vatish, D. A. 
Mitchell, R. Notman, M. I. Gibson, Biomater. Sci. 2013, 1, 478-485. 
[119] C. Budke, T. Koop, ChemPhysChem 2006, 7, 2601-2606. 
[120] G. Paradossi, F. Cavalieri, E. Chiessi, C. Spagnoli, M. Cowman, J. Mat. Sci. 
Mat. Med. 2003, 14, 687-691. 
[121] S.-F. Chong, A. A. A. Smith, A. N. Zelikin, Small 2013, 9, 942-950. 
[122] T. Hall-Manning, M. Spurgeon, A. M. Wolfreys, A. P. Baldrick, Food Chem. 
Toxicol. 2004, 42, 321-333. 
[123] R. W. R. Crevel, K.J. Cooper, L.K. Poulsen, L. Hummelshoj, C. Bindslev-
Jensen, A.W. Burks,  and H.A. Sampson, Food Chem. Toxicol. 2007, 45, 79-
87. 
[124] S. Deville, C. Viazzi, J. Leloup, A. Lasalle, C. Guizard, E. Maire, J. Adrien, L. 
Gremillard, PLoS ONE 2011, 6, e26474. 
[125] O. Mizrahy, M. Bar-Dolev, S. Guy, I. Braslavsky, PLoS ONE 2013, 8, 
e59540. 
[126] J. E. Lovelock, C. Polge, Biochem. J. 1954, 58, 618-622. 
[127] J. E. Lovelock, Biochem. J. 1954, 56, 265-270. 
[128] T. R. Henderson, R. F. Henderson, J. L. York, Ann. N. Y. Acad. Sci. 1975, 243, 
38-53. 
[129] Y. Murata, T. Watanabe, M. Sato, Y. Momose, T. Nakahara, S.-i. Oka, H. 
Iwahashi, J. Biol. Chem. 2003, 278, 33185-33193. 
[130] M. Plachinta, T. Zhang, D. M. Rawson, Cryoletters 2004, 25, 415-424. 
	 62	
[131] T. Arakawa, J. F. Carpenter, Y. A. Kita, J. H. Crowe, Cryobiology 1990, 27, 
401-415. 
[132] G. M. Fahy, B. Wowk, J. Wu, S. Paynter, Cryobiology 2004, 48, 22-35. 
[133] B. T. Storey, E. E. Noiles, K. A. Thompson, Cryobiology 1998, 37, 46-58. 
[134] A. Eroglu, J. A. Lawitts, M. Toner, T. L. Toth, Cryobiology 2003, 46, 121-
134. 
[135] I. S. Bhandal, R. M. Hauptmann, J. M. Widholm, Plant Physiol. 1985, 78, 
430-432. 
[136] L. L. Kuleshova, D. R. MacFarlane, A. O. Trounson, J. M. Shaw, Cryobiology 
1999, 38, 119-130. 
[137] G. Strauss, P. Schurtenberger, H. Hauser, BBA - Biomembranes 1986, 858, 
169-180. 
[138] C. S. Pereira, P. H. Hünenberger, J. Phys. Chem. B 2006, 110, 15572-15581. 
[139] T. J. Anchordoguy, A. S. Rudolph, J. F. Carpenter, J. H. Crowe, Cryobiology 
1987, 24, 324-331. 
[140] J. F. Carpenter, T. N. Hansen, Proc. Nat. Acad. Sci. U. S. A. 1992, 89, 8953-
8957. 
[141] C. Koshimoto, P. Mazur, Cryobiology 2002, 45, 49-59. 
[142] S. Qadeer, M. A. Khan, M. S. Ansari, B. A. Rakha, R. Ejaz, A. U. Husna, M. 
Ashiq, R. Iqbal, N. Ullah, S. Akhter, Anim. Reprod. Sci. 2014, 148, 26-31. 
[143] J.-H. Wang, Cryobiology 2000, 41, 1-9. 
[144] H. Bagis, T. Akkoç, A. Tasş, D. Aktoprakligil, Mol. Reprod. Dev. 2008, 75, 
608-613. 
[145] J. F. Carpenter, T. N. Hansen, Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 8953-
8957. 
	 63	
[146] M. M. Tomczak, D. K. Hincha, S. D. Estrada, W. F. Wolkers, L. M. Crowe, R. 
E. Feeney, F. Tablin, J. H. Crowe, Biophys. J 2002, 82, 874-881. 
[147] M. M. Tomczak, D. K. Hincha, S. D. Estrada, R. E. Feeney, J. H. Crowe, BBA 
- Biomembranes 2001, 1511, 255-263. 
[148] S. Matsumoto, M. Matsusita, T. Morita, H. Kamachi, S. Tsukiyama, Y. 
Furukawa, S. Koshida, Y. Tachibana, S.-I. Nishimura, S. Todo, Cryobiology 
2006, 52, 90-98. 
[149] K. Matsumura, S.-H. Hyon, Biomaterials 2009, 30, 4842-4849. 
[150] J. C. Kefer, A. Agarwal, E. Sabanegh, Int. J. Urol. 2009, 16, 449-457. 
[151] D. R. Câmara, S. V. Silva, F. C. Almeida, J. F. Nunes, M. M. P. Guerra, 
Theriogenology 2011, 76, 342-350. 
[152] W. Zhang, K. Yi, C. Chen, X. Hou, X. Zhou, Anim. Reprod. Sci., 132, 123-
128. 
[153] J. Gadea, F. García-Vazquez, C. Matás, J. C. Gardón, S. Cánovas, D. Gumbao, 
J. Androl. 2005, 26, 396-404. 
[154] E. Uchendu, M. Muminova, S. Gupta, B. Reed, In Vitro Cell. Dev. Biol. - 
Plant 2010, 46, 386-393. 
[155] G. John Morris, E. Acton, Cryobiology 2013, 66, 85-92. 
[156] G. Morris, E. Acton, K. Faszer, A. Franklin, H. Yin, R. Bodine, J. Pareja, N. 
Zaninovic, and R. Gosden, Reprod. Biomed. Online 2006, 13, 421-426. 
[157] R. Spindler, B. Rusenhahn, and B. Glassmacher, Cryobiology 2011, 63, 306-
307. 
[158] F. Fonseca, M. Marin, G. J. Morris, Appl. Environ. Microbiol. 2006, 72, 6474-
6482. 
	 64	
[159] X. Han, H. B. Ma, C. Wilson, J. K. Critser, Microfluid. Nanofluid. 2008, 4, 
357-361. 
[160] R. V. Devireddy, D. J. Swanlund, T. Olin, W. Vincente, M. H. T. Troedsson, 
J. C. Bischof, K. P. Roberts, Biol. Reprod. 2002, 66, 222-231. 
[161] S. Kumar, J. D. Millar, P. F. Watson, Cryobiology 2003, 46, 246-253. 
[162] W. F. Rall, D. S. Reid, J. Farrant, Nature 1980, 286, 511-514. 
[163] D. G. Whittingham, M. Wood, J. Farrant, H. Lee, J. A. Halsey, J. Reprod. 
Fertil. 1979, 56, 11-21. 
[164] L. E. Towill, P. Mazur, Plant Physiol. 1976, 57, 290-296. 
[165] P. Mazur, Am. J. physiol. 1984, 247, C125-142. 
[166] M. A. Henry, E. E. Noiles, D. Gao, P. Mazur, J. K. Critser, Fertil. Steril. 1993, 
60, 911-918. 
[167] NHS, Vol. 2015, 2015. 
[168] J. R. Hess, Blood Trans. 2010, 8, s9-s15. 
[169] J. D. R. Kurach, R. Almizraq, B. Bicalho, J. P. Acker, J. L. Holovati, 
Transfusion 2014, 54, 1595-1603. 
[170] R. L. Sparrow, Blood Transfus. 2012, 10, s7-s11. 
[171] R. MacDonald, Anaesthesia 1977, 32, 544-553. 
[172] D. Wang, J. Sun, S. B. Solomon, H. G. Klein, C. Natanson, Transfusion 2012, 
52, 1184-1195. 
[173] I. Chin-Yee, N. Arya, M. S. d'Almeida, Transfus. Sci. 1997, 18, 447-458. 
[174] L. Van de Watering, Vox Sang. 2011, 100, 36-45. 
[175] M. G. Egidi, A. D’Alessandro, G. Mandarello, L. Zolla, Blood Transfus. 2010, 
8, s73-s81. 
	 65	
[176] I. B. Bakaltcheva, C. O. Odeyale, B. J. Spargo, Biochim. Biophys. Acta 1996, 
1280, 73-80. 
[177] C. R. Valeri, Transfusion 1975, 15, 195-218. 
[178] T. Peyrard, B. N. Pham, P. Y. Le Pennec, P. Rouger, Immunohematology / 
American Red Cross 2009, 25, 13-17. 
[179] T. Takahashi, A. Hirsh, E. Erbe, R. J. Williams, Biophys. J. 1988, 54, 509-
518. 
[180] M. J. G. Thomas, E. S. Parry, S. G. Nash, S. H. Bell, Transfus. Sci. 1996, 17, 
385-396. 
[181] L. E. McGann, Cryobiology 1978, 15, 382-390. 
[182] R. R. Bruno, W. Neuhaus, N. Roewer, C. Wunder, M. A. Schick, Anesth. 
Analg. 2014, 119, 570-577. 
[183] J. P. Nolan, M. G. Mythen, Br. J. Anaesth. 2013, 111, 321-324. 
[184] A. W. Rowe, E. Eyster, A. Kellner, Cryobiology 1968, 5, 119-128. 
[185] H. Chao, P. L. Davies, J. F. Carpenter, J. Exp. Biol. 1996, 199, 2071-2076. 
[186] R. J. Deans, A. B. Moseley, Exp. Hematol. 2000, 28, 875-884. 
[187] L. K. Branski, G. G. Gauglitz, D. N. Herndon, M. G. Jeschke, Burns 2009, 35, 
171-180. 
[188] F. H. Gage, J. Ray, L. J. Fisher, Annu. Rev. Neurosci. 1995, 18, 159-192. 
[189] J. Hanna, A. Hubel, Organogenesis 2009, 5, 134-137. 
[190] M. K. Mateos, D. Barbaric, S.-A. Byatt, R. Sutton, G. M. Marshall, Transl. 
Pediatr. 2015, 4, 76-92. 
[191] H. Kolb, J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. 
Heim, W. Wilmanns, Blood 1990, 76, 2462-2465. 
	 66	
[192] J. P. Lewis, M. Passovoy, S. A. Conti, P. A. McFate, F. E. Trobaugh, Jr., 
Transfusion 1967, 7, 17-32. 
[193] D. Fountain, M. Ralston, N. Higgins, J. B. Gorlin, L. Uhl, C. Wheeler, J. H. 
Antin, W. H. Churchill, R. J. Benjamin, Transfusion 1997, 37, 585-591. 
[194] C. B. Ware, A. M. Nelson, C. A. Blau, BioTechniques 2005, 38, 879-880, 882-
873. 
[195] S. Mollamohammadi, A. Taei, M. Pakzad, M. Totonchi, A. Seifinejad, N. 
Masoudi, H. Baharvand, Hum. Reprod. 2009, 24, 2468-2476. 
[196] B. E. Reubinoff, M. F. Pera, G. Vajta, A. O. Trounson, Hum. Reprod. 2001, 
16, 2187-2194. 
[197] R. T. Francoeur, Oryx 1972, 11, 364-366. 
[198] C. Polge, A. U. Smith, A. S. Parkes, Nature 1949, 164, 666. 
[199] D. Royere, C. Barthelemy, S. Hamamah, J. Lansac, Hum. Reprod. Update 
1996, 2, 553-559. 
[200] J. Beirao, L. Zilli, S. Vilella, E. Cabrita, R. Schiavone, M. P. Herraez, Biol. 
Reprod. 2012, 86, 59. 
[201] A. Bernard, B. Fuller, Hum. Reprod. Update 1996, 2, 193-207. 
[202] A. Borini, M. A. Bonu, G. Coticchio, V. Bianchi, M. Cattoli, C. Flamigni, 
Fertil. Steril. 2004, 82, 601-605. 
[203] D. L. Wright, A. Eroglu, M. Toner, T. L. Toth, Reprod. BioMed. Online 2004, 
9, 179-186. 
[204] S. J. Paynter, B. J. Fuller, Methods. Mol. Biol. 2007, 368, 313-324. 
[205] S. P. Leibo, Theriogenology 2008, 69, 37-47. 
[206] L. O'Neil, S. J. Paynter, B. J. Fuller, R. W. Shaw, A. L. DeVries, Cryobiology 
1998, 37, 59-66. 
	 67	
[207] J. W. Jo, B. C. Jee, C. S. Suh, S. H. Kim, PLoS ONE 2012, 7, e37043. 
[208] R. Thorat, A. Ingle, Nat. Protoc. 2012, 62, 1038-1044. 
[209] A. M. Van Wagtendonk-De Leeuw, J. H. G. Den Daas, T. A. M. Kruip, W. F. 
Rall, Cryobiology 1995, 32, 157-167. 
[210] S. Martinez-Paramo, V. Barbosa, S. Perez-Cerezales, V. Robles, M. P. 
Herraez, Cryobiology 2009, 58, 128-133. 
[211] K. Nishijima, M. Tanaka, Y. Sakai, C. Koshimoto, M. Morimoto, T. 
Watanabe, J. Fan, S. Kitajima, Cryobiology 2014, 69, 22-25. 
[212] J. M. Shaw, C. Ward, A. O. Trounson, Hum. Reprod. 1995, 10, 396-402. 
[213] HRSA, Vol. 2015, US Department of Health and Human Services, 2015. 
[214] R. D. Hughes, R. R. Mitry, A. Dhawan, Transplantation 2012, 93, 342-347. 
[215] J. H. Southard, T. M. van Gulik, M. S. Ametani, P. K. Vreugdenhil, S. L. 
Lindell, B. L. Pienaar, F. O. Belzer, Transplantation 1990, 49, 251-257. 
[216] C. Terry, A. Dhawan, R. R. Mitry, R. D. Hughes, Cryobiology 2006, 53, 149-
159. 
[217] S. C. Strom, R. A. Fisher, M. T. Thompson, A. J. Sanyal, P. E. Cole, J. M. 
Ham, M. P. Posner, Transplantation 1997, 63, 559-569. 
[218] F. Bertuzzi, S. Marzorati, A. Secchi, Cur. Mol. Med. 2006, 6, 369-374. 
[219] P. B. Stiegler, V. Stadlbauer, S. Schaffellner, G. Halwachs, C. Lackner, O. 
Hauser, F. Iberer, K. Tscheliessnigg, Transplant Proc. 2006, 38, 3026-3030. 
[220] M. J. Taylor, S. Baicu, Organogenesis 2009, 5, 155-166. 
[221] S. Matsumoto, M. Matsusita, T. Morita, H. Kamachi, S. Tsukiyama, Y. 
Furukawa, S. Koshida, Y. Tachibana, S.-I. Nishimura, S. Todo, Cryobiology 
2006, 52, 90-98. 
	 68	
[222] G. Amir, L. Horowitz, B. Rubinsky, B. S. Yousif, J. Lavee, A. K. Smolinsky, 
Cryobiology 2004, 48, 273-282. 
[223] B. Leader, Q. J. Baca, D. E. Golan, Nat. Rev. Drug Discov. 2008, 7, 21-39. 
[224] P. Matejtschuk, in Cryopreservation and Freeze-Drying Protocols, Vol. 368 
(Eds.: J. Day, G. Stacey), Humana Press, 2007, pp. 59-72. 
[225] J. F. Carpenter, J. H. Crowe, Cryobiology 1988, 25, 244-255. 
[226] E. Cao, Y. Chen, Z. Cui, P. R. Foster, Biotechnol. Bioeng. 2003, 82, 684-690. 
[227] A. Hedoux, L. Paccou, S. Achir, Y. Guinet, J. Pharm. Sci. 2013, 102, 2484-
2494. 
[228] N. K. Jain, I. Roy, Protein Sci. 2009, 18, 24-36. 
[229] J. Lee, E.-W. Lin, U. Y. Lau, J. L. Hedrick, E. Bat, H. D. Maynard, 
Biomacromolecules 2013, 14, 2561-2569. 
 
 
  
	 69	
Chapter 2 
2. Latent Ice Recrystallization Inhibition Activity in 
Non-Antifreeze Proteins; Ca2+ Activated Plant 
Lectins and Cation-Activated Antimicrobial Peptides. 
	
D. E. Mitchell and M. I. Gibson, Biomacromolecules. 2015, Accepted. 
 
This chapter contains a paper describing ice recrystallization inhibition (IRI) activity 
of non-antifreeze proteins. Firstly describing the investigation of l-type lectins for 
their similarity to antifreeze proteins and their ability to inhibit ice crystal growth. 
This is followed by the examination of the short amphipathic protein nisin A and 
associated IRI activity. DEM undertook all experimental work. Both authors wrote the 
manuscript. 
 
2.1.   Abstract 
Organisms living in polar regions have evolved a series of antifreeze (glyco) proteins 
(AFGPs) to enable them to survive by modulating the structure of ice. These proteins 
have huge potential in cellular cryopreservation, ice-resistant surfaces, frozen food 
and cryosurgery, but are limited by their relatively low availability and questions 
regarding their mode of action. The identification of new structures and sequences 
	 70	
capable of inhibiting ice growth is crucial to aid our understanding of these. Sequence 
analysis found that human l-type lectins have high homology to type II AFPs, but 
these lectins are not widely available. Here we show that calcium binding plant l-type 
lectins, which have similar biological function to human c-type lectins (glycan 
recognition), but no sequence homology to AFPs, display potent calcium dependant 
ice recrystallization inhibition (IRI) activity. This IRI can be ‘switched on/off’ simply 
by changing Ca2+ concentration. To prove that many proteins may exist with the 
potential to display IRI, a second motif was considered; amphipathicity. All known 
AFPs have defined hydrophobic/hydrophilic domains, rationalising this. The cheap 
and widely used antimicrobial Nisin, was found to have cation-dependant IRI activity, 
controlled by either acid, or addition of histidine-binding ions such as zinc or nickel, 
which promote its amphipathic structure. These results demonstrate a new approach 
to the identification of antifreeze protein mimetic macromolecules and may help shed 
light on their underlying mechanisms of action as well as developing ‘minimum 
synthetic mimics’ of AFPs.  
 
2.2.   Introduction 
Antifreeze proteins and glycoproteins (AF(G)Ps) are found in a wide variety of 
different organisms that habitually experience freezing temperatures. They were 
initially discovered in Arctic and Antarctic fish species but have since been reported 
in a wide range of plants and insects.[1-5] AFPs provide protection through two main 
methods, thermal hysteresis and ice recrystallization inhibition (IRI).[6] The former is 
the depression of the freezing point relative to that of the melting point,[7] while the 
latter is the slowing of the rate of ice crystal growth (Ostwald ripening) process.[8] The 
underlying mechanisms for each action are still under investigation and it has 
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emerged that TH and IRI activities are not necessarily linked. In 2003 Enaide et al. 
reported that simplified AFGPs could retain potent IRI activity while displaying 
essentially zero TH activity.[9] Furthermore, Ben and co-workers have developed a 
range of structures that posses only IRI activity including carbohydrate based 
surfactants, synthetic antifreeze proteins and several small molecules.[10-12]  Davies et 
al. have also shown that the magnitude of TH does not always scale with IRI.[13]  
IRI-active compounds could have huge application in frozen foods, cryosurgery and 
cryopreservation.[14-16] For example, ice crystal growth (recrystallization) during 
thawing has been shown to be a major contributor to cell death during cellular 
cryopreservation. Carpenter et al. showed that AFPs could enhance cryopreservation 
of red blood cells but benefit was limited by the onset of dynamic ice shaping (DIS), 
which actually resulted in reduced cell recovery.[17] There are various conflicting 
results on AF(G)P supplemented cryopreservation showing both benefit and 
detriment, where detrimental effects are normally due to DIS.[16, 18-19] Despite these 
challenges, there is an urgent need for new cryopreservatives as alternatives to the 
current state-of-the-art formulations, which employs (toxic) organic solvents and also 
for the preservation of cell types which cannot currently be frozen. Ben et al. have 
shown that IRI specific glycopeptides and alkyl glycosides have shown some 
improvement in cryopreservation.[20] In addition, Gibson et al. have demonstrated that 
IRI-active synthetic polymers dramatically enhance non-vitreous cryopreservation of 
red blood cells.[21] Despite these structurally diverse IRI mimetics, an understanding 
of the structural motifs essential for activity remain elusive.   
 
Another outstanding challenge is the development of ‘smart’ AFP derivatives with 
switchable activity, enabling them to be activated both spatially and temporally. 
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Current understanding has revealed that amphiphilicity (segregated hydrophilic and 
hydrophobic domains) are needed for IRI activity, with most AFPs showing defined 
regions.[22] Ben et al. have shown that hydrophobically modified saccharides have 
(rather weak) IRI activity associated with their amphiphilicity.[10] Despite this 
progress, there are still few compounds which are potent IRI inhibitors, which in turn 
has limited their application and biophysical studies to understand their remarkable 
properties to slow ice growth.  
 
AFPs display a wide variety of secondary and tertiary structures and amino acid 
sequences while all binding to the same ice substrate.[23] AFPs have been grouped into 
several different sub-types based on structure, for example type 1 AFPs consist of a 
long amphipathic alpha helix,[24] while type 2 AFPs are cysteine rich globular proteins 
containing several disulphide bonds.[25] In an attempt to understand the evolutionary 
origins of AFPs, sequence alignment studies have been undertaken. This has revealed 
strong similarity to other families of proteins such as lectins and apolipoproteins.[26] A 
defining characteristic of these protein families is that they discriminate between 
related classes of molecules; for example lectins bind specific carbohydrates. Due to 
this similarity it may be possible that there exists many protein structures, that subject 
to the correct evolutionary conditions could have become AFPs and hence might 
display some latent activity. To this end a c-type lectin from rattlesnake Crotalus atrox 
has been evaluated for specific ice crystal face binding, although not IRI activity.[27]  
 
The aim of this study was to investigate if non-antifreeze proteins can still display ice 
recrystallization inhibition activity, based on their functional and structural 
similarities to known AFPs, rather than the traditional chemical biology approaches 
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based on sequence similarities. The ability to modulate AFP function by application of 
external stimuli is also studied as a route to ‘smart’ AFP mimetics.  
2.3.   Results and Discussion 
Inspired by the work of Graham et al. and others[25, 28] which unravelled the genetic 
history of AFPs, sequence alignment of type 2 AFP from the Sea raven, Hemitripterus 
americanus against all known proteins within the protein databank (PBD) was 
conducted to identify those proteins with high sequencial homology. This search 
agreed with previous reports, showing that in addition to other type 2 AFPs a range of 
l-type lectins also had high sequential similarity with the overall sequence identified 
as a member of the lectin superfamily. c-type lectins most closely related to type 2 
AFP include human langerin (c-type transmembrane protein on Langerhans cells), 
human lithostathine and a rat mannose binding protein, Figure 2.1. Interestingly 
lithostathine has been found to play a role in the prevention of pancreatic stones by 
preventing calcite crystal growth, a somewhat similar role to an AFP suggesting there 
may be common crystallization-inhibiting motifs which has evolved. As reported by 
Rubinsky et al. a c-type lectin from rattle snake Crotalus atrox has Ca2+ dependent ice 
shaping activity, but no reports on IRI activity have been made.[27]  
 
Figure 2.1. Schematic of homology between type 2 antifreeze proteins, c-lectins, 
and the functional relationship to plant lectins. 
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While the lectins described above are most sequentially similar to type 2 AFP, they 
can be challenging to produce in large quantities, requiring (mammalian cell) 
recombinant expression. Furthermore, the use of human lectins (or rattlesnake venom) 
in biomedical applications would be limited by immunogenicity and associated 
problems. Therefore, we decided to move on from sequence similarity, to functional 
similarities. Specifically, the calcium binding l-type lectins found in plants; some 
plant lectins have found medical applications such as banana lectin in HIV 
inhibition.[29] These have structural similarities (particularly in the carbohydrate 
recognition domain; CRD) to the human c-type lectins, but do not have significant 
relationship to native type 2 AFPs. A range of plant lectins were selected based on 
them being commercially availability in reasonable quantities; concanavalin A (ConA, 
Mw 104 kDa), soybean agglutinin (SBA, Mw 120 kDa) and ricinus communis 
agglutinin 120 (RCA120, Mw 120 kDa).  
 
To determine if the lectins demonstrate any antifreeze-protein associated activity, a 
modified ‘splat’ assay was employed to screen for ice recrystallization inhibition 
(IRI). Briefly, buffered 10 µL solutions of the analyte of interest were dropped onto a 
glass slide chilled to -80 °C to produce a wafer of small ice crystals. These were 
annealed at -8 °C and the average ice crystal size recorded after a fixed period of time, 
and compared to a negative control to give the mean largest grain size (MLGS). The 
smallest size (as a percentage) from this assay is ~ 20 % (as an ice crystal cannot have 
zero size). HEPES buffer was employed in place of the normal PBS to enable the 
addition of divalent ions (Ca2+), which cannot be used in PBS (due to calcium 
phosphate precipitation). Assessment of the IRI activity of ConA at 5 mg.mL-1 is 
shown in Figure 2.2A. As can be seen, ConA showed no activity, being statistically 
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identical to our negative control, PEG (poly(ethylene glycol)).[30] However, for ConA 
to bind its native glycans (α-mannose/glucose), it is essential for Ca2+ to be present 
(or similar divalent ions) in the carbohydrate recognition domain inspiring us to 
repeat the experiment in the presence of CaCl2. Under these conditions, there was 
definite IRI activity, suggesting that ConA is also a l-type antifreeze protein, which 
can be ‘turned on’ (or off) by addition of calcium ions. Calcium dependent ice binding 
has also been reported for Rainbow smelt and Atlantic herring fish species and the 
Antarctic bacteria Marinomonas primoryensis.[31-32]  
 
Figure 2.2. IRI activity of ConA in HEPES buffer. (A) Effect of (5 mg.mL-1) CaCl2 
addition. [ConA] = 5 mg.mL-1, [CaCl2] = 5 mg.mL-1, [PEG] = 5 mg.mL-1; (B). 
Concentration dependence of ConA with 5 mg.mL-1 CaCl2. Error bars represent ± SD 
from a minimum of 3 repeats. MLGS = mean largest grain size relative to HEPES 
buffer or HEPES and calcium chloride buffer control. ** Signifies p < 0.01 relative to 
PEG control.  
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Control experiments of CaCl2 doped buffer revealed the IRI activity was not due to 
the metal ions (unlike for example ZrAc which has some unique activity to inhibit ice 
growth) (ESI, Appendix 1).[33] Concentration-dependence of the IRI activity was also 
measured, Figure 2.2B. Whilst far weaker than native AFPs, PVA, this activity is 
stronger than synthetic analogues such as poly(ampholytes) which are potent 
cryopreservation enhancers.[34-36]  
 
ConA exists as a tetramer around pH 7, but at lower pHs it dissociates into its 
monomeric or dimeric units, providing an accessible route to study the IRI activity in 
more detail. In pH 5 acetate buffer ConA is a dimer and showed statistically 
significant, but only slightly enhanced activity relative to the native tetramer 
measured at pH 7.4 (see ESI, Appendix 1). This implies that the overall 
tertiary/quaternary structure of the protein might not be essential for activity and that 
the carbohydrate recognition domain (which has similarity to ice binding domains) is 
the crucial component. To evaluate if this is a general phenomena, or unique to ConA, 
the lectins SBA and RCA120 were also evaluated by the splat assay, with and without 
Ca2+, and the results shown in Figure 2.3.  
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Figure 2.3. IRI activity of l-type lectins with and without 5 mg.mL-1 CaCl2. Error 
bars represent ± SD from a minimum of 3 repeats, MLGS = mean largest grain size 
relative to HEPES buffer or HEPES and calcium chloride buffer control. ** Signifies 
p < 0.01 relative to PEG control. 
 
Rather remarkably, both SBA and RCA inhibited ice crystal growth at just 5 mg.mL-1 
with both requiring the addition of Ca2+ to ‘switch on’ the activity, to similar extent to 
ConA. To rule out this being a non-specific effect, ConA and SBA were both 
denatured (confirmed by circular dichroism, ESI, Appendix 1) by boiling and re-
tested. Pleasingly, this reduced their activity in both cases, confirming it was a 
specific structural feature of the proteins producing activity not a broad 
macromolecular effect, Figure 2.4A. In addition the fact that catalase has no activity 
demonstrates that this is not a common property of all proteins. It should be noted that 
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heating to 80 °C is not expected to completely denature (and there will be some 
refolding) hence the MLGS value does not return to 100 %. The results above suggest 
there are structural features of the lectin, assumed to be related to the carbohydrate 
recognition domain that generates the IRI activity.  
 
The effect of adding in competing carbohydrate ligands, which will bind the CRD (in 
presence of Ca2+) was measured and the results shown in Figure 2.4B. There was a 
very weak enhancement in activity upon addition of the sugars, which in the case of 
SBA/GalNAc was statistically significant but was only small. This would appear to 
rule out the CRD (carbohydrate recognition domain) directly binding to the ice (as the 
sugars would be competing ligands). Alternatively, it might be that the sugar has a 
similar hydrogen bonding network as the water, and therefore it is tolerated. A 
detailed site-directed mutagenesis study would be required to undercover this, which 
is beyond the scope of the present study. No ice shaping was observed (which would 
imply specific ice face interaction), but this effect is normally only seen at high AFP 
concentrations (>20 mg.mL-1); it was not possible to obtain homogenous protein 
solutions at these concentrations. Therefore, direct ice interaction cannot be ruled out, 
but there is building evidence that many (macro)molecules can inhibit ice growth 
without ice binding by disruption of the quasi-liquid layer/eutectic phase interface.[30, 
35, 37]  
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Figure 2.4. IRI inhibition/activation studies of SBA and RCA. (A) Effect of 
denaturation; (B) IRI effect of the addition of competitive carbohydrates (10 mM). 
GalNac = N-acetylgalactosamine, Gal = galactose. Error bars represent ± SD from a 
minimum of 3 repeats, MLGS = mean largest grain size relative to HEPES buffer or 
HEPES and calcium chloride buffer control. ** signifies p < 0.01 relative to 
respective undenatured sample (or undenatured ConA for catalase) * signifies p < 
0.05 relative to respective sugar-free lectin solution. 
 
The reasons for the observed activity remains unclear (as with many features of 
AF(G)Ps), but given the evolutionary origins of type 2 AFPs from lectins, perhaps not 
surprisingly. Lectins evolved to recognize the difference between sugars and water – a 
challenging task as both are essentially hydrated –OH groups. An antifreeze protein 
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could be considered to discriminate between water and ice – a similar problem. The 
current understanding of antifreeze protein suggests that amphipathic characteristic is 
required – spatially defined hydrophilic and hydrophobic faces. Our initial analysis of 
the lectins’ crystal structures did not show an obvious amphiphilicity, but 
crystallography only provides a static, not dynamic, description of protein structure 
and function. 
 
Inspired by the above observations, we considered the possibility that there might be a 
wider range of proteins (or peptides), which might have the structural features 
essential for reproducing IRI properties, but due to a lack of evolutionary stress have 
never specifically developed into antifreeze proteins. Given the amphipathic structure 
of AFPs, it would seem that other amphipathic proteins would make good lead 
molecules. Host-defense, cationic antimicrobial peptides are well-known amphipathic 
proteins and several are commercially available.[38] To test our hypothesis that latent 
antifreeze activity might remain, nisin A was selected as a model antimicrobial. Nisin 
is readily available, low molecular weight (34 amino acids, 3354 g.mol-1) and widely 
used in the dairy industry. It has also been recently reported the Xodes Scapularis tick 
antifreeze glycoprotein has antimicrobial activity proving additional support to the 
hypothesis of re-purposing antimicrobial peptides.[39] To function as an antimicrobial 
nisin A requires a sufficiently low pH to protonate histidine 27 and 31, which enforces 
the correct amphipathic conformation to enable cell membrane disruption/pore 
formation.[40-42] Figure 2.5 shows a space-filling model illustrating the 
hydrophilic/hydrophobic domains of nisin A compared to Type 1 AFP from Winter 
flounder, illustrating the spatiality segregated hydrophilic and hydrophobic domains 
which we propose is a key component in IRI activity. This peptide provides a 
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convenient tool to test the amphipathic hypothesis and the IRI activity of nisin A was 
tested as a function of pH and concentration, Figure 2.6. It should be noted that in 
Figure 2.6A, activity at each pH is reported relative to a blank of that pH solution. 
 
 
Figure 2.5. Space filling models of peptides with hydrophilic (red) and 
hydrophobic (blue) domains indicated. A) Winter flounder type I AFP; B) Nisin A. 
 
The results shown reveal that nisin A has clear IRI activity comparable to several 
other synthetic macromolecules described in the literature.[34-35] Based on its known 
pH dependent antimicrobial activity, we surmise that protonation of the Histidine 
residues, (pKa value ~ 6) in the acetate buffer (pH = 5) was the controlling factor. 
This switchable activity is unique, and may provide a tool for targeted activation of 
AFP-properties, in applications such as cryo-surgery.[43] 
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Figure 2.5. IRI activity of nisin A. (A) pH dependence; (B) concentration 
dependence at pH 5. Error bars represent ± SD from a minimum of 3 repeats, MLGS 
= mean largest grain size relative to PBS buffer or pH 5 acetate buffer controls. ** 
signifies p < 0.01 relative to control. 
 
However, pH itself may not always be a useful (or desirable) trigger. Histidines are 
well know to bind to metal ions such as nickel or zinc (forming the basis of His-tag 
purifications for example),[44] and we therefore reasoned that addition of these ions 
might also be able to promote the formation of the correct conformation for IRI 
activity. Figure 2.6 shows IRI activity of nisin A with addition of these metal ions, 
compared to control solutions containing the metal ions alone. 
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Figure 2.6. Metal ion activation of nisin A IRI activity upon addition of nickel 
and zinc acetate at 5mg.mL-1. A) In PBS buffer at pH = 7.4; B) Acetate buffer, pH = 
5. Error bars represent ± SD from a minimum of 3 repeats, MLGS = mean largest 
grain size relative to PBS buffer , pH 5 acetate buffer controls or buffer with nickel 
acetate added only. ** signifies p < 0.01 relative to Nisin in PBS buffer only. 
 
For both Zn and Ni additives in PBS (pH 7.4, no protonation of his-residues) there 
was clear ‘switching on’ of activity compared to the buffer alone. This demonstrates 
that metal ions can be used in place of H+ to induce the conformation changes in nisin 
A required for activity, although the magnitude of IRI is slightly less. A control 
experiment conducted at pH 5 (acetate buffer) where histidines were already 
protonated showed no effect of the metal ions, ruling out other interactions. These 
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results show that easily available, relatively small, antimicrobial peptides have latent 
IRI activity that can be activated by the use of specific metal ions providing a new 
paradigm in AFP biomimetics. Considering the huge progress in the rational design of 
antimicrobial peptide mimics, it is anticipated that a similar approach will yield new 
IRI active compounds, without the need to mimic AFP structure. These findings will 
aid our understanding of ice growth inhibiting macromolecules and aid in the pursuit 
of cell/tissue cryopreservation for regenerative medicine, in addition to other fields 
where ice is a problem. 
 
2.4.   Conclusions 
Here we demonstrate that proteins and peptides with little structural homology to 
antifreeze proteins can have surprisingly potent ice recrystallization inhibition 
activity, based upon two motifs. L-type plant lectins, which are widely available and 
are available at relatively low cost are shown to be calcium-dependent ice 
recrystallization inhibitors, with their activity easier modulated by the addition of 
calcium, providing some ‘switching’ capability. The activity was shown to be present 
in three different plant lectins, suggesting it is a universal property of lectins. As 
antifreeze proteins are known to be amphipathic, a second class of peptides was also 
tested, antimicrobial peptides. The 34 amino acid peptide nisin A was found to have 
surprisingly strong IRI activity that was activated by a change in pH and 
consequently, protonation of its histidine residues, again providing a unique switch. 
To enable antifreeze activity at physiological pH, nickel or zinc ions were employed 
as the stimulus, which can bind the histidine residues and promote the same 
conformation change. These results show that new antifreeze protein function can be 
discovered in non-cold acclimatized species and that this provides a route to 
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‘switchable’ antifreeze materials whose function can be tuned by externally applied 
stimuli, and also eventually leading towards multifunctional macromolecular 
cryoprotectants.  
2.5.   Experimental 
2.5.1.   Materials 
Poly (ethylene glycol) (100 kDa), HEPES, sodium acetate, glacial acetic acid, sodium 
hydroxide pellets, calcium chloride, glyceraldehyde, nisin A, zinc acetate and nickel 
acetate were purchased from Sigma Aldrich (UK). Lectins; concanavalin A (Con-A), 
soybean agglutinin (SBA) and ricinus communis agglutinin 120 (RCA120) were 
purchased from Vector Laboratories (USA). Nisin was dialyzed against PBS buffer 
for 24 hours (5 buffer changes) to ensure that all salts were removed before use. 
HEPES buffer solution (10 mM) was prepared using solid powder and adjusted to pH 
7.4 using sodium hydroxide pellets. Sodium acetate buffer (0.2 M) was prepared by 
mixing sodium acetate and glacial acetic acid in deionized water and adjusted to pH 5 
with sodium hydroxide pellets. 
 
2.5.2.   Ice recrystallisation inhibition (splat) assay. 
Ice recrystallisation inhibition was measured using a modified splay assay.[45] A 10 µL 
sample of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a 
chilled glass coverslip sat on a piece of polished aluminium placed on dry ice. Upon 
hitting the chilled glass coverslip, a wafer with diameter of approximately 10 mm and 
thickness 10 µm was formed instantaneously. The glass coverslip was transferred onto 
the Linkam cryostage and held at -8 °C under N2 for 30 minutes. Photographs were 
obtained using an Olympus CX 41 microscope with a UIS-2 20x/0.45/∞/0-2/FN22 
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lens and crossed polarizers (Olympus Ltd, Southend on sea, UK), equipped with a 
Canon DSLR 500D digital camera. Images were taken of the initial wafer (to ensure 
that a polycrystalline sample had been obtained) and after 30 minutes. Image 
processing was conducted using Image J, which is freely available.[46] In brief, ten of 
the largest ice crystals were measured and the single largest length in any axis 
recorded. This was repeated for at least three wafers and the average (mean) value 
was calculated to find the largest grain dimension along any axis. The average of this 
value from three individual wafers was calculated to give the mean largest grain size 
(MLGS). This average value was then compared to that of a PBS buffer negative 
control providing a way of quantifying the amount of IRI activity. 
 
2.5.3.   Analysis of sequence alignment. 
Sequences of proteins were analysed using the online BLAST sequence alignment 
tool[47], while three dimensional structures of proteins were imaged using pymol[48]. A 
type 2 AFP from Sea raven, Hemitripterus americanu (pdb code 2AFP, accession 
number P05140) was searched against using the protein databank proteins database 
and blastp algorithm. The sequences of those proteins defined as having significant 
alignments by BLAST were used for further sequence alignment. Multiple sequence 
alignment was conducted using Jalview Desktop with Muscle with defaults multiple 
sequence alignment web service for alignment.[49]  
 
2.5.4.   Use of Lectins and nisin. 
The lectins used in this study were kept as a solid lyophilized powder until required 
for testing, then made up in the appropriate buffer in 5mg.mL-1 solutions and diluted 
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as needed. Denaturation of the protein was achieved by incubation of the protein at 
80°C for 15 minutes.  
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Chapter 3 
 
3. Quantitative Study on the Antifreeze Protein 
Mimetic Ice Growth Inhibition Properties of 
Poly(ampholytes) Derived from Vinyl-Based 
Polymers 
 
D.E. Mitchell, M. Lilliman S.G. Spain and M. I. Gibson, Biomater. Sci. 
2014, 2, 1787-1795. 
 
This chapter contains a paper on the synthesis and testing of poly(ampholytes) as ice 
recrystallization inhibition (IRI) molecules, aiming to identify the structural motifs 
and proportion of positive and negative charges required for IRI activity.  
 
DEM synthesized all polymers used here, except carbohydrate centred polymers, 
which were synthesized by MI. DEM and SGS undertook size exclusion 
chromatography (SEC) of polymers, while DEM was responsible for characterization 
through NMR spectroscopy. All IRI testing and dye exclusion assay was carried out 
by DEM. DEM and MIG prepared the manuscript. 
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3.1.   Abstract 	
Antifreeze (glyco) proteins (AF(G)Ps) from the blood of polar fish species are 
extremely potent ice recrystallization inhibitors (IRI), but are difficult to synthesise or 
extract from natural sources. Despite this challenge, materials which display IRI are 
appealing due to their ability to enhance cellular cryopreservation, for applications 
including regenerative and transplantation medicine. Here, poly(ampholytes), which 
contain a mixture of cationic and anionic side chains are quantitatively evaluated for 
their IRI activity. Poly(aminoethyl methacrylate), obtained by RAFT polymerization, 
is functionalised with succinic anhydride to generate the poly(ampholytes). The 
charge balance of the side chains is shown to be crucial, with only 50 : 50 mixtures 
having strong IRI activity, which also scales with molecular weight. This is the first 
example of a non-hydroxylated synthetic polymer with quantifiable IRI activity and 
raises questions about the mechanism of IRI, as the polymers have no obvious ice-
binding motif. The ampholytic structure is shown to be transferable to carbohydrate-
centred polymers with activity retained, but poly(betaines) are shown to be inactive. 
 
3.2.   Introduction 	
Since their discovery in the serum of Arctic fish species, antifreeze proteins (AFPs) 
and antifreeze (glyco)proteins (AF(G)Ps) have attracted significant attention due to 
their unique ice-interacting properties and their potential applications in 
cryopreservation, anti-icing surfaces, food storage and more.[1-3] AF(G)Ps have three 
key macroscopic properties;[4-5] i) Thermal hysteresis (TH) – the non-colligative 
depression of the freezing point, which does not affect the equilibrium melting point; 
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ii) Dynamic ice shaping (DIS) where the shape of ice crystals is altered due to specific 
inhibition of difference faces on the ice surface; iii) Ice recrystallization inhibition 
(IRI) whereby the AF(G)Ps slow the rate of ice crystal growth (Ostwald ripening). 
The underlying mechanism of action for each individual property is still under 
investigation.[6-8] Nishimura and co-workers synthesised several derivatives of 
AF(G)Ps, varying the carbohydrate and peptide components enabling them to identify 
the core motifs that were essential to maintain the TH and DIS activity.[9] Combined 
with previous studies, which have also shown that AF(G)Ps are not tolerant to many 
structural modifications,[1] it would seem that very particular requirements in terms of 
functional groups and tertiary structure are essential for AF(G)P activity. However, in 
most of these studies only TH and DIS were tested for, not IRI meaning its link to 
structure is less clear. In 2003 Enaide et al. observed that dramatically simplified 
glycoproteins could retain IRI activity but display essentially zero TH or DIS.[10] This 
observation suggested that there might be multiple molecular mechanisms that give 
rise to the same macroscopic properties and that it is possible to design new 
molecules that specifically display IRI activity.[11] Several glycopeptides and even 
small molecules have since been identified with varying degrees of IRI activity.  
 
Analysis of the process of cellular cryopreservation has revealed that ice growth 
during thawing is a major contributor to cell death.[12] Consequently, any new 
materials that can inhibit ice growth (i.e. IRI activity) may find application to enhance 
the storage of urgently needed donor tissue for transplantation. In 2013 in the USA, 
118,000 individuals were on organ waiting lists and demand almost always outstrips 
supply.[13-14] New regenerative medicines, or drug screening methods, based on stem 
cells also require improved (cryopreservation) storage methods.[15-16] Attempts at 
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cryopreservation with AF(G)Ps have reported varying degrees of success. Addition of 
AF(G)P to erythrocytes gave some cryopreservation enhancement, but above a critical 
concentration, its benefits stopped, limiting it use.[17] This was found to be due to the 
formation of needle-like (spicular) ice crystals due to the DIS/TH activity of 
AF(G)Ps. Subsequent studies on the addition of AF(G)P to sperm resulted led to 
decreased motility[18] and there is evidence that AF(G)P may be toxic to human cells. 
[19] There are several other conflicting studies showing both benefits and problems of 
AF(G)Ps in cryopreservation, normally due to ice shaping, which have prevented their 
application.[20-21] IRI-specific synthetic glycopeptides showed a marginal benefit in 
the cryopreservation of human embryonic liver cells.[22] 
 
Due to the difficulties in synthesising glycopeptides,[23] AF(G)P mimics are required, 
especially if they specifically reproduce only IRI for cryopreservation. Inada et al.[24] 
and Gibson et al.[25-26] have shown that poly(vinyl alcohol), PVA, is an extremely 
potent IRI despite having little or no structural similarity to AF(G)P. PVA with as few 
as 20 repeat units (MN = 880 g.mol-1) can inhibit ice growth at concentrations below 1 
mg.mL-1. Gibson and co-workers showed that addition of just 1 mg.mL-1 PVA to 
erythrocytes enabled their cryopreservation without the need for any organic 
solvents,[27] such as glycerol or DMSO, which are themselves cytotoxic at high 
concentrations and not suitable for transfusion.  
 
Synthetic polymers are particularly appealing as biomimetics due to their scalable 
synthesis, tuneable structure, and range of different monomers, and have been 
employed as mimics of mussel adhesive proteins,[28] antibacterial peptides[29] and 
glycoproteins,[30-31] for example. Despite this appeal, very few synthetic polymers 
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have been demonstrated (quantitatively) to have IRI activity and it has become clear 
that simply having a poly(hydroxylated) structure (such as PVA) is not sufficient to 
guarantee IRI.[32] Hydrophobicity is known to be a crucial component, with crystal 
structures of native AFPs showing defined hydrophobic and hydrophilic domains.[2, 33] 
Chemical modification of PVA (hydrophobic/hydrophilic substituents) also removes 
activity meaning that solution or surface absorbed conformation maybe important and 
there are few other lead structures to design new IRI-active compounds. Most 
polymers tested (in our hands) simply have no activity. Intriguingly, Matsumura et al. 
observed that poly(ampholytes) (which have both positive and negative charges) are 
very effective cryoprotectants, enabling solvent-free cryopreservation of stem cells.[34] 
They observed that the 50 % carboxylated poly(lysine) had very weak ice shaping 
effects (DIS). Similar results have been observed for ampholytic polysaccharides and 
vinyl polymers, but their IRI activity has not been quantitatively studied.[35-36] 
 
The aim of this study was therefore to investigate the poly(ampholyte) structure as a 
new motif for IRI active polymers which would open the door to a diverse range of 
non-PVA based AF(G)P mimetic polymers with highly tuneable structures and 
properties. Such biomaterials will help address the urgent needs of tissue storage, 
transport and logistics,[13] and lead to real clinical benefits building on our recent 
observations of the link between IRI and cell survival in cryopreservation 
 
3.3.   Results and Discussion 	
In order to obtain structure-property relationships between mixed charge polymers 
(polyampholytes) and their ice recrystallization inhibition activity it was necessary to 
devise a synthetic strategy that was compatible with controlled (radical) 
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polymerization. The planned synthetic strategy is shown in Scheme 3.1, using 
poly(aminoethyl methacrylate) (PAEMA) derived from RAFT polymerization as the 
cationic polymer, as an alternative to poly(lysine). Reaction with succinic anhydride 
can then produce the mixed charged polymer, inspired by carboxylated poly(lysine), a 
known cryoprotectant. 
 
3  
Scheme 3.1. IRI active molecules and poly(ampholyte) synthetic method A.) 
Native AFGP and previously reported IRI active macromolecules; B.) Synthetic 
method used in this report to obtain poly(ampholytes) 
 
A library of PAEMAs were synthesized using 4-cyanopentanoic acid dithiobenzoate 
(CTP) as the chain transfer agent, with 4,4′-azobis(4-cyanovaleric acid) (ACVA) as 
the radical source. A constant [monomer]:[CTA] ratio was employed in all 
experiments, with the polymerization time being varied to provide control over chain 
length. The monomer conversion was determined by 1H NMR spectroscopy against 
an internal mesitylene standard. All polymers were characterized by 1H NMR to 
provide an estimation of Mn, by comparing the benzylic resonances derived from the 
RAFT agent to the polymer backbone, Table 3.1. Size exclusion chromatography 
(SEC) of these polymers was attempted in a range of aqueous buffers, but in all cases 
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very broad dispersities were obtained, which can be ascribed to the well known self-
reactivity of PAEMA which can lead to cross-linking[37].  (ESI, Appendix 2.) To 
reduce this polymers were not handled in aqueous solution unless essential, and the 
solutions were acidified to ensure protonation of the amine groups. Previous reports 
of the polymerization of PAEMA suggest that it is a controlled process under 
identical RAFT conditions, [38] and the values for MN extracted by end-group analysis 
are in agreement with that from conversion, suggesting the RAFT mediating agent is 
present at the chain ends. From this point on, the molecular weight is defined as that 
obtained from end group analysis. However, there must be assumed to be error in 
these measurements which are considered when interpreting data (below). 
 
Table 3.1. Polymerization of aminoethyl methacrylate 
Entry(a)	 Time	
(hrs)	
Conversion		
(%)	
MN,	Theo	(b)	
(g.mol-1)	
MN,NMR	(c)	
(g.mol-1)	
11	k	 0.75	 8.2	 5400	 11000	
20	k	 1		 18	 11900	 20000	
23	k	 2	 35	 23100	 23000	
27	k	 3		 44	 29100	 27000	
33	k	 3.5		 52	 34400	 33000	
40	k	 5	 61	 40400	 40000	
67	k	 6	 74	 49000	 67000	
(a) [Monomer]:[CTA]:[I] = 400:1:0.2 was used in all polymerizations; (b) 
Theoretical MN determined from monomer feed ratio and conversion (1H NMR); 
(c) Mn determined by end group analysis. 
 
In order to generate mixed-charge polymers with pendant carboxylic acid groups ring-
opening of succinic anhydride was employed, Scheme 3.1. All the polymers in Table 
3.1 were functionalized in this manner to give approximately 50 mol% (±5%) COOH 
functionality (ESI, Appendix 2). In order to screen the effect of COOH density on IRI 
activity (vide infra) 33 kg.mol-1 PAEMA was functionalized at a range of COOH 
densities, Table 3.2. The degree of functionalization in each case was estimated by 1H 
	 98	
NMR spectroscopy. 50 mol % carboxylated poly(lysine) was also synthesized from 
commercial poly(lysine) by the same method as a positive control. 
 
 
 
Table 3.2. Functionalization of PAEMA with succinic anhydride. 
Entry	 MN,	
PAEMA	
(kg.mol-1)	
Succinic	
Anhydride	
(mol	%)	
f	COOH		
(mol	%)(a)	
MN	
Copolymer	
(kg.mol-1)	
P1	 11	 80	 50	 15.2	
P2	 20	 80	 50	 27.6	
P3	 27	 80	 50	 37.4	
P4	 33	 80	 50	 45.7	
P5	 44	 80	 50	 60.9	
P6	 67	 80	 50	 92.7	
	 	 	 	 	
P7	 33	 0	 0	 33.0	
P8	 33	 20	 18	 37.5	
P9	 33	 50	 32	 41.1	
P10	 33	 70	 40	 43.1	
P11	 33	 80	 50	 45.7	
P12	 33	 90	 56	 47.2	
P13	 33		 100	 60	 48.2	
P14	 33		 125	 63	 49.0	
P15	 33	 150	 76	 52.3	
P16	 33	 175	 82	 53.8	
(a) Determined from PAEMA (CH2-CH2) to succinic anhydride ratio using 1H NMR 
 
With this large panel of polymers at hand, quantitative ‘splat test’ measurements were 
undertaken to correlate polymer structure to ice recrystallization inhibition activity. 
Briefly, this assay involves dropping a small volume (~10 µL) of phosphate buffered 
saline containing the polymers onto a CO2(S) cooled glass slide sat on an aluminium 
plate. This generates large numbers of very small (<10 µm) ice crystals which are 
allowed to grow at – 6 °C for 30 minutes before being photographed through crossed 
polarizers. The mean largest grain size (MLGS) is measured and reported relative to a 
PBS standard, with smaller ice crystal sizes indicating a more active compound. 
Poly(ethyleneglycol) (PEG, 100 kDa) is used as a negative control polymer as it is 
well known to have no significant IRI activity.[25-26] The first polymer to be tested was 
50 mol % carboxylated poly(lysine), which has been shown to be a useful 
cryoprotectant but has never been quantitatively assessed for IRI activity, Figure 3.2. 
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This polymer was shown to only have very weak IRI activity, giving ~ 60 % MLGS 
at 20 mg.mL-1 compared to PEG which gave ~ 75 % MLGS at the same 
concentration. This is significantly weaker than the most well known polymeric IRI 
compound, poly(vinyl alcohol) which can inhibit ice growth below 1 mg.mL-1. 
However, this still represents one of only a handful of polymers with definitive IRI 
activity and is an interesting lead structure for further investigation especially 
considering the known cryoprotectant properties of carboxylated poly(lysine) and 
their significant structure differences to AF(G)Ps. Encouraged by these results, a 
relatively long PAEMA (P6) 67 kg.mol-1 with 50 mol % COOH was assessed for 
activity at a variety of concentrations. Pleasingly, this polymer showed significant IRI 
activity at concentrations up to 20 mg.mL-1, with an MLGS of ~ 40 %, significantly 
more active than the corresponding poly(lysine) derivative. Example micrographs of 
ice wafers grown with P4 are shown in Figure 3.1, and graphically in Figure 3.2. 
 
 
 
Figure 3.1. Cryomicrographs of ice wafers which have been annealed at -8 °C for 
30 minutes. A) PBS control; B) P4, 20 mg.mL-1. Scale bar = 100 µm. 
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Fig. 3.2. Ice recrystallization inhibition by poly(ampholytes). A) Comparison of 
PEG and carboxylated poly(lysine); B) Comparison of PEG to PAEMA-co-succinic 
anhydride (50% functionality), P6, Error bars represent ± SD from a minimum of 3 
repeats. MLGS = mean largest grain size relative to phosphate buffered saline control. 
 
To ensure that the observed IRI activity was due to the mixed-charge nature of the 
polymers, P7 – P16 with varying degrees of carboxylation were investigated, Figure 
3.3. Polymers with 0 to 90 % COOH (the highest achievable using this synthetic 
method) showed no IRI activity. As the density of COOH groups approached 50 
mol% the IRI activity steadily increased (smaller crystals) demonstrating that the ratio 
of the two side chains is the crucial structural motif for activity. This is rather 
remarkable, and questions the mechanism of action of IRI-active polymers which are 
assumed to need defined ice-binding motifs (hydroxyls) which are not present here. 
Almost all other IRI active materials tested (PVA, native AFGP, carbohydrates) show 
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a strong molecular weight dependence on activity, with larger polymers having more 
IRI. Figure 3.3B shows the molecular weight dependency on IRI for the 50 % COOH 
polymers, P1 – P6. The shortest polymer used here (10 kg.mol-1) had essentially zero 
IRI, and activity steadily increased as molecular weight increased, with the longest 
polymer (67 kg.mol-1) giving average ice grain sizes half that of the shortest (10 
kg.mol-1) (which is equal to 4 fold decrease in ice area). 
4  
Fig. 3.3. Ice recrystallization inhibition activity of PAEMA-derived polymers 
measured at 20 mg.mL-1; A) effect of degree of carboxylation on activity; B) effect 
of molecular weight at 50 % carboxylation. Error bars represent ± SD from a 
minimum of 3 repeats. MLGS = mean largest grain size relative to phosphate buffered 
saline control. 
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There are currently no satisfactory models for explaining the mechanism by which 
IRI active polymers slow ice crystal growth, which has limited their a priori design. 
To test if this mixed–charge motif is a universal method for obtaining IRI polymers, a 
series of other polymers bearing multiply charged species were investigated. Poly(2-
methacryloyloxyethyl phosphorylcholine) (PMPC) and poly([2-(methacryloyloxy) 
ethyl]dimethyl-(3-sulfopropyl) (PMEDS)  ammonium hydroxide) were synthesized 
by RAFT polymerization of their corresponding monomers, Figure 3.4A. PMPC was 
obtained with MN = 25 kg.mol-1 and MW/MN = 1.12, and PMEDS MN = 21 kg.mol-1 
and MW/MN = 1.10. These monomers contain cationic and anionic charges on every 
repeat unit, but of a different nature to the PAEMA derivatives. Quantitative IRI 
testing revealed that both of these poly(betaines) had essentially zero IRI activity, 
with their observed MLGS being statistically identical to the negative PEG control at 
concentrations up to 15 mg.mL-1.  At 20 mg.mL-1 PMPC had a weak enhancement 
which was only statistically different from PEG at 95 % confidence. This implies that 
the distribution and nature (COOH, SO3) of the charges is crucially important, and 
will be the subject of future investigations. 
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Fig. 3.4. Structure of polymers with multiple charged species and associated IRI 
activity. A) Structures of PMPC and PMEDS; B) Ice recrystallization inhibition 
activity. Error bars represent ± SD from a minimum of 3 repeats. MLGS = mean 
largest grain size relative to phosphate buffered saline control. ## indicates a 
statistical difference (p < 0.05) according to students T-test. 
 
As a final test to determine if the mixed side-chain approach is a universal one, a 
series of carbohydrate-centred polymers with mixed charges were synthesised (ESI, 
Appendix 2).[39] Briefly, a series mono, di and tri-saccharides were reacted with 
methacrylic anhydride to install a reactive methacrylate group on each of the 
hydroxyls. Addition of L-cysteine to the methacrylated cores by Michael addition 
(‘thiol-ene click’) enabled introduction of both an amine and carboxylic acid group at 
each position ensuring a discrete number of functional groups which is not possible 
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using radical polymerizations. 
 
Table 3.3. Carbohydrate-centred poly(ampholytes) 
Core	Sugar	 Valency	 MN,	Theo	(a)	
(g.mol-1)	
Glucose	 5	 1126	
Cellobiose	 8		 1855	
Stachyose	 15	 2690	
  (a) Assuming complete functionalization with cysteine. 
 
The two smallest polymers (with either 5 or 8 side chains) displayed very little IRI 
activity that was statistically identical to PEG. However, the longest oligomer with 12 
side chain units gave statistically significant smaller MLGS values compared to PEG 
and the other carbohydrate-based polymers. Whilst the actual values obtained indicate 
that these polymers have relatively low activity, it allowed the precise role of valency 
to be probed, showing that longer polymers are essential when using mixed-charge 
IRI polymers, but that the concept is a universal one. The structure of these polymers 
is also desirable as they are composed simply of carbohydrates and amino acids, 
which is appealing for biomedical applications.  
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Fig. 3.5. Structure and associated IRI activity of carbohydrate centred 
poly(ampholytes) A) structure of carbohydrate-centred poly(ampholytes); B) Ice 
recrystallization inhibition activity. Error bars represent ± SD from a minimum of 3 
repeats. MLGS = mean largest grain size relative to phosphate buffered saline control. 
### indicates a statistical difference (p < 0.01) according to students T-test. 
 
The data presented above clearly demonstrate that mixed charge side chain polymers 
can inhibit ice growth, but still does not answers the many questions which remain 
regarding their mode of action. Gibson and Ben have both shown that hydrophobicity, 
without aggregation, is crucial in the design of new IRIs.[11, 32, 40]. This questions the 
commonly held theory that hydroxyl groups which are regularly spaced to interact 
directly with the ice crystal lattice are the crucial motifs to get IRI (or indeed thermal 
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hysteresis and dynamic ice shaping).[41] Terahertz spectroscopy investigations suggest 
that AF(G)Ps can disrupt the quasi-liquid layer (interfacial water) prevent exchange of 
water molecules and hence inhibiting growth.[6, 8] This mechanism would seem to 
require a hydrophobic domain to either disrupt the water structure or to bind to 
hydrophobic faces on the ice surface. AFP binding to ice has recently been speculated 
to be due to anchored clathrate-like water molecules using both hydrophobic 
interactions as well as crystal-matching.[42] A method to probe hydrophobic domains 
in polymers is dye inclusion assays. Addition of a hydrophobic dye that does not 
fluoresce in aqueous solution, but does in non-polar environments allows the ability 
of a polymer to solubilize hydrophobic compounds to be measured. This is the basis 
of critical micelle determination for self-assembling amphiphiles, which require a 
hydrophobic domain. The (polymer) concentration dependant fluorescence of several 
of the polymers described here were measured and compared to PVA, Figure 3.6. 
Addition of PVA at less than 10 mg.mL-1 lead to significant fluorescence, 
highlighting its ability to present a hydrophobic domain (and hence its application in 
colloidal stabilisers[43]). Quantifying the amount of dye incorporation is challenging 
due to potential self-quenching effects and non-linear fluorescence response, but we 
would estimate that the PVA can incorporate up to half the dye applied (43 µM) at the 
highest concentration tested. The non-IRI active PMPC gave rise to fluorescence of 
~2500 units at concentrations up to 50 mg.mL-1, significantly lower than observed for 
PVA. P3 showed essentially no fluorescence enhancement relative to PMPC, 
suggesting that P3 does not present a hydrophobic face in solution to solubilise the 
dye. Dynamic light scattering did not indicate micellisation in any cases. This testing 
does not rule out specific interactions with an ice surface though, nor does it suggest 
that that additional hydrophobicity would not enhance activity, but rather than 
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mechanistically the ampholyte structure does not induce a hydrophobic face. Indeed, 
studies by Matsumura et al. suggest that adding hydrophobicity into poly(ampholytes) 
can enhance their cryoprotective effect, but the influence of this on IRI has not been 
determined.[36] The charge-balanced nature of the poly(ampholytes) may be able to 
disrupt the quasi-liquid layer (or pre-melt layer) at the ice/water interface which is 
hypothesised to inhibit ice growth, but direct measurements of this challenging 
interface are non-trivial. Future work will focus on unravelling the structural 
requirements of IRI activity, and delineating the observable macroscopic properties 
from the underlying molecular-level mechanisms, as well as probing their application 
in cryopreservation. 
 
 
Fig. 3.6. Dye inclusion assay using diphenyl hexatriene. λex =  360 nm λemission 
at 460 nm. 
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3.4.   Conclusions 
 
 
This study represents the first detailed analysis of poly(ampholytes) as AF(G)P-
mimetic, IRI active polymers. The significance of this work lies in the fact that the 
poly(ampholyte) structure is synthetically very accessible, but also very different to 
all previously recorded IRI-active polymers which are thus far limited to 
poly(hydroxylated) structures. It was demonstrated that the ratio of cationic to anionic 
groups was crucial, with a 1:1 balance giving maximal IRI activity, and that longer 
polymers had enhanced activity. The nature of the cation/anion was also found to be 
important as poly(betaines) showed no appreciable activity. 
  
The remarkable activity of these polymers opens the door to the rational design of 
new, IRI-active polymers, which are not based on hydroxyl-group presentation and 
can be obtained from both vinyl and biological backbones. This also questions the 
underlying mode of action of IRI-active compounds, challenging the paradigm of 
precise-ice face recognition by hydroxyl groups. Ultimately, the development of IRI 
active polymers will impact regenerative medicine through enhanced 
cryopreservation of donor (stem) cells, or even whole organs. 
 
3.5.   Experimental Section 	
3.5.1.   Materials 	
Aminoethyl methacrylate (AEMA), 2-methacryloyloxyethyl phosphorylcholine 
(MPC), 4-cyanopentanoic acid dithiobenzoate (CTP), 4,4-Azobis(4-cyanovaleric 
acid) (V-501), succinic anhydride, ethylene sulphate, methacryloyloxy ethyl 
dimethyl-(3-sulfopropyl)ammonium hydroxide (MEDS)  poly-ε-lysine hydrobromide 
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(30-70 kDa), poly(ethylene glycol) (PEG, 100 kDa size), trehalose, sucrose, 
diphenylhexatriene (DPH), acetic acid and sodium acetate were purchased from 
Sigma Aldrich (UK). PEG was dialyzed over 24 hours with 5 water changes, while all 
other reagents were used as received unless otherwise stated. Phosphate-buffered 
saline (PBS) solution was prepared using preformulated tablets (Sigma-Aldrich) in 
200 mL of Milli-Q water (>18.2 Ω mean resistivity) to give [NaCl] = 0.138 M, [KCl] 
= 0.0027 M, and pH 7.4. 
 
3.5.2.   Physical and analytical methods 	
1H and 13C NMR spectra were recorded on Bruker DPX-300 and DPX-400 
spectrometers using deuterated solvents obtained from Sigma-Aldrich. Chemical 
shifts in ppm (δ) are reported relative to residual tetramethylsilane (TMS). 
Fluorescence spectrometry was undertaken using a Synergy HT multi-mode 
microplate reader (BioTek UK, Bedfordshire, UK). 
 
Aqueous SEC was attempted using two different conditions. The first of these was 
performed on an Agilent 1260 Infinity Quaternary system utilizing 0.1 M HCl with 
0.1 % TFA at a flow rate of 1 mL.min-1 while column and detector temperatures were 
maintained at 35 °C. The instrument was fitted with a PL aquagel guard column (50 × 
7.5 mm, 8 µm) and a PSS NOVEMA cationic column (300 X 8.0 mm, 10µm), The 
data was analyzed using Agilent GPC/SEC software.  The second was performed on 
Cationic (acidic) aqueous GPC was performed on a Shimadzu Prominence UPLC 
system fitted with a differential refractive index detector. The eluent was 1 M acetic 
acid containing 0.3 M NaH2PO4 (pH 3) at a flow rate of 1 mL.min-1 with column and 
detector cell temperatures maintained at 35 °C. The instrument was fitted with a 
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Polymer Labs Aquagel-OH guard column (50 × 7.5 mm, 8 µm) followed by a pair of 
PL Aquagel-OH columns (30 and 40, 300 × 7.5 mm, 8 µm). Column calibration was 
achieved using narrow poly(2-vinyl pyridine) standards (Polymer Standards Service, 
Germany) of known molecular weight in the range 0.8-256 kDa. Molecular weights 
and dispersity values were calculated using Shimadzu LabSolutions software with 
GPC analysis add-on. 
 
3.5.3.   Dye inclusion assay 	
80 µL Aliquots of 6 kDa PVA, 25kDa pAEMA and pMPC   20 µL of 0.01 mg.mL-1 
DPH were added to a black solid-bottom (Greiner bio-one) 96-well plate and samples 
incubated at 25 °C for a minimum of 30 minutes. The fluorescence of each sample 
was then measured with excitation at 360 nm and emission at 460 nm using top-
excitation. Measurements were taken in triplicate. 
 
3.5.4.   Ice recrystallisation inhibition (splat) assay 	
Ice recrystallisation inhibition was measured using a modified splay assay.[44] A 10 
µL sample of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a 
chilled glass coverslip sat on a piece of polished aluminium placed on dry ice. Upon 
hitting the chilled glass coverslip, a wafer with diameter of approximately 10 mm and 
thickness 10 µm was formed instantaneously. The glass coverslip was transferred 
onto the Linkam cryostage and held at −8 °C under N2 for 30 minutes. Photographs 
were obtained using an Olympus CX 41 microscope with a UIS-2 20x/0.45/∞/0-
2/FN22 lens and crossed polarizers (Olympus Ltd, Southend on sea, UK), equipped 
with a Canon DSLR 500D digital camera. Images were taken of the initial wafer (to 
ensure that a polycrystalline sample had been obtained) and after 30 minutes. Image 
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processing was conducted using Image J, which is freely available.[45] In brief, ten of 
the largest ice crystals in the field of view were measured and the single largest length 
in any axis recorded. This was repeated for at least three wafers and the average 
(mean) value was calculated to find the largest grain dimension along any axis. The 
average of this value from three individual wafers was calculated to give the mean 
largest grain size (MLGS). This average value was then compared to that of a PBS 
buffer negative control providing a way of quantifying the amount of IRI activity. 
This testing method ensures that positive results are only reported if all ice crystals 
are inhibited, as opposed to a average per wafer, which would smooth out the 
presence of rouge ice crystal growth. 
	
3.5.5.   Synthesis of poly(amino ethyl methacrylate), PAEMA. 	
Aminoethyl methacrylate monomer was polymerised by aqueous reversible addition-
fragmentation chain transfer (RAFT) polymerisation as previously detailed[38]. The 
monomer to CTA ratio was 400:1 while CTA to initiator ratio was 5:1. AEMA 
monomer (825 mg, 5.4 mmol) V-501 (0.7 mg, 0.0025 mmol) and CTP (3.5 mg, 0.013 
mmol) were dissolved in 0.6 mL of acetate buffer at pH 5.2 (produced using 0.27 
mol.L-1 acetic acid and 0.73 mol.L-1 sodium acetate) in a 50 ml round bottomed flask, 
from a stock solution and subsequently diluted to 5ml with the addition of further 
acetate buffer. The flask was purged with nitrogen for 45 minutes and placed in an oil 
bath at 70 °C. The reaction was allowed to proceed to produce polymers of varying 
molecular weight. After the required amount of time (30-540 minutes) the reaction 
was quenched using liquid nitrogen. Dialysis (membrane size 3.5 kDa) using acetate 
buffer (24 hours, 5 changes) and lyophilisation were then used to purify the product. 
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1H NMR (D2O): δ 4.21 (br, 2H, -OCH2); δ 3.31 (br, 2H, -NH2CH2); δ 1.95 (br, 2H, -
CH2); δ 0.83–1.36 (br, 3H, -CH3).  
 
3.5.6.   Functionalization of PAEMA with succinic anhydride. 	
Functionalization of the amino groups present within the PAEMA was used to 
produce polyampholyte polymers. This was achieved using a method detailed in the 
literature[46].  Briefly, succinic anhydride was added in a range of ratios to 20 mg of 
PAEMA and this was dissolved in distilled water. The solution was then placed in an 
oil bath at 50 °C and allowed to react for 1 hour. Purification of the polymer was then 
achieved by dialysis using deionized water (24 hours, 5 water changes) and 
lyophilisation. 1H NMR was used to determine level of functionalization. 1H NMR 
(D2O): δ 4.21 (br, 2H, -OCH2); δ 4.05 (br 2H CH2CH2COO-) δ 3.50 (br 2H, -
COCH2CH2); δ 3.31 (br, 2H, -NH2CH2); δ 1.95 (br, 2H, -CH2); δ 0.83–1.36 (br, 3H, 
-CH3). 
 
3.5.7.   Polymerization of 2-methacryloyloxyethyl phosphorylcholine (MPC).  	
MPC was polymerised using RAFT polymerization in an aqueous solution[47] 500 mg 
(1.7 mmol) of monomer, 7.5 mg (0.017 mmol) of CTP and 3.25 mg (0.003 mmol) of 
V-501 were dissolved in 5ml deionized water containing 5 wt% (0.6 mmol) NaHCO3 
in a 50ml round- bottomed flask equipped with a magnetic stir bar. The mixture was 
the stirred to ensure dissolution of CTP and V-501 and subsequently purged with 
nitrogen for 45 minutes. The mixture was then placed in a preheated oil bath at 70°C 
and the reaction was allowed to proceed for 6 hours. The polymerisation was stopped 
by quenching in liquid nitrogen and purified using dialysis using deionized water (24 
hours, 5 water changes) and lyophilisation. 1H NMR (D2O): δ 4.26 (br, 4H, -
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CH2CH2OP-), δ 4.17 (br, 2H, -COOCH2-), δ 4.03 (br, 2H, -POCH2-), δ 3.52 (br, 2H 
–CH2N-), δ 3.09 (br, 9H, N(CH3)3), δ 1.95 (br 2H –CH2-), δ 0.9 (br, 3H, -CH3). 
 
3.5.8.   Polymerization of methacryloyloxy ethyl dimethyl- (3-sulfopropyl) 
ammonium hydroxide (MEDS).  	
MEDS was polymerised using RAFT polymerization in an aqueous solution as 
undertaken for MPC. 500 mg (1.8 mmol) of monomer, 7.5 mg (0.017 mmol) of CTP 
and 3.25 mg (0.003 mmol) of V-501 were dissolved in 5 ml deionized water 
containing 5 wt% (0.6 mmol) NaHCO3 in a 50 ml round- bottomed flask equipped 
with a magnetic stir bar. The mixture was the stirred to ensure dissolution of CTP and 
V-501 and subsequently purged with nitrogen for 45 minuets. The mixture was then 
placed in a preheated oil bath at 70 °C and the reaction was allowed to proceed for 6 
hours. The polymerisation was stopped by quenching in liquid nitrogen and the 
sample purified using dialysis using deionized water (24 hours, 5 water changes) and 
lyophilisation. 1H NMR (D2O): δ 4.46 (br, 2H, -OCH2CH2-), δ 3.76 (br, 2H -
CH2CH2SO3), δ 3.55 (br, 2H –CH2CH2N-), δ 3.11 (br, 2H, -NCH2CH2-), δ 2.88 
(br, 4H, -N(CH2)2-), δ 2.32 (br, 2H, -CH2CH2CH2-), δ 0.94 (br, 3H, -CH3)  
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Chapter 4 
 
4. Gold Nanoparticle Aggregation as a Probe of 
Antifreeze (Glyco) Protein-Inspired Ice 
Recrystallization Inhibition and Identification of New 
IRI Active Macromolecules 
		
D. E. Mitchell, T. Congdon, A. Rodger and M. I. Gibson. In Revision. 
 
 
This chapter contains a paper on the analysis of an absorbance based gold 
nanoparticle assay for the high-throughput screening of ice recrystallization activity. 
DEM synthesized gold nanoparticles, PAEMA-co-SA polymers and undertook all 
analytical investigation. TC synthesized PVA polymers. DEM and AR carried out 
circular dichroism spectroscopy and subsequent analysis. DEM and MIG wrote the 
manuscript. 
 
4.1.   Abstract 
Antifreeze (glyco)proteins are found in polar fish species and act to slow the rate of 
growth of ice crystals; a property known as ice recrystallization inhibition. The ability 
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to slow ice growth is of huge technological importance especially in the 
cryopreservation of donor cells and tissue, but native antifreeze proteins are often not 
suitable, nor easily available. Therefore, the search for new materials that mimic this 
function is important, but currently limited by the low-throughout assays associated 
with the antifreeze properties. Here 30 nm gold nanoparticles are demonstrated to be 
useful colorimetric probes for ice recrystallization inhibition, giving a visible optical 
response and is compatible with 96 well plates for high-throughout studies. This 
method is faster, requires less infrastructure, and has easier interpretation than the 
currently used ‘splat’ methods. Using this method, a series of serum proteins were 
identified to have weak, but specific ice recrystallization inhibition activity, which 
was removed upon denaturation. It is hoped that high-throughput tools such as this 
will accelerate the discovery of new antifreeze mimics.  
 
4.2.   Introduction 
To survive in the harsh cold environments at high altitude or in the Earth’s polar 
regions, Nature has evolved a series of mechanisms to enable extremophiles to 
survive, and thrive. One particular method of survival employed by freeze-avoiding[1] 
(as opposed to freeze tolerant)[2] species is the production of antifreeze proteins and 
antifreeze glycoproteins (AF(G)Ps).[3] These proteins act to i) lower the equilibrium 
freezing point in a non-colligative fashion – thermal hysteresis[4] (TH); ii) shape ice 
crystals (via binding to specific crystallographic faces) – dynamic ice shaping (DIS); 
iii) inhibit the growth of ice crystals – ice recrystallization inhibition (IRI).[5] The 
property of IRI is particularly interesting, as ice crystal growth during thawing has 
been associated with cellular damage during cryopreservation.[6] Considering this, 
AF(G)Ps have been investigated for their ability to enhance cryopreservation,[6] with 
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the aim of improving the availability of transplantable materials for regenerative 
medicine. The results of this have been mixed, with reports of AF(G)Ps both 
enhancing and reducing cell viability post-thawing.[6-8] This has been attributed to 
their unwanted effects of DIS/TH, which can promote the formation of needle-like 
(spicular) ice crystals.[9] There are also concerns about the toxicological and 
immunological affects of AF(G)PS,[10] along with the inherent cost of 
producing/purifying them from natural sources.  
 
Therefore, the development of new IRI-specific molecules/macromolecules has been 
pursued. Ben et al. have reported that simplified glycopeptides and glycolipids have 
potent IRI and can enhance cryopreservation.[11-13] Gibson and co-workers have 
shown that synthetic polymers can mimic AF(G)Ps function and shown this to 
enhance red blood cell cryopreservation.[14-16] However, there are still few examples 
of synthetic AF(G)P mimics, which is in part limited by the time-consuming nature of 
the assays required to probe their activity. The TH assay requires the growth of single 
ice crystals in nanolitre droplets, whereas IRI activity is tested by the ‘splat’ assay; 
this involves forming many wafers of sub 10 micron ice crystals and monitoring their 
growth over time.[17] Neither of these assays are suitable for high-throughput analysis, 
requiring temperature-controlled microscope stages and significant image analysis. To 
speed the process Ben et al. introduced domain recognition software,[18] which aids 
image processing but the data collection burden is not removed. Several other 
methods involving capillaries and light scattering have been suggested,[19-21] but these 
do not give quantitative data or require user ‘interpretation’ of the results and have not 
been widely adopted.  
 
	 120	
Interestingly, Kim et al., [22] suggested that gold nanoparticles could be used to 
measure thermal hysteresis colourimetrically. Gold nanoparticles show a distinct shift 
from red to blue colouration upon aggregation and has been employed for a range of 
bioassays from DNA-sequence comparison,[23] bacteria analysis,[24] viral analysis,[25] 
glycan analysis,[26] metal detection[27] and more. Kim et al.[22] reported that the 
aggregation of gold particles correlated with the TH activity of an AFP. The 
mechanism of this was not clear though as freezing then thawing gold nanoparticles 
should not actually be affected by TH. The macroscopic effect of TH is to lower the 
freezing point (by circa. 2 °C) but in the reported assays, activity was seen at 
temperatures significantly below this and using AFP concentrations which are too low 
for TH activity. We believe these observations actually correlates better with IRI 
activity, which is maintained at lower concentrations.[28-29] When an aqueous solution 
is frozen, the ice crystals will grow larger by ice recrystallization, reducing the overall 
ice surface area. As all solutes are excluded from ice crystal, the gold particles in 
between will be forced closer together leading to aggregation. Anything that 
possesses IRI activity would prevent this ice crystal growth, meaning the overall 
surface area would be larger preventing aggregation from occurring. Despite the 
previous reports suggesting this is a TH assay, if it can be adapted for IRI the method 
is very appealing as it could be conducted in multiwell plates, the output can be read 
by a standard plate-reader (or visually) and only needs a standard – 20 °C freezer. The 
combination of readily available equipment requirements and multi-well plate 
compatibility would make this a potential high-throughput assay for testing a diverse 
range of compounds.  
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In this manuscript, we report a study into the use of gold nanoparticles (AuNPs) as a 
simple, and rapid, tool for screening for IRI activity.  Using well-defined synthetic 
polymers, with known IRI activity, but no (or weak) thermal hysteresis we show that 
the inhibition of gold particle aggregation correlates with IRI. The utility of this in a 
96 well plate format is reported to enable higher-throughput screening in comparison 
to the splat assay. 
 
4.3.   Results and Discussion 
To test the applicability, if any, of the reversible freezing of colloidal gold as a probe 
for IRI activity (rather than the previously explored thermal hysteresis)[22] a range of 
synthetic polymers with known IRI activity were selected. Poly(vinyl alcohol), PVA, 
was chosen as the positive control due to is well-known IRI activity, which has been 
investigated in detail.[28] As a negative control poly(ethylene glycol) and poly(N-vinyl 
pyrolidone), PVP, were selected as they have no significant IRI in the relevant 
concentration range.[30-31] Figure 4.1 shows the results of a ‘splat’ test, which 
measures the ripening of ice crystals over time, in both the absence and presence of 
PVA, highlighting its inhibitory effect on ice crystal growth. Briefly, this assay 
involves seeding large numbers of small ice crystals and monitoring their growth to 
obtain the mean largest grain size (MLGS) to quantify activity. Using this assay, it 
has been shown that concentrations of PVA below 1 mg.mL-1 are sufficient to halt ice 
crystal growth. 
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Figure 4.1. Ice recrystallization inhibition activity of PVA; (A) Example 
micrograph of crystals grown in PBS alone; (B) Example micrograph of crystals 
grown in 5 mg.mL-1 PVA; (C) IRI activity as a function of polymer concentration. 
MLGS = mean largest grain size relative to a PBS control (%). Error bars represent 
the standard deviation from at least three measurements. (PVA MW= 6.8 kDa). 
30 nm mercaptosuccinic acid (MSA) functionalized gold particles were prepared 
using literature methods,[22, 32] to assess the viability of this method to measure IRI 
activity. The gold nanoparticle solutions containing the compounds to be tested for 
IRI were frozen in 96-well plates at -20 °C for 2 hours in a standard laboratory freezer 
(-20 °C). The samples were then thawed slowly at 23 °C (ambient temperature) to 
maximise ice recrystallization, and their UV-visible absorption spectra recorded as 
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well as optical photographs, as shown in Figure 4.2A. From visual inspection of the 
samples it was clear that the AuNPs with added PVA were still dispersed 
(characteristic red colour), but other samples had aggregated. The concentration 
dependence of AuNPs with PVA was also measured and the success of the assay was 
found to not depend on gold concentration. A concentration of ~ 80 ug.mL-1 is used 
from this point onwards (ESI, Appendix 3). 
 
Figure 4.2. Absorbance spectra changes of gold nanoparticles (AuNPs) solutions 
upon freeze/thawing; (A) Effect of freezing and thawing gold nanoparticle solutions, 
with decrease in absorbance at 520 nm. Inset photos show colour changes associated 
with AuNP freeze/thaw; (B) Gold nanoparticle UV-Vis spectra after freeze-thaw in 
the presence of additives at a concentration of 10 mg.mL-1 (PEG MW 4 kDa, PVA 
MW 6.8kDa). Arrows are to guide the eye in the direction of change. 
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In order to ‘score’ the relative degree of aggregation post-thawing, the reduction in 
the absorbance peaks at 520 nm between pre- and post-thaw were measured to give a 
qualitative comparison between different additives (ESI, Appendix 3) with higher 
values indicating less aggregation and hence more IRI activity.  To assess the use of 
this colloidal assay a range of different molecular weight PVAs from 800 – 20000 
g.mol-1 were synthesised using RAFT/MADIX polymerization[28] (ESI, Appendix 3). 
The PVA’s are labelled according to their degree of polymerization (chain length) 
from this point. Above 1 mg.mL-1 all the PVAs prevented aggregation of the gold 
particles after a freeze/thaw cycle, in agreement with the ‘splat’ assay. When the 
concentration was decreased below 1 mg.mL-1 there were clear differences between 
the polymers of different molecular weight, as shown in the zoomed-in region in 
Figure 4.3. The largest polymer (PVA244) was capable of inhibiting aggregation as 
low as 0.1 mg.mL-1, but the shortest (PVA10) lead to AuNP aggregation in this 
concentration range, demonstrating that high molecular weight polymers have 
increased IRI activity. 
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Figure 4.3. Concentration dependence on the absorbance at 520 for different 
degrees of polymerization of PVA post freeze/thaw. (A) Concentration dependence 
of IRI activity from 0 to 5 mg.mL-1; (B) Zoomed-in region from 0 to 1 mg.mL-1 
showing concentration dependence resolution for low concentrations. Error bars 
represent ± SD from a minimum of 3 repeats. 
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In an attempt to correlate these observable spectral features with our ‘gold standard’ 
splat assay, the whole data set was plotted as Abs520 versus MLGS, Figure 4.4. There 
was a clear correlation between the MLGS and Abs520, with lower absorbance values 
correlating with smaller MLGS values.  
 
 
 
Figure 4.4. Comparison of MLGS values (relative to a PBS control) versus 
absorbance from all PVA/AuNP aggregation assay. MLGS is expressed as a 
percentage of PBS buffer control. 
 
Variable volume experiments were also conducted to ensure that this was a 
recrystallization-specific effect. Briefly, smaller volumes will thaw faster, reducing 
the opportunities for recrystallization, compared to larger volumes. A short screen of 
this (ESI, Appendix 3) confirmed that 100 µL total volume per well (in a 96 well 
plate) lead to aggregation of the gold after freeze-thaw, but lower volumes lead to less 
	 127	
aggregation. This also supports our hypothesis that recrystallization inhibition, not 
thermal hysteresis is the effect being probed and that the conducting these 
experiments in 96 well plates, as opposed to 384 well plates may be preferable. 
 
The data presented above suggests that the AuNP method may be a useful screening 
assay for IRI activity. To probe this, a range of compounds with and without known 
IRI activity were screened; Poly(amino-ethyl methacrylate) 50 % carboxylated with 
succinic anhydride, PAEMA-co-SA (35 kDa), α-cyclodextrin dextran (40 kDa),  
trehalose, poly(vinyl pyrolidone) (PVP, MW 40 kDa)  and bovine serum albumin 
(BSA). Of these only PAEMA-co-SA is known to have IRI activity and this is 
significantly less active than PVA, typically requiring concentrations of ~ 20 mg.mL-1 
to have IRI activity, compared to 1 mg.mL-1 for PVA.[33] The IRI activity of trehalose 
and other sugars has been reported. However, this required concentrations of 220 mM 
(which is > 50 mg.mL-1) to show significant ice inhibition and is only considered to 
be weakly active, with close to no activity in the concentration range used here.[34] 
PVP is a well known kinetic hydrate inhibitor, but does not have strong IRI.[35]  
Figure 4.5 shows the results of screening 6 compounds/macromolecules for IRI using 
this AuNP based assay. 
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Figure 4.5. Screening for IRI activity using AuNP Assay; (A) Chemical structures 
of the compounds being interrogated; (B) AuNP colloidal aggregation results. Error 
bars represent ± SD from a minimum of 3 repeats. Dotted line is to guide the eye – 
data points above this indicate IRI activity. 
As expected, PAEMA-co-SA showed a reduction in aggregation across a range of 
concentrations, in line with its known IRI activity, which correlates well with its 
MLGS (ESI, Appendix 3). Using dye inclusion assays PAEMA-co-SA shows no 
activity, suggesting that it is not acting as a surfactant, which could provide 
stabilisation to the AuNPs and is a potential source of false-positives.[30, 33] PVP, 
dextran and cyclodextrin solutions all aggregated following freeze/thaw for all 
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concentrations tested. This is in agreement with observations that none of these have 
IRI activity in the splat test. Most interestingly, BSA gave a result that would indicate 
IRI activity. This could be interpreted as it stabilising the gold nanoparticle surface 
(through non-specific absorption) or a real IRI affect. To the best of our knowledge, 
the IRI activity of BSA has not been quantitatively studied so we set out to investigate 
this. To ensure that we were probing protein-structure related effects, some of the 
BSA was denatured by heating (95 °C for 30 minutes). Circular dichroism 
spectroscopy (Figure 4.6A) confirmed this by the decrease in molar elipticity at 210 
and 225 nm. These changes seen in the CD spectra were small, but BSA is known to 
be quite tolerant to heating and can refold, although not necessarily into the same 
conformation.[36-37] The native, and denatured forms were then subjected to the splat 
test as a function of concentration, Figure 4.6B. 
 
The splat test revealed that folded BSA does have real, if not very potent, IRI activity. 
This is surprising, as in our hands very few synthetic materials or proteins show any 
appreciable IRI with PAEMA-co-SA and PVA being amongst the few. The denatured 
BSA showed no IRI activity, indicating a remarkable tertiary-structure dependence, 
which has not been previously explored. This is of particular interest as many 
cryoprotectant solutions contain large quantities of serum proteins and this data 
implies that modulation of ice crystal growth may be an unexpected benefit in these 
systems. 
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Figure 4.6. IRI activity of BSA. (A) Circular dichroism spectra of BSA at 500  
µg.mL-1 before and after heat-denaturation; (B) Comparison of active and denatured 
BSA. Error bars represent ± SD from a minimum of 3 repeats. MLGS = mean largest 
grain size relative to PBS control. 
To determine whether this is a general property of serum proteins, human serum 
albumin (HSA) and ovine serum albumin (OSA) were also tested using both the 
AuNP and splat test methods. The AuNP screening method indicated some freeze-
thaw resistance and the splat test confirmed that the OSA and HSA both had activity 
in line with the BSA, Figure 4.7.  
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Figure 4.7. IRI activity of serum proteins. A) Gold nanoparticle aggregation assay; 
B) ‘Splat’ assay. BSA = bovine serum albumin, OSA = ovine (sheep) serum albumin 
and HSA = human serum albumin. MLGS = mean largest grain size relative to PBS 
control. Error bars indicate SD from a minimum of 3 repeats.  
 
BSA is often used as a negative control in antifreeze protein assays (although at lower 
concentrations than used here) this should be taken into account in the future as it 
clearly does have activity, although the features that cause this are not clear. One role 
of serum proteins in vivo is as a carrier for various substances such as fatty acids and 
certain steroids, while also maintaining the oncotic pressure in the blood.[38-39] To 
carry these substances it possesses several binding domains and hydrophobic 
regions.[40] This distribution of hydrophobic and hydrophilic regions is a common 
feature in antifreeze proteins perhaps explaining the reason for its activity.[41] In a 
small molecule context, Ben et al. has shown that addition of increasingly 
hydrophobic alkyl chains to sugars can result in enhanced IRI which would seem to 
agree with this hypothesis for BSA activity.[42] 
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This study shows that AuNP reversible freeze/thaw cycles and the subsequent 
aggregation appears to be linked to the rate of ice crystal growth (recrystallization) 
rather than the previously hypothesized TH activity.[22] Our results demonstrate that it 
may be a useful tool for screening IRI, but that splat tests are still required to confirm 
activity of newly identified compounds. In particular, this method may be useful 
when screening structural variations of a single material (e.g. a polymer) where any 
nonspecific effects (such as particle binding) are common to all the structures, 
enabling false positives to be removed. The identification of serum albumin activity 
also suggests that IRI might be a more common property of proteins than previously 
thought. This opens up the opportunity to identify latent antifreeze-protein activity 
from non-extremophile organisms.  
 
4.4.   Conclusions 
Here the application of gold nanoparticles as convenient probes for ice 
recrystallization inhibition activity has been investigated. During thawing, extensive 
ice crystal growth occurs, reducing the available surface area for particles, meaning 
the gold particles are more likely to aggregate if crystal growth occurs. UV-visible 
spectroscopy can be employed to probe activity by measuring the characteristic red to 
blue shift of AuNP solutions as they aggregate. The degree of aggregation was found 
to correlate well with ice recrystallization inhibition activity determined by the (gold 
standard) splat assay. Previous studies had suggested that this reversible assay was 
due to freezing point depression (thermal hysteresis), but here synthetic polymers 
without freezing point depression activity gave strong aggregation inhibition, 
confirming IRI not TH was the mechanism being probed.   
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This assay has significant advantages in terms of speed and throughput compared to 
the splat test, which is the current ‘gold standard’ for ice recrystallization. This 
includes compatibility with 96 well plates for automated analysis and the use of a 
standard – 20 °C lab freezer and easy colourimetric readout. Using this method, the 
IRI activity of serum proteins was identified for the first time and quantified by the 
‘splat’ test and linked to the tertiary structure/folding of the proteins. At this time, the 
potential for false positives cannot be ruled out across all chemical space, but this 
represents a step towards a fully automated IRI activity-screening platform. 
 
4.5.   Experimental Section 
4.5.1.   Physical and analytical methods 
1H and 13C NMR spectra were recorded on Bruker DPX-300 and DPX-400 
spectrometers using deuterated solvents purchased from Sigma-Aldrich. Chemical 
shifts are reported relative to residual non-deuterated solvent. Infrared data was 
recorded on a Bruker Vector 22 GI003097. The THF GPC system comprised of a 
Varian 390-LC-Multi detector suite fitted with differential refractive index (DRI), 
light scattering (LS) and ultra-violet (UV) detectors equipped with a guard column 
(Varian Polymer Laboratories PLGel 5 µm, 50 x 7.5 mm) and two mixed D columns 
of the same type. The mobile phase was THF with 5 % triethylamine (TEA) eluent at 
a flow of 1.0 mL.min-1, and samples were calibrated against Varian Polymer 
Laboratories EasiVials linear poly(styrene) and poly(methylmethacrylate) standards 
(162-2.4 x 105 g.mol-1) using Cirrus v3.3. Characterization of AuNPs was carried out 
using differential light scattering (DLS) spectroscopy (Malvern Instruments Zetasizer 
Nano-ZS). Circular dichroism (CD) spectra were recorded on a spectropolarimeter 
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(Jasco J-720, Jasco UK) using a data interval of 0.2 nm. Samples were dissolved in 
PBS buffer diluted two-fold with deionised water, and the spectrum was measured 16 
times and averaged. The spectrum of a blank sample containing only buffer was then 
subtracted giving a final spectrum for each protein. UV-visible spectroscopy was 
conducted on a microplate reader; Synergy HT multi-mode microplate reader, BioTek 
UK. 
 
4.5.2.   Materials 
Hydrogen tetrachloroaurate trihydrate (HAuCl4.3H2O), sodium citrate dehydrate  
(C6H5Na3O7.2H2O), mercaptosuccinic acid (MSA), dextran, α-cyclodextrin (MW 
972.84 g.mol-1), trehalose, bovine serum albumin (BSA), human serum albumin 
(HSA), ovine serum albumin (OSA) and poly(ethylene glycol) (PEG) were purchased 
from Sigma Aldrich. Poly(amino ethyl methacrylate–co-succinic anhydride) was 
synthesized as previously reported30 and poly(vinyl alcohol) was synthesized as 
detailed in the ESI.  All reagents were of analytical grade. Commercial polymers 
(PEG, PVP and dextran) were dialysed against deionized water for 24 hours with 5 
water changes prior to use against a 3000 MWCO membrane. Phosphate-buffered 
saline (PBS) solution was prepared using preformulated tablets (Sigma-Aldrich) in 
200 mL of Milli-Q water (>18.2 Ω mean resistivity) to give [NaCl] = 0.138 M, [KCl] 
= 0.0027 M, and pH 7.4. 
 
4.5.3.   Synthesis of gold nanoparticles 
Gold Nanoparticle (AuNPs) were synthesized according to the literature.[32] Briefly, 
6.7 mg of hydrogen tetrachloroaurate was dissolved in 50 mL of distilled water in a 
50 mL round bottom flask, equipped with a magnetic stir bar. The solution was then 
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heated to 100 °C while stirring and 2 mL of sodium citrate solution (2 mM, 17.6 mg) 
was added. The solution changed colour to purple and then red and the reaction was 
allowed to proceed for a further 20 minutes. The colloidal suspension was then 
allowed to cool to room temperature and 2 mL of mercaptosuccinic acid solution (30 
mM, 9 mg) was added, and the functionalization was allowed to proceed overnight at 
room temperature, purification was achieved by centrifugation (7000 g, 10 minutes) 
and resuspension in deionized water. The resulting concentration of AuNPs was 58 
µg.mL-1. Dynamic light scattering confirmed that the gold particles were ~ 30 nm in 
size (PDI 0.23).  
 
4.5.4.   Freeze-thaw assay 
The standard assay involved the addition of 50 µL of test product prepared as a serial 
dilution from 10 – 0 mg.mL-1 (or higher concentrations as needed) in a 96 well plate. 
To this, 50 µL of as-prepared AuNPs were added. To determine the affect of the 
solution volume on the assay the quantities of test and AuNP solution were varied 
although the ratio remained 1:1. All experiments were undertaken in triplicate. Freeze 
thaw was achieved by placing the plate in a standard domestic freezer for 2 hours at -
20 °C and leaving to thaw on the lab bench at room temperature. The UV-vis spectra 
were corrected for scattering by drawing a straight line between 450 and 680 nm and 
measuring the absorbance at 520 nm, between this line and the peak. The optimal 
concentration of gold is 80 µg.mL-1 (see ESI, Appendix 3). 
 
4.5.5.   Ice recrystallization inhibition (splat) assay 
Ice recrystallization inhibition was measured using a modified splay assay.[17] A 10 
µL sample of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a 
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chilled glass coverslip sat on a piece of polished aluminium placed on dry ice. Upon 
hitting the chilled glass coverslip, a wafer with diameter of approximately 10 mm and 
thickness 10 µm was formed instantaneously. The glass coverslip was transferred 
onto the Linkam cryostage and held at −8 °C under N2 for 30 minutes. Photographs 
were obtained using an Olympus CX 41 microscope with a UIS-2 20x/0.45/∞/0-
2/FN22 lens and crossed polarizers (Olympus Ltd, Southend on sea, UK), equipped 
with a Canon DSLR 500D digital camera. Images were taken of the initial wafer (to 
ensure that a polycrystalline sample had been obtained) and after 30 minutes. Image 
processing was conducted using Image J, which is freely available.[43] In brief, ten of 
the largest ice crystals were measured and the single largest length in any axis 
recorded. This was repeated for at least three wafers and the average (mean) value 
was calculated to find the largest grain dimension along any axis. The average of this 
value from three individual wafers was calculated to give the mean largest grain size 
(MLGS). This average value was then compared to that of a PBS buffer negative 
control providing a way of quantifying the amount of IRI activity. 
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Chapter 5 
5. Antifreeze Protein Mimetic, Supramolecular 
Metallohelices with Potent Ice Recrystallization 
Inhibition Activity 
 
D. E. Mitchell, R. A. Kaner, P. Scott and M. I. Gibson, in preparation 
	
This chapter contains a paper on the use of amphipathic metallohelices as ice 
recrystallization inhibitors. MIG and DEM wrote the manuscript. PS and RK 
undertook the synthesis of the materials. DEM undertook all ice recrystallization 
inhibition studies. All others read and contributed to the manuscript. 			
5.1.   Abstract 
Antifreeze proteins are produced by extremophile species to control ice formation and 
growth and have potential applications in many fields. There are few examples of 
synthetic materials which can reproduce their potent ice recrystallization inhibition 
property. Here, the first instance of using supramolecular chemistry to generate potent 
ice recrystallization inhibitors is reported. Self-assembled enantiomerically pure, 
amphipathic metallohelicies were synthesized, and the most potent compounds fully 
inhibited ice growth at 20 mM. This opens up a new field of organometallic antifreeze 
protein mimetics. 
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5.2.   Introduction 
Antifreeze proteins (AFPs) found in the blood of cold-acclimatized species have 
evolved to enable life to flourish in hostile, ice-rich environments. Despite 40 years of 
study there are still questions about the function of AFPs and their interactions with 
ice, although recent microfluidic experiments have suggested an irreversible binding 
process.[1] AFPs posses three key properties; (i) thermal hysteresis (TH)- the non-
colligative depression of freezing point relative to that of the melting point;[2] (ii) 
dynamic ice shaping (DIS)- where the shape of ice crystals is altered due to binding to 
specific faces on the ice crystal surface;[3] (iii) ice recrystallization inhibition (IRI)- 
where the rate of ice crystal growth (Ostwald Ripening) is inhibited.[4] Any compound 
which can control ice growth has huge potential application as frozen food texture 
modifiers,[5] in cryosurgery,[6] or advanced coatings.[7] The lack of synthetic mimics 
however, have limited the application of AFPs, except in the case of ‘ice structuring 
proteins’ in some ice cream formulations.[8]  
 
In 2001 Ben and co-workers found that short glycopeptides could reproduce the IRI 
activity found in AFPs,[9] suggesting that there could be a viable synthetic route to 
new cryoprotectants. Several glycopeptides, glycopolymers and small molecules that 
posses some level of IRI activity have since been uncovered.[10-12] Many of these 
require relatively challenging synthesis and their usefulness as cryoprotectants is still 
under investigation. Gibson et al. have shown that synthetic polymers can also show 
IRI activity, based on either poly(vinyl alcohol) or poly(ampholyte) motifs.[13-14] Both 
of these have been applied to enhance the non-vitreous cryopreservation of blood, 
highlighting the potential of synthetic IRIs.[15-16] There is still a lack of understanding 
of the structural features essential for IRI activity, and the synthesis of a range of new 
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IRI’s tailored to a variety of applications would be possible if fully understood. 
Structural analysis of AFPs shows that they are all rigid proteins, with many based on 
an amphiphilic alpha helix.[17-18] This implies that other, synthetic helical materials 
might be interesting candidates for mimics. 
 
The alpha-helical secondary structure is extremely common in many proteins 
including those involved in disease, therefore the synthetic design of similar 
structures is of high interest. Some time ago, Lehn and co-workers noted that 
helicates; multimetallix and multistrand coordination complexes resemble alpha-
helices in terms of their diameter and charge.[19]  They have much higher symmetry 
(commonly D3) however, and usually lack water solubility/stability and external 
functionality and are formed as racemates.[20] In contrast we have recently developed 
ranges of optically pure, water-soluble metallohelical architectures,[21-23]  including 
most recently systems that have directional amphipathic architectures akin to small α-
helical peptides.[24] Despite their complexity they are synthesised via self-assembly 
from small building blocks on a practical scale. Structural integrity and 
stereoselection are provided by extensive intramolecular π-stacking.[25-26] Interestingly 
the size and shape corresponds well to that of a type 1 AFP, while the tunability of 
these organometallic strucutres allows a library of different functional groups to be 
included, making it possible to accurately assess those strucutral properties required 
for IRI activity.  
 
In this study we probe the concept that metallohelical structures may behave as AFP 
mimetics, through the analysis of a library of different ligand structures. Thus 
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providing a new and unique insight into the properties requires for IRI activity, and a 
new biomimetic strategy. 
5.3.   Results and Discussion 
The size and shape of a Type I AFP is shown in Figure 5.1A, revealing approximate 
dimensions of 2.5 x 1.2 nm. Using our previously reported methodology, we 
assembled ligand L1 with Fe3+ to generate the metallohelix M1, Figure 5.1B. A 
comparison of the crystal structure of this helix with the AFP, reveals similar size and 
dimensions making them good lead molecules as structural AFP mimetics. Crucially, 
due to the arrangement of the ligands, these complexes have amphipathic character, 
again relating to the amphiphillic nature of the AFPs, which always have defined 
hydrophilic and hydrophobic faces. With this complex to hand, we tested for IRI 
activity using a modified ‘splat’ assay. Briefly, a small droplet of complex M1 in PBS 
buffer was dropped onto a microscope slide at -80 °C to generate a large number of 
small crystals. These were annealed at -8 °C for 30 minutes, and the mean largest 
grain size (MLGS) calculated relative to a PBS control. Smaller values indicated more 
inhibition and hence more activity. Values below 20 % are not possible as this is the 
relative size of the seed crystals. 
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Figure 5.1. Biomimetic approach employed here. A) Crystal structure of Type I 
AFP with dimensions of the helix highlighted B) Synthesis of compound M1; C) 
Crystal structure of compound M1 and dimensions of the helix indicated. Images 
obtained using PyMOL. 
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Figure 5.2. IRI activity of compound M1Λ. A.) Concentration dependence of M1Λ; 
B.) Example ice wafer of PBS buffer control; C.) Example wafer of M1Λ.  Error bars 
represent minimum of three repeats, MLGS = mean largest grain size relative to 
phosphate buffer saline control. ** represents a significance of p < 0.01 relative to 
poly(ethylene glycol) (PEG, 30 mg.mL-1) negative control. Images are of equal 
magnification, scale bars are 50 µm. 
	
Figure 5.2 clearly shows a dose-dependent decrease in the MLGS as a function of the 
concentration of compound M1Λ. Example micrographs show ice crystals grown in 
PBS (Figure 5.2B) and with 30 mg.mL-1 (0.018 M) compound M1Λ. Note, compound 
M1Λ has a strong red purple color, which accounts for the unusual coloration of the ice 
wafer. Whilst the absolute activity of this complex in itself is not very high, it is 
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remarkable in that it is the first example of a self-assembled AFP mimetic, compared 
to the traditional peptide-based approach. 
Encouraged by this remarkable observation, we synthesized a focused library of 
related compounds, all based on the triplex scaffold. This synthetic strategy produces 
both enantiomers enabling any chiral (if any) effects to be observed. The ligands used 
are shown in Table 5.1. All compounds were fully characterized by 1H and 13C NMR 
along with mass spectrometry and were enantiomerically pure (ESI, Appendix 4). The 
ease in which this large diversity can be inserted within a common scaffold of similar 
dimensions highlights the benefits of this chemistry.  
 
Table 5.1. Metallohelix library. 
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Each of the complexes in Table 5.1 was subsequently tested for IRI activity in the 
range of 25 – 2 mM using the ‘splat’ assay. Molar concentrations were used for 
comparison, due to the slight variation in molar mass between these complexes to 
ensure a fair comparison. A wide range of activities were observed ranging from zero 
to complete inhibition demonstrating a structural link to activity. 
 
Figure 5.3. IRI activity of metallohelix library. A.) IRI activity concentration 
dependence of mettallohelices; B.) Example ice wafer of PBS buffer control; C.) 
Example wafer of M2Λ. Error bars represent minimum of three repeats, MLGS = 
mean largest grain size relative to phosphate buffer saline control. Images are of equal 
magnification, scale bars are 50 µm. 
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Two compounds M2Λ and M2Δ displayed remarkable activity. They both could 
completely inhibit all ice growth at 20 mM, but did not show any sign of dynamic ice 
shaping (unlike AFPs). In comparison to previously reported non-polymer IRI-active 
small molecules, the metallohelices shown here are more potent than the majority of 
IRI active carbohydrate based surfactants described in the literature,[12] and 
significantly better than all small sacchride molecules, with the exception of the 
sugar; n-octyl-β-D-galactopyranoside and a lysine based cationic surfactant, for which 
similar levels of activity was reported.[10] The other complexes used had varying 
levels of activity. It has been established that hydrophobicity is essential in IRI 
specific compounds, but a comparison of hydrophobicity with IRI activity showed no 
trend. L5 ligand is the most hydrophobic but yields the least inhibition, while L3,; the 
most hydrophilic is in the middle in terms of potency. There were also no obvious ice-
binding groups (i.e. hydrogen bonders). In fact, the individual ligands are only sparing 
soluble in water, and only become soluble when complexed, and hence they are all 
intrinsically hydrophobic. Due to this low solubility it was not possible to evaluate the 
IRI activity of the ligands alone, highlighting that the self-assembly is crucial to 
activity. 
 
We recently identified that a short peptide Nisin A had IRI activity which appeared to 
be due to its facially amphiphilic structure;[27] opposing hydrophobic/hydrophilic 
faces which would be able to disrupt transfer between ice crystals. A comparison of 
the most active and least active structures, looking along their z-axis revealed that 
both contain separated regions of more hydrophilicity (oxygen atoms). However, a 
clear difference relating to their activity was not possible to extract. Part of the 
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challenge is that these ligands are intrinsically hydrophobic, and hence any 
hydrophilcity is based on ether linkages, which are difficult to define as hydrophilic. 
Nonetheless, these complex clearly show that self-assembly of non-biological 
components can generate potent AFP mimics. 
 
5.4. Conclusions 
The above metallohelcies represent the first use of supramolecular chemistry to 
produce an IRI active molecule. Using this method it was possible to produce 
compounds, which can completely inhibit ice recrystallization at 20 mM. These 
complexes are easier to synthesize than glycopeptides, and have the benefit over 
polymeric inhibitiors in that they have no molecular weight disperstiy. There are also 
synthetically tractable, which we believe will enable precise-structure activity 
relationships to be drawn to both understand the fundamentals of ice growth 
inhibition, but to enable us to obtain ever-more potent IRIs. New synthetic IRI 
molecules will have huge impact across fields including cryo-medicine, 
transplantation medicine, frozen food, aqua culture, ice-resistant coatings and more. 
 
5.5.   Experimental Section 
5.5.1.   Materials 
All solvents and chemicals purchased from commercial sources (Sigma-Aldrich, 
Acros, Fisher Scientific or Alfa Aesar) were used without further purification unless 
otherwise stated. Sodium hydride dispersions in mineral oil were placed in a Schlenk 
vessel under an inert atmosphere and washed three times with diethyl ether to remove 
the oil, then dried and stored under argon in an MBraun dry box.  Where appropriate, 
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reactions were carried out under argon using a dual manifold argon/vacuum line and 
standard Schlenk techniques or in an MBraun dry box. Necessary solvents were dried 
by heating to reflux for 3 days under nitrogen over the appropriate drying agents 
(potassium for tetrahydrofuran, sodium/potassium alloy for diethyl ether, and calcium 
hydride for acetonitrile and pyridine) and degassed before use. Tetrahydrofuran and 
diethyl ether were additionally pre-dried over sodium wire. Dried solvents were 
stored in glass ampoules under argon. All glassware and cannulae were stored in an 
oven at > 375 K.  
 
Deuterated solvents were purchased from Sigma-Aldrich and Cambridge Isotope 
Laboratories. Phosphate-buffered saline (PBS) solution was prepared using 
preformulated tablets (Sigma-Aldrich) in 200 mL of Milli-Q water (>18.2 Ω mean 
resistivity) to give [NaCl] = 0.138 M, [KCl] = 0.0027 M, and pH 7.4. 
 
 
5.5.2.   Physical and analytical methods 	
NMR spectra were recorded on Bruker Spectrospin 300/400/500 MHz spectrometers. 
Routine NMR assignments were confirmed by 1H-1H (COSY) and 13C-1H (HMQC) 
correlation experiments where necessary. The spectra were internally referenced 
using the residual protio solvent (CDCl3, CD3CN etc.) resonance relative to 
tetramethylsilane (δ = 0 ppm). ESI mass spectra were recorded on an Agilent 
Technologies 1260 Infinity spectrometer or a Bruker Daltonics MicroTOF 
spectrometer. Infra-Red spectra were measured using a Bruker Alpha-P FTIR 
spectrometer. Elemental analyses were performed by Medac Ltd. Chobham, Surrey 
GU24, 8JB, UK or Warwick Analytical Service, Coventry, CV4 7EZ. 
	 151	
Optical rotation measurements were performed on a Perkin Elmer Polarimeter 341 by 
Warwick Analytical Services, Coventry, UK. In all cases the following parameters 
were used: solvent: methanol, temperature: 20 °C, pathlength: 100 mm, wavelength: 
589 nm. 
 
Thermogravimetric analysis (DSC1-1600 scanning calorimeter) was used to 
determine the amount of water of crystallisation present in the chloride salts of iron 
(II) triplex metallohelices.  
 
5.5.3.   General synthesis of HHT-[Fe2Ln]Cl4  
Anhydrous iron(II) chloride (2 eq.) was added to a stirred solution of the either the 
desired RC-chiral amine (3 eq.) and 5-(2,2'-bipyridin-5-ylmethoxy)picolinaldehyde (3 
eq.) or the desired substituted aldehyde (3 eq.) and (R)-2-(2,2'-bipyridin-5-
ylmethoxy)-1-phenylethanamine (3 eq.) in methanol (20 ml) at ambient temperature 
to give a purple solution that was then heated to reflux (65 °C) for 24 – 48 h. The 
reaction was allowed to cool to ambient temperature, filtered through a celite plug and 
the solvents were removed in vacuo to give the desired dark purple solid (see ESI, 
Appendix 5 for full synthetic details). Note that the presence of water of 
crystallisation in these compounds was confirmed by NMR and IR spectroscopy and 
the absence of other solvents was confirmed also by NMR. The hydration number 
was then determined by thermogravimetric analysis and the relevant mass loss was 
correlated with microanalytical data.  
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5.5.4.   Ice recrystallisation inhibition (splat) assay.  
Ice recrystallisation inhibition was measured using a modified splay assay.[28] A 10 
µL sample of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a 
chilled glass coverslip sat on a piece of polished aluminum placed on dry ice. Upon 
hitting the chilled glass coverslip, a wafer with diameter of approximately 10 mm and 
thickness 10 µm was formed instantaneously. The glass coverslip was transferred 
onto the Linkam cryostage and held at -8 °C under N2 for 30 minutes. Photographs 
were obtained using an Olympus CX 41 microscope with a UIS-2 20×/0.45/∞/0–
2/FN22 lens and crossed polarizers (Olympus Ltd, Southend on sea, UK), equipped 
with a Canon DSLR 500D digital camera. Images were taken of the initial wafer (to 
ensure that a polycrystalline sample had been obtained) and after 30 minutes. Image 
processing was conducted using Image J, which is freely available.[29] In brief, ten of 
the largest ice crystals in the field of view were measured and the single largest length 
in any axis recorded. This was repeated for at least three wafers and the average 
(mean) value was calculated to find the largest grain dimension along any axis. The 
average of this value from three individual wafers was calculated to give the mean 
largest grain size (MLGS). This average value was then compared to that of a PBS 
buffer negative control providing a way of quantifying the amount of IRI activity.  
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Chapter 6 
 
6.   Rational, yet Simple, Design and Synthesis of an 
Antifreeze-Protein Inspired Polymer for Cellular 
Cryopreservation 
 
D. E. Mitchell, N. R. Cameron and M. I. Gibson, Chem. Commun. 2015, 
51, 12977-12980.		
 
This chapter contains a paper on the design and synthesis of a novel polyampholyte 
polymer. This is subsequently found to inhibit ice recrystallization, be non-cytotoxic 
and to dramatically enhance cellular survival rates of red blood cells (RBCs) 
undergoing cryopreservation. 
 
DEM synthesised the polymers and performed all characterisation. Ice 
recrystallization inhibition, cytotoxicity and cryo-survival assays were performed by 
DEM. Manuscript was prepared by DEM, NRC and MIG. 
 
6.1.   Abstract 
Antifreeze (glyco) proteins AF(G)Ps are potent ice recrystallization inhibitors, which 
is a desiarable property to enhance cryopreservation of donor tissue/cells.  Here we 
present the rational synthesis of a new, biomimetic, ice-recrystallization inhibiting 
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polymer derived from a cheap commodity polymer, based on an ampholyte structure. 
The polymer is used to enhance the cryopreservation of red blood cells, demonstrating 
a macromolecular solution to tissue storage.  
 
6.2.   Introduction 
In the freezing polar regions of the Earth, Nature has evolved a number of methods to 
survive. One of these is freeze avoidance[1] (as opposed to freeze tolerance)[2] using 
antifreeze proteins (AFPs) or antifreeze glycoproteins (AF(G)Ps). Ever since they 
were discovered in polar fish species AF(G)Ps have attracted interest due to their 
ability to interact with ice[3] and their potential applications in cryopreservation, 
cryosurgery, food-storage, anti-icing surfaces and more.[4-7] AF(G)Ps have three key 
properties; (i) thermal hysteresis (TH) – the non-colligative depression of the freezing 
point, which does not affect the equilibrium melting point;[8] (ii) dynamic ice shaping 
(DIS) where the shape of ice crystals is altered due to binding to specific faces on the 
ice surface;[9] (iii) ice recrystallization inhibition (IRI) whereby the rate of ice crystal 
growth (Ostwald ripening) is slowed.[10] IRI is a particularly interesting property as it 
has been found that ice recrystallization during thawing is a major contributor to cell 
death.[11-12]  
New cryoprotectants are urgently needed to improve the availability of 
cells/tissues/organs to address the needs of a growing and ageing population. For 
example, blood can only be stored for a maximum of 42 days and stock quantities 
vary over the course of a year, meaning that there is always a shortage.[13] Emerging 
regenerative medicine therapies based on stem cells also require efficient cryostorage. 
The current state-of-the-art cryoprotection involves the addition of large amounts of 
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organic solvents such as glycerol or DMSO. Whilst successful, these solvents can 
cause cellular toxicity and, ideally, should not be directly transfused. There are also 
some cell types for which no effective cryopreservation solution exists.   
 
Considering the above, there have been several attempts at cryopreservation using 
AF(G)Ps but these have met with mixed results. For example, addition of AFP to 
erythrocytes gave some cryopreservation enhancement, but above a critical 
concentration, it actually decreased viability.[14] This was found to be due to the 
formation of needle-like (spicular) ice crystals due to the DIS/TH activity of AF(G)Ps. 
There are several other studies demonstrating both benefits and problems of AF(G)Ps 
in cryopreservation, with the problems normally due to ice shaping, which have 
prevented their application.[15-16] Furthermore there is some evidence that AF(G)Ps 
can be toxic to human cells.[17] In 2003 Ben and co-workers demonstrated that short 
glycopeptides could specifically reproduce IRI, but not TH/DIS suggesting that there 
may be a synthetic route to new cryoprotectant molecules. [18] Several glycopeptides, 
glycopolymers and even small molecules have since been identified with varying 
degrees of IRI activity.[19-22] Some of these are still relatively challenging to 
synthesize and their cryopreservation activity is still under investigation. As an 
alternative both Gibson and coworkers and Inada et al. have separately investigated 
synthetic polymers as AF(G)P mimics, in particular the use of poly(vinyl alcohol) 
(PVA) which has strong IRI activity,[23-24] with very few other polymers reported with 
this unique property. Polymers are easy to access on a large scale, are highly tunable 
in terms of composition and architecture and are widely used in personal care and 
pharmaceutical industries making them appealing additives. Addition of just 0.1 wt % 
of PVA was found to enhance red blood cell cryopreservation by inhibiting ice 
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growth.[25] Matsumura and coworkers identified that carboxy-modified poly(ε-lysine) 
could enhance stem cell cryopreservation although the mechanism was unclear.[26] 
Gibson and co-workers used controlled radical polymerization to generate well 
defined poly(ampholytes) with both amino and carboxy side chains with definite IRI 
activity but that a 1:1 ratio of cationic to anionic groups was required for maximum 
activity and unambiguously demonstrated that IRI was (in part) the cryoprotective 
mechanism of poly(ampholytes).[27] To enable exploitation of IRI active polymers, 
there still exists a need to identify new materials, ensure their availability in quantities 
needed for application and to demonstrate their biological potential. 
 
This manuscript describes an easy and accessible synthetic route to new 
poly(ampholytes) with definite IRI activity, derived from the bulk commodity 
polymer; poly(methyl vinyl ether-alt-maleic anhydride) (GantrezTM) widely used in 
the coatings industry. The synthetic route ensures perfectly alternating 
cationic/anionic charges to maximize activity (as opposed to previous routes). This 
new material was then shown to dramatically enhance red blood cell cryopreservation 
enabling solvent-free storage of this crucial component of modern medicine. 
 
6.3.   Results and Discussion 
Previously polyampholytes have been prepared by post-polymerisation 
functionalization of poly(amines) which intrinsically gives rise to a statistical 
distribution of the charged groups.[28] Considering Nature requires explicit control 
over sequence distribution in AFGPs, but tolerates molecular weight distribution, we 
devised a synthetic strategy to match this. The low cost (< $20 kg-1), but structurally 
defined, commodity polymer PMVEMA (Mw = 311 kDa) contains alternating 
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anhydrides in the main side chain, providing an opportunity to obtain alternative 
polymers via ring-opening, but has large dispersity as it is obtained by free-radical 
polymerization (as with most bulk-polymers). The poly(ampholyte) was prepared by 
nucleophilic ring-opening of the anhydride ring with N-Boc-ethanolamine, followed 
by TFA deprotection in high yield with a minimum of synthetic steps, Figure 6.1.  
Following exhaustive dialysis, conversion of the anhydrides to esters was confirmed 
by IR spectroscopy and quantitative incorporation of the ethanolamine group was 
determined by 1H NMR (Appendix 5).  
 
 
Figure 6.1. Synthesis of new poly(ampholyte) by ring opening of the maleic 
anhydride units. A) Synthetic route employed; B) IR spectra showing conversion of 
anhydride into carboxylic acid and ester, confirming substitution. 
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With this new, low cost, poly(ampholyte) to hand it was necessary to evaluate its IRI 
activity. A modified splat test was employed, which involves creating a wafer of 
small ice crystals, which are then allowed to grow at – 8 °C, and then their average 
crystal sizes are measured, relative to a control (PBS). Small MLGS (mean largest 
grain size) values indicate increased IRI activity. As a negative control we included a 
high molecular weight (100 kDa) poly(ethylene glycol), PEG. This PEG was chosen 
to ensure that any viscosity-related effects (due to high molecular weight) do not bias 
our measurements. In keeping with reports of other poly(ampholytes), this new 
polymer was capable of inhibiting 50 % of ice growth at 20 mg.mL-1. Whilst this is 
less active than our positive control, PVA, it is still a definite effect and somewhat 
surprising given the huge structural differences between this polymer and Native 
AF(G)Ps, and represents one of only a handful of synthetic polymers with this activity. 
Inhibiting ice growth at a concentration of 20 mg.mL-1 is also relatively low in a 
cryopreservation context: Up to 40 wt % (~ 400 mg.mL-1) is required for tradition 
organic solvents applied in cryopreservation.  
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Figure 6.2. Ice recrystallization inhibition of PMVEMA-co-EA. A) Comparison 
with PEG (100 kDa) as a negative control and PVA10 as a positive. Mean largest grain 
size is expressed as a percentage of PBS buffer. Error bars represent ± SD from a 
minimum of 3 repeats; B) Example micrographs of ice wafers with and without 
polymeric IRI agent. Both images are of equal magnification, scale bars represent 50 
µm. 
Our previous studies have shown that addition of PVA to red blood cells dramatically 
reduces ice-induced damage, but that the level of cell recovery using PVA alone was 
relatively low (< 40 %).[25] To improve this, hydroxyethyl starch (HES) was selected 
as a co-cryopreservative – it is non-penetrating macromolecules and does not lead to 
vitrification, unlike e.g. DMSO. HES is used clinically as a plasma expander, so is 
ideally suited to blood-contacting applications. Cytocompatibilty of the 
poly(ampholyte) was evaluated by incubation with fresh ovine red blood cells (RBCs) 
for 4 hours, after which the degree of haemolysis was measured, Figure 6.3A (cell 
recovery = 1/haemolysis, see ESI, Appendix 5). At concentrations up to 40 mg.mL-1 
(above what is needed in later experiments) there was no statistically significant 
	 163	
indication of haemolysis, indicating the polymers were compatible with RBCs. At 
concentrations as high as 100 mg.mL-1, haemolysis was observed, as would be 
expected for almost any foreign additive at such high concentrations. At these very 
high (> 50 mg.mL-1) concentrations the polymer solution also becomes very viscous, 
which might contribute to apparent toxicity, due to the challenge of separating 
undamaged cells. To assess the polymers’ cryopreservation enhancement, RBCs were 
prepared in an isotonic cryopreservation solution containing HES, and different 
amounts of the poly(ampholyte) were added. Cells were frozen by rapid cooling by 
placing into liquid nitrogen (-196 °C) and stored in nitrogen vapour for 5 days. 
Following this time the cells were thawed at room temperature for 1 hour. These 
thawing conditions are crucial – ice recrystallization is maximised under slow 
thawing conditions (the property being probed here) and is representative of large 
volume cryopreservation (e.g. blood bags, or organs) where thermal gradients across 
the sample lead to ice growth. Control experiments using fast thawing were also 
conducted, which improves recovery in these low volumes but is challenging in a 
‘real world’ situation (ESI, Appendix 5). It should be noted that differential scanning 
calorimetry confirmed no vitrification occurred during freezing. The results of the 
cryopreservation are shown in Figure 6.3B. 
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Figure 6.3. Recovery of red blood cells when slow-thawed on the bench top. A) 
Cytocompatibility assay of RBCs with p(ampholyte) and the working range 
highlighted in red. Incubation time = 4 hours; B) Cell recovery after freezing (-196 °C, 
5 days) and thawing (room temperature, 1 hour). Recovery is expressed as a fraction 
of an unfrozen positive control, error bars represent ± SD from a minimum of 3 
repeats. 
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Using HES alone, only 20 % of the RBCs were recovered. However, addition of 5 
mg.mL-1 poly(ampholyte) increased this to 30 %, and addition of 20 mg.mL-1 
increased it to an impressive 60 %. Higher concentrations could not be tested due to 
the increased solution viscosity in the cryopreservation solution. The dose-
dependence of the cryopreservation correlates well with the observed IRI activity of 
the polymers and the dose required is far less than was required for a lysine-based 
poly(amphotyle) when cryopreserving stem cells,[26] which needed > 100 mg.mL-1 for 
cryopreservation. It should again be highlighted that by using slow-thawing 
conditions, we are maximising potential for cell damage to provide a rigours test – 
higher levels of recovery could be achieved with fast thawing (~ 80 %) but our aim is 
to eliminate all recrystallization associated damage. Considering the ease, and scale, 
of the polymer synthesis and its clear beneficial effect on improving blood 
cryopreservation this demonstrates that biomimics of AF(G)Ps can have a huge 
impact on improving the availability of donor cells. The work presented here also 
demonstrates that the rational design of ice-modifying macromolecules, tuned to their 
specific application is possible. In the long term, this will enable us to fully 
understanding how macromolecules (synthetic and biological) control crystallisation 
processes. Future work will extend to a wide range of cell types and also obtain 
structure-function relationships to enable an understanding of why certain polymers 
can inhibit ice growth. 
 
6.4.   Conclusions 
We have demonstrated a new, facile, biomimetic approach to engineering ice-
recrystallization inhibiting polymers, inspired by antifreeze proteins. A region-regular 
poly(ampholyte) was synthesized from a bulk commodity precursor and shown to 
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have specific ice recrystallization inhibition activity. The poly(ampholyte) was non-
toxic to red blood cells and facilitated a remarkable enhancement in the post-freezing 
cell recovery by inhibiting ice growth during thawing. This demonstration shows that 
the identification, and translation of new cryopreservatives is possible, using synthetic, 
as opposed to biological approaches. It is also a step towards the ability to routinely 
mimic these proteins, which have a complex function, which will bring benefits both 
to cryopreservation (and other fields) but to our understanding of interfacial process at 
ice crystals.  
 
6.5.   Experimental Section 
6.5.1.   Materials 
Poly(methyl vinyl ether-alt-maleic anhydride) (PMVEMA Mw 311 kDa), ethanol 
amine, Di-tert-butyl dicarbonate (BOC), poly(ethylene glycol ) (PEG, 100 kDa size), 
mannitol, hydroxyethyl starch (HES), sodium chloride, tetrahydrofuran and 
trifluoroacetic acid were purchased from Sigma Aldrich (UK). Ovine red blood cells 
in Alserver’s solution were purchased from TCS biosciences (UK). Phosphate-
buffered saline (PBS) solution was prepared using preformulated tablets (Sigma-
Aldrich) in 200 mL of Milli-Q water (>18.2 Ω mean resistivity) to give [NaCl] = 
0.138 M, [KCl] = 0.0027 M, and pH 7.4. 
 
6.5.2.   Physical and analytical methods 
1H and 13C NMR spectra were recorded on Bruker DPX-300 and DPX-400 
spectrometers using deuterated solvents obtained from Sigma-Aldrich. Chemical 
shifts in ppm (δ) are reported relative to residual tetramethylsilane (TMS). FTIR 
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spectra were acquired using a Bruker Vector 22 FTIR spectrometer with a Golden 
Gate diamond attenuated total reflection cell. A total of 128 scans were collected on 
samples in their native (dry) state. Bright and fluorescence microscopy were 
performed on an Olympus CKX41 with MoticamPro 205C and CoolLed pE-300-W 
light source, images analysed using Motic Images Advanced 3.2. Cells used were 
screened, pathogen-free, defibrinated sheep red blood cells in Alsever’s solution. All 
incubations of red blood cells were visualised at 1/10 dilution in PBS, with 2 µL 
solution on a glass slide with a glass cover slip. Absorbance was measured on a 
microplate reader (Synergy HT multi-mode microplate reader, BioTek UK). 
 
6.5.3.   Synthesis of N-boc ethanolamine. 
3.57 g Di-tert-butyl dicarbonate was added to 1 g ethanolamine (1:1 molar ratio) and 
reacted at room temperature for 2 hours, producing N-boc ethanolamine. 1H NMR 
(CDCl3): δ 4.92 (br, 1H –ROH); δ 3.74 (br, 2H –OCH2); δ 3.51 (s, 1H -CH2NHCOO); 
δ 3.32 (br 2H– CH2CH2NH); δ 1.67 (br, 9H OC(CH3)3).  Mass Spectrometry: m/z  
(EI-) calc for (CH3)3COCONHCH2CH2OH, 161.2; found 160.2 [M]-.  
 
6.5.4.   Functionalization of PMVEMA with N-Boc ethanolamine.  
2 g of N-boc-ethanolamine was added to 0.4 g PMVEMA (Mw 311 kDa) dissolved in 
10 mL THF. The mixture was warmed to 55°C and allowed to react for 24 hours. This 
was then dialysed against deionized water (7 water changes 48 hours) and lyophilized. 
Functionalization was confirmed by NMR and FTIR spectroscopy. 1H NMR (D2O): δ 
3.66 (br 2H –OCH2CH2); δ 3.47 (br 3H -OCH3); δ  3.32 (br H –CH2NHCOO); δ 2.91- 
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3.12 (br 2H CHCH(COO)CH)); δ 2.62 (br 2H CH2CH2NH); δ 1.92 (br 2H -
CHCH2CH); δ 1.28 (br 9H -OC(CH3)3). 
6.5.5.   Removal of boc protecting group.  
0.3 g N-Boc functional-PMVEMA dissolved in methanol was treated with 2 mL 
trifluoroacetic acid. The mixture was reacted at room temperature for 3 hours. This 
was followed by dialysis (7 water changes, 48 hours) against deionized water and 
lyophilisation. To substitute the trifluoroacetate ion for a chloride ion, dialysis against 
10 mM sodium chloride (5 water changes) was used followed by dialysis against 
deionized water (5 water changes) to removal excess salt. 1H spectroscopy was used 
to determine functionalization. 1H NMR (D2O): δ 3.66 (br 2H –OCH2CH2); δ 3.47 (br 
3H -OCH3); δ  3.32 (br 2H –CH2NHCOO); δ 2.91- 3.12 (br 2H CHCH(COO)CH)); δ 
2.62 (br 2H CH2CH2NH); δ 1.92 (br 2H -CHCH2CH);  
6.5.6.   Ice recrystallisation inhibition (splat) assay.  
Ice recrystallisation inhibition was measured using a modified splay assay.[1] A 10 µL 
sample of polymer dissolved in PBS buffer (pH 7.4) was dropped 1.40 m onto a 
chilled glass coverslip sat on a piece of polished aluminum placed on dry ice. Upon 
hitting the chilled glass coverslip, a wafer with diameter of approximately 10 mm and 
thickness 10 µm was formed instantaneously. The glass coverslip was transferred 
onto the Linkam cryostage and held at -8 °C under N2 for 30 minutes. Photographs 
were obtained using an Olympus CX 41 microscope with a UIS-2 20×/0.45/∞/0–
2/FN22 lens and crossed polarizers (Olympus Ltd, Southend on sea, UK), equipped 
with a Canon DSLR 500D digital camera. Images were taken of the initial wafer (to 
ensure that a polycrystalline sample had been obtained) and after 30 minutes. Image 
processing was conducted using Image J, which is freely available.[2] In brief, ten of 
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the largest ice crystals in the field of view were measured and the single largest length 
in any axis recorded. This was repeated for at least three wafers and the average 
(mean) value was calculated to find the largest grain dimension along any axis. The 
average of this value from three individual wafers was calculated to give the mean 
largest grain size (MLGS). This average value was then compared to that of a PBS 
buffer negative control providing a way of quantifying the amount of IRI activity.  
 
6.5.7.   Hemolysis testing. 
Samples containing 250 µL red blood cells (RBCs) and 250 µL of polymer solution 
were incubated at 37 °C for 30 minutes prior to testing. After centrifugation to 
concentrate down the RBCs, 10 µL of the supernatant was added to 90 µL of PBS 
buffer in a 96 well plate. The absorbance was measured at 450 nm and compared 
against a PBS buffer positive control (i.e. 100 % recovery) and a deionised water 
negative control (0 % recovery) to determine the cell survival rate. RBCs leach heme 
into the supernatant when they die, providing an easily available method of testing 
cell survival rate. Samples were tested as 6 repeats.  
 
6.5.8.   Cryopreservation of RBCs.  
A 250 µL aliquot of prepared RBCs (ovine origin, packed cell volume between 32 
and 52 %) was added to 250 µL of a standard cryosolution (containing HES (350 
mg.mL-1), mannitol (30 mg.mL-1) sodium chloride (6.5 mg.mL-1)) and vortexed 
gently to ensure mixing. pMVEMA-co-EA was added at various concentrations to 
this cryosolution in order to determine whether any beneficial effect could be seen.  
These were then rapidly frozen in triplicate by immersion into liquid nitrogen and 
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stored within a liquid nitrogen container for 5 days.  Thawing was either performed at 
42 °C for 2 minutes in a water bath, or on the bench top for 1 hour.  
6.5.9.   Measurement of red blood cell haemolysis and cell recovery.  
A 250 µL aliquot of red blood cell / cryoprotectant solution was centrifuged in a 1.5 
mL Eppendorf tube for 5 minutes at 6000 rpm. Then 10 µL of the supernatant was 
removed and added to 90 µL of PBS in a well of a 96-well plate.  Absorbance was 
measured at 450 nm and compared to an unfrozen positive control containing 250 µL 
prepared RCBs and 250 µL PBS buffer. 100 % hemolysis samples were prepared by 
adding 250 µL RCBs to distilled water. Cell recovery was calculated by subtracting 
the attained haemolysis (%) from 100 (%) giving a figure for cell recovery (%). 
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Chapter 7 
 
7. A Simple Polymeric Solution to the Challenge of 
Therapeutic Protein Storage 
 
D. E. Mitchell, R. C. Deller, J. Gutierrez-Marcos and M. I. Gibson, in 
preparation 
 
 
 
This chapter contains a paper on the use of polymers poly(ethylene glycol) and 
poly(vinyl alcohol) as protectants in the cryo-storage of proteins, including 
antibodies. DEM undertook freeze-thaw assays of all proteins described below and 
was responsible for dynamic light scattering and circular dichroism analysis. RCD 
was involved in initial compound screening using β-galactosidase and JGM assisted 
in Taq polymerase assay. DEM and MIG wrote the manuscript. 
 
 
7.1.   Abstract 
Proteins have many applications as therapeutics or as tools within research, including 
the rapidly expanding field of antibodies as drug treatments. However the limited 
stability presents a major issue. Current solutions to this problem involve the addition 
of large volumes of additives many of which have been found to have an adverse 
effect on protein activity and potential toxicological concerns for in vivo applications. 
Thus the use of therapeutic proteins has yet to reach its potential due to the limiting 
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factor of long term storage. Here, a mixture of poly(vinyl alcohol) (PVA) and 
poly(ethylene glycol) (PEG) has been shown to protect the proteins β- galactosidase 
(β-Gal), glucose oxidase (GO) and Taq polymerase (Taq) when frozen at -20 °C and -
80 °C over a period of several days, by inhibiting ice recrystallization. Furthermore 
the antibody rabbit IgG was also successfully persevered, showing that this polymer 
mixture has enormous potential for the long term storage of protein therapeutics.  
Since both polymers are relatively cheap and non-toxic it is anticipated that they 
could have applications in both medicine and research. 
 	
7.2.   Introduction 
The use of proteins both as laboratory reagents and as medicines in a clinical setting 
has become widespread since the adoption of insulin as the first protein therapeutic 
over 30 years ago.[1] This includes the use of antibodies as therapeutics for the 
treatment of cancer,[2] Alzheimer’s disease,[3]  inflammatory diseases[4] and many 
others, with antibody based drugs currently the fastest growing class of protein 
therapeutics.[1] The limited storage lifetime presents a major challenge however, with 
many potentially useful proteins degrading in very short timespans.[5] Adverse 
conditions such as hot and cold temperatures,[6] sunlight,[7] and dehydration[8] have all 
previously been found to degrade proteins. Current methods rely on lyophilisation or 
freezing in solutions containing large concentrations of various additives, including 
sugars,[9] salts,[10] and osmolytes.[11] Lyophilisation exposes the protein to low 
temperatures and pressures, dehydration and changes in pH, while freezing in solution 
requires additives which are often been found to have an adverse effect on protein 
activity.  Sugars such as sucrose and dextran are added in both frozen and lyophilized 
formulations in order to stabilise the protein and prevent aggregation,[12] while 
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osmolytes stabilize proteins due to their favourable hydration effects.[13] Currently 
trehalose, the sugar and osmolyte, is widely used in a range of protein storage 
formulations.[14] In addition, several polymeric cryoprotectants have been investigated 
including poly(ethylene glycol) (PEG).[15] Recently Maynard and co-workers, have 
shown that trehalose glycopolymers can enhance the recovery by up to 50 % over 
trehalose alone of β-Galactosidase (β-Gal) when lyophilzed,[16] thus demonstrating the 
potential of polymeric materials. This approach however, requires the synthesis of a 
protein- polymer conjugate, which has less activity than the natural protein and would 
require extensive testing to gain FDA approval.  
 
Although Lyophilzation can be effective, limited access to expensive freeze-drying 
machinery and the difficulty in freeze drying very small amounts of protein, make 
reliable storage in a standard, widely accessible -20 °C freezer highly appealing. A 
major hurdle to be overcome in the storage at this temperature is that of ice 
recrystallization: the growth of ice crystals which can damage and denature biological 
materials.[17] In nature, many organisms have evolved to thrive at freezing 
temperatures, due to their ability to express a unique type of protein called an 
antifreeze (glycol) protein (AF(G)P) which inhibits ice recrystallization.[18] The ice 
recrystallization inhibition (IRI) property exhibited by these proteins is of immense 
interest in the field of cryopreservation. However, mixed success has been reported 
when AF(G)Ps have been added to cryopreservation solutions,[19-20] and to the best of 
our knowledge there has been no successful storage of proteins using AF(G)Ps, 
presumably due to the difficulty in separating the proteins post thaw and potential 
immunogenic effects for in-vivo uses. For this reason synthetic mimetics are highly 
appealing; and therefore Gibson and co-workers and Inada et al. have separately 
		
	 176	
investigated polymers for IRI activity in particularly the use of poly(vinyl alcohol) 
(PVA) which has strong activity.[21-22] Furthermore, work by Mitchell et al. has shown 
that polyampholyte polymers also possess this ability.[23] Recent studies have also 
demonstrated the potential of these polymers in the cryopreservation of various cell 
types,[24-26] however there has been very limited investigation into whether successful 
storage of proteins is also possible. This manuscript describes the use of IRI active 
polymers to produce a highly effective cryopreservation solution, and compares this 
to other widely used cryoprotectants, using a very simple freezing protocol.  
 
7.3.   Results and Discussion 
β–galactosidase (β-Gal) has previously been found to be a useful enzyme when 
exploring cryopreservation.[27] Various polymer and / or small molecule solutions 
were tested to investigate whether they display cryoprotective activity.  Samples were 
frozen at -20 °C and thawed on the bench top, giving a relatively slow freezing and 
thawing rate, Figure 7.1. This mimics the conditions used in a laboratory or clinical 
setting, while also is highly suboptimal for maximum recovery, thus providing a 
robust test of the protective activity shown by the potential cryoprotectants.[28] β-Gal 
activity was determined using a colourmetric assay based on the hydrolysis of ortho-
Nitrophenyl-β-galactoside and subsequent colour change.  
 
It appears that only the PEG/ PVA mix and trehalose has a postive effect on the 
amount of recovery. PVA is well known to inhibit ice recrystallization preventing the 
growth of harmful ice crystals. Therefore the discovery that PVA alone doesn’t have 
any protective activity suggests that damage by ice crystal growth is not the only 
factor when considering the reason why freezing and thawing damages β-Gal. It is 
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also apparent that compounds such as PVP and HES which are commonly added to 
cryoprotective solutions also result in poor recovery. Both PEG and trehalose are 
known to stabilize proteins under lyophilization suggesting that this stabilization 
effect is required in addition to IRI activity.[29-31] Trehalose is also known to aid the 
formation of a vitrified state,[14] which would mean there would be a lack of damaging 
ice crystals present. Furthermore, trehalose and PEG can replace water in the 
hydration shell of a protein reducing damage.[14-15] 
 
 
Figure 7.1. Recovered activity of β-galactosidase after freezing for 3 days at -20 
°C and thawing. Results are expressed as a percentage of fresh, unfrozen protein. 
Error bars are from a minimum of six repeats, and ** represents p < 0.01 relative to 
PBS buffer control. PEG, PVP, Trehalose and HES at concentration of 100 mg.mL-1, 
PVA at 1 mg.mL-1. 
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The concentrations of PVA, PEG and trehalose were also varied to find optimal and 
lowest effective concentrations (ESI, Appendix 6). It was found that PEG 
concentration could be decreased to 40 mg.mL-1, with PVA concentration remaining 
constant. In comparison, trehalose concentration could only be decreased to 75 
mg.mL-1. Thus when a lower concentration of additive is desirable PEG and PVA 
would be preferable to trehalose. PVA can still provide significant protection at 0.5 
mg.mL-1 corresponding well to previous investigation into concentration dependant 
IRI activity.[32]  
 
Although having an IRI active compound is not sufficient for recovery, it may be the 
case that it is necessary in non-vitrifying solutions, as seen by the large increase in 
recovery when PVA is added to PEG in Figure 7.1. To this end another IRI active 
polymer, poly(aminoethyl methacrylate)-co-succinic anhydride (PAEMA-co-SA),[23] 
was tested in a similar manner both with and without PEG, Figure 7.2. It appears that 
the addition of PAEMA-co-SA also results in a dramatic increase in recovery, thus 
suggesting that IRI activity is the critical factor in protein preservation. Ice 
recrystallization leads to bigger ice crystals, resulting in reduced total surface area, 
and consequently the average distance between proteins is significantly reduced. This 
reduced inter-protein distance means that individual protein molecules are more likely 
to aggregate together reducing activity. An IRI molecule maintains small crystals and 
a large surface area reducing the probability of this happening, in addition to 
preventing the damaging effects of individual ice crystals. Interestingly the activity 
drops slightly when PVA and PAEMA-co-SA are added together to PEG. It is 
hypothesised that this is due to dynamic ice shaping (DIS) leading to needle like, 
spicular crystals, a property exhibited by IRI molecules at higher concentrations due 
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to preferential binding to certain faces of the ice crystal, which has been found to be 
problematic in cellular cryopreservation studies.[24, 33-34]  
 
 
Figure 7.2. Recovery of β-galactosidase with PAEMA-co-SA (20 mg.mL-1) 
samples frozen for 3 days at -20 °C. Recovery is expressed as a percentage of fresh, 
unfrozen protein, error bars are from a minimum of six repeats, and ** represents p < 
0.01 relative to PBS buffer control. PEG concentration 100 mg.mL-1, PVA 
concentration 1mg.mL-1.  
 
To explore whether the secondary structure of the β-Gal is being damaged via 
freezing and thawing circular dichroism (CD) was undertaken, Figure 7.3. A general 
reduction in the spectrum intensity is observed, in addition to a change in spectrum 
shape. This corresponds to the recovery levels obtained in Figure 7.1, suggesting that 
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the secondary structure of the protein is being damaged and/or protein aggregation is 
occurring leading to the observed loss of activity. In addition dynamic light scattering 
(DLS) showed some level of aggregation occurs when frozen and thawed, with those 
samples that contain PVA demonstrating less aggregation than those without, 
although performing DLS of protein-polymer mixes is a significant challenge so it is 
difficult to draw conclusions from this (ESI, Appendix 6). 
 
Figure 7.3. Circular dichroism spectra of freeze thaw samples of β- galactosidase 
at concentration 150 µg.mL-1.  
 
In most molecular biology laboratories a -80 °C freezer is used. Therefore the 
experiment was repeated at this lower temperature. The lower storage temperature 
reduces ice crystal growth and ensures a single solid phase, thus suggesting that the 
conditions should be more favourable to storage, but cold induced denaturation could 
be problematic. PEG and PVA mixture and trehalose by itself were stored at -80 °C 
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for three days in order to assess the effect of storage at this lower temperature, Figure 
7.4. Similar to those samples stored at -20 °C, PEG and PVA together provide a very 
potent method of protein storage. Again, it seems that they act synergistically and 
separately there is little protective effect. This suggests that although there would be 
less ice recrystallization at this lower temperature, it is still an important 
consideration, possibly due to the slow thawing process.  
 
Figure 7.4- Freeze thaw spectra of β-galactosidase frozen at -80 °C for 3 days. 
Recovery is expressed as a percentage of fresh, unfrozen protein, error bars are from a 
minimum of six repeats, ** signifies p < 0.01 relative to PBS buffer control. (PEG, 
Trehalose at 100 mg.mL-1, PVA at 1 mg.mL-1 concentrations.) 
 
For many therapeutic applications longer term storage would be highly appealing, 
therefore samples were frozen for a period of 1, 2 and 4 weeks, Figure 7.5. The longer 
term storage will allow time for increased ice recrystallization and any cold induced 
injury to occur. At -20 °C the level of protection given by the PVA and PEG 
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combination diminishes as the time period increases, while trehalose still gives 
recovery levels of near 100 %, Figure 7.5a. In contrast, at -80 °C PVA and PEG still 
provide a good level of protection, Figure 7.5b. This suggests that storage at -80 °C 
would be optimal and achievable since the majority of laboratories dealing with 
biological material are equipped with a -80 °C freezer. It is thought that, this is due to 
reduction in ice recrystallization at this lower temperature. Even at -20 °C the lifespan 
of the protein can be extended by over a week making it relevant for many therapeutic 
uses.    
 
Figure 7.5. Long term study of the freezing and thawing of β-galactosidase. (A) 
Freezing at  -20 °C (B) Freezing at -80 °C for 4 weeks. Recovery is expressed as a 
percentage of fresh, unfrozen protein, error bars are from a minimum of six repeats. 
** Signifies p < 0.01, * signifies p < 0.05 relative to PBS buffer control. PEG, 
Trehalose, HES were used at 100 mg.mL-1 PVA at 1 mg.mL-1. 
 
As some widely used cryoproctants such as glycerol have been found to have a 
detrimental effect on the activity of proteins,[35] it is important to ascertain whether 
the protective solutions described here are having a negative effect on protein activity 
prior to freezing.  If there is a negative effect then the level of recovery could never 
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reach 100 % and the storage mixtures would have limited use. Samples were tested 
prior to freezing against a positive control of PBS buffer only, which has no negative 
effect on the protein.[27] For comparison purposes 10 and 20 wt% glycerol solutions 
were also tested, Figure 7.6. The solutions described here were found to display no 
negative effect on the assay, in contrast to glycerol, which reduces the activity quite 
dramatically. This demonstrates that the PEG and PVA mix would likely be more 
beneficially in formulations where glycerol is currently used. Trehalose also gave a 
small decrease in activity, highlighting the benefit of polymers. 
 
Figure 7.6. Recovery of unfrozen control β-galactosidase samples in the presence 
of various additives. Recovery is expressed as a percentage of fresh, unfrozen 
protein, error bars are from a minimum of six repeats. HES, treholse, PEG at 
100mg.mL-1 and PVA 1mg.mL-1. ** Represents p < 0.01 with respect to positive PBS 
buffer control. Value over 100 % is due to the relative absorbance between positive 
control and PVA sample. 
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In addition to the protection given to β-Gal when frozen and thawed, other proteins 
were examined to determine whether this a generally applicable method. Taq 
polymerase (Taq) is an extremely important protein due to its high thermal stability 
and ability to amplify sequences of DNA. It allows polymerase chain reaction (PCR) 
to be applied to a range of DNA based molecular biology and without it DNA 
analysis would be extremely difficult. Unfortunately, the freezing of Taq results in 
almost total loss of activity, unless large amounts of glycerol is added, making it an 
interesting target for the previously discussed polymer solutions. To this end samples 
of Taq were stored at -20 °C for 3 days as for β-Gal, thawed and tested using 
quantitative PCR (QPCR). QPCR was used to detect differences between samples, as 
it provides numerical data on the efficiency of the Taq, Figure 7.7. Briefly, QPCR 
involves the use of a DNA binding fluorescent dye, which provides a fluorescent 
reading of how many DNA helices have been polymerised by the Taq. The more 
efficient the Taq, the more DNA strands, and the greater the level of fluorescence. As 
glycerol is normally added as a cryoprotectant in commercially available Taq a 
sample with this present was also tested for comparison. The number of cycles taken 
to reach a threshold fluorescence was used as an indication of how good the recovery 
was, i.e. the lower the number of cycles the more efficient the Taq. The Taq sample in 
buffer alone gave no measurable activity. 
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Figure 7.7. QPCR cycle threshold data for various samples frozen at -20 °C for 5 
days. Error bars were found from a minimum of three repeats, ** represents p < 0.01 
relative to unfrozen control. Glycerol w/w%, PEG at 100 mg.mL-1 and PVA 1 
mg.mL-1. Initial DNA concentration was 20 ng.mL-1. 
 
The PEG/PVA mix seems to be the best cryoprotectant, while increasing the glycerol 
concentration appears to have a slightly detrimental effect. This correlates well with 
the results discussed above for β-Gal and suggests that PEG and PVA mixed together 
provide a viable way of the cryostorage of a range of proteins.  
 
To further probe the cryoprotectivity of PEG and PVA, glucose oxidase (GO) was 
tested in the same manner. Similar polymer samples were produced and placed in a -
20 °C freezer for 7 days. They were then thawed and tested with unfrozen samples 
acting as positive controls. As observed for Taq and β-Gal the addition of polymers 
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provides an increase level of protection (ESI, Appendix 6). In PBS buffer only, 
activity drops dramatically showing that the damage caused by freezing and thawing 
is common amongst proteins and PEG and PVA mixed together provides a viable 
method of cryostorage. 
 
Antibodies have attracted widespread interest due to their ability to treat a wide range 
of medical issues, such as many cancers and the Ebola virus.[36-37],	and are forcast to 
have a market value of over $2.5 Billion by 2019.[38] However, therapeutic antibodies 
are limited by storage lifetime. Rabbit IgG was stored at -20 °C for 4 days using the 
PEG and PVA mixture described above to determine whether this mixture would be a 
viable solution to this problem, Figure 7.8.   
 
 
Figure 7.8. Recovered activity of rabbit IgG when stored at -20 °C for 4 days. ** 
represents p < 0.01, error bars are from a minimum of 6 repeats. PEG and trehalose 
were used at a concentration of 100 mg.mL-1 while PVA was used at 1 mg.mL-1 
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Recovery in the PEG/ PVA mix is significantly enhanced when compared to PBS 
buffer alone and also provided a slight enhancement over trehalose.  This 
demonstrates that this mixture is a viable method of storing antibodies, potentially 
helping to address the stability issues in the use of antibody therapeutics which 
currently hold back this emerging and highly promising field. 
 
7.4.   Conclusions 
Overall, the polymer combination of PVA/ PEG has been found to be an effective 
combination in the cryoprotection of proteins, as found for β-Gal, Taq and GO. It is 
hypothesised that PVA is required to inhibit ice recrystallization (IR) and this is 
reinforced by the data shown here for a mixture of PAEMA-co-SA and PEG. PEG is 
known to stabilize proteins, so this may be required to increase stability in proteins 
which undergo cold deformation. Over longer periods of time trehalose appears to 
perform better than the PEG/ PVA mix, possibly due to vitrification, although molar 
concentrations are significantly higher which may be a worry for applications where 
higher concentrations are an issue. Furthermore PEG and PVA have been found to be 
more beneficial than glycerol, which is currently widely used. 
 
The successful freezing storage of an antibody demonstrates that this particular mix 
would be of benefit in the storage of antibody therapeutics a problem that is currently 
limiting their widespread use in a clinical setting. Therefore, it is anticipated that the 
polymer solutions described here can help provide a method of the storage of proteins 
and antibodies, and expand the range of currently available therapeutics and 
laboratory reagents.  
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7.5.   Experimental Section 
7.5.1.   Materials 
β-galactosidase (β-Gal), glucose- oxidase (GO), o- dianosidine, glucose, horse radish 
peroxidase (HRP), o-nitrophenyl-β-D-galactoside (ONPG), ethanol, poly(ethylene 
glycol) (PEG, 2.5 kDa), poly(vinyl pyrolidone) (PVP, 5 kDa), succinic anhydride, 
aminethyl methacrylate rabbit IgG and trehalose were purchased from Sigma Aldrich. 
EvaGreen dye was purchased from VWR chemicals while M13 primers, dNTPs PCR 
buffer (including MgCl2) were purchased from Invitrogen. Rabbit IgG assay kit and 
Taq polymerase was purchased from Life technologies. CDNA was provided by the 
lab of Jose Gutierez-Marcos (University of Warwick Life Sciences department) 
Phosphate-buffered saline (PBS) solution was prepared using preformulated tablets 
(Sigma-Aldrich) in 200 mL of Milli-Q water (>18.2 Ω mean resistivity) to give 
[NaCl] = 0.138 M, [KCl] = 0.0027 M, and pH 7.4. Taq polymerase was dialysed 
against glycerol free taq buffer prior to use using Amicon 0.5ml centrifugal filters 
(Merck, Irl) [Tris-HCL] = 10 mM, [KCl] = 100 mM, [DTT] = 1mM, [EDTA] = 0.1 
mM, 0.5 wt% Tween 20, 0.5 wt% Triton X. Poly(vinyl alchol) (PVA, 5.1 kDa) and 
poly(aminoethyl methacrylate) (PAEMA, 32 kDa) functionalised with approximately 
50 % COOH groups (PAEMA-co-SA) were synthesized as detailed previously.[23, 32] 
All reagents were used as received unless otherwise stated. 
 
7.5.2.   Physical and analytical methods 
Absorbance spectroscopy was undertaken using a Synergy HT multi-mode microplate 
reader (BioTek UK, Bedfordshire, UK). Quantitative polymerase chain reaction 
(QPCR) was carried out on a real-time PCR detection system while a thermocycler 
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was used for standard PCR reactions. PCR was undertaken using the following 
protocol, initiation at 94 °C for 1 minute, denaturation at 94 °C for 20 seconds, 
annealing at 56 °C for 20 seconds and elongation at 72 °C for 30 seconds. Twenty-
five cycles were used and followed by a final elongation at 72 °C for 5 minutes.  
 
Circular Dichroism (CD) spectra were recorded on a spectropolarimeter (Jasco J-720, 
Jasco UK) using a data interval of 0.2 nm. The spectrum was measured 16 times and 
averaged. The spectrum of a blank sample containing only buffer or the appropriate 
cryoprotectant was then subtracted giving a final spectrum for each protein. Dynamic 
light scattering was undertaken on a Malvern Zetasizer Nano ZS, and size was 
measured using intensity particle size distribution. 
 
7.5.3. β-galactosidase assay 
β-Gal activity was determined by a colorimetric assay involving the use of ONPG. 
Briefly aliquots of 30 µL of 4 mg.mL-1 ONPG were added to wells of a 96 well plate 
containing 50 µL of 20 µg.mL-1 β-Gal solution. This was then incubated at room 
temperature for 5 minutes and quenched by addition of 50 µL of 1M Na2CO3 solution. 
Absorbance was measured at 420 nm. 
 
7.5.4.   Glucose oxidase assay 
Activity of GO was determined using the oxidation of o-dianosidine through a 
peroxidase-coupled reaction[39]. Briefly 2.5 mg of o-dianosidine was dissolved in 2 
mL of ethanol, which was further diluted by the addition of 8 mL of PBS buffer 
resulting in a 10 mL stock solution. A Horseradish peroxidase (HRP) stock solution 
of 100 µg.mL-1 was prepared by dissolving HRP into a solution of 18 % w/w glucose 
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in distilled water, while GO samples were prepared at a concentration of 2 µg.mL-1. 
30 µL of GO sample was added to 30 µL of HRP solution into separate wells of a 96 
well plate, then 150 µL of o-dianosidine was added and the mixture was incubated for 
3 minutes. Finally absorbance was measured at 450 nm. 
  
7.5.5.   Quantitative polymerase chain reaction assay 
Cryoprotectants at required concentrations were added to Taq in the appropriate 
buffer solution in 20 µL volumes. QPCR was undertaken using standard protocols. 
EvaGreen dye was used as the DNA-binding fluorescent dye, sample volumes were 
20 µL. Briefly, samples of 2.5 µL PCR buffer, 1 µL dNTPs, 1.5 µL Eva Green 
fluorescent dye, 1 µL forward and reverse primers, 1 µL of Taq at 1.25 U.µL-1 and 12 
µL PCR water, were prepared. Samples were tested in triplicate with three dilutions of 
template DNA at 20, 10 and 5 ng, with appropriate positive and negative controls. 
 
7.5.6.   Rabbit IgG assay 
Activity of rabbit IgG was determined using an “Easy-Titer rabbit IgG assay kit” 
(Life technologies).  125 µL Solutions of 125 µg.mL-1 of IgG were prepared and 
frozen for 4 days. Upon thawing, 20 µL of IgG sensitized beads were pipetted into 
wells of a 96 well plate and 20 µL of IgG solution was added. The plate was then 
incubated under shaking for 5 minutes at room temperature after which 100 µL of 
blocking buffer was added and the plate was incubated for a further 5 minutes. 
Absorbance was measured at 405 nm using a plate reader, and samples were 
compared to a freshly made up positive control. 
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7.5.7.   Freeze-thaw methodology 
Samples were made in triplicate at the appropriate concentrations and frozen by 
placing in a freezer either at -20 °C or -80 °C. The samples were then held at this 
temperature within the freezer for the appropriate amount of time and then thawed on 
the bench top. 
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Chapter 8 
8. Conclusions 
Since their discovery antifreeze proteins (AFPs) and antifreeze glycoproteins 
(AFGPs) have been of great interest due to their unique properties, particularly ice 
recrystallization inhibition (IRI). Molecules possessing this property have potential 
benefits in many areas, including cellular cryopreservation, therapeutic protein 
storage, frozen food and ice resistant surfaces. However these are severely limited by 
lack of understanding of their method of action, relatively low availability and 
potential immunogenic issues.  
 
The identification of new structures that posses IRI activity is crucial to understanding 
and overcoming these challenges.  To this end, proteins which show some sequential 
or structural homology to AFPs were investigated for this effect. L-type lectins, which 
show some evolutionary similarity to type 2 AFPs, were shown to be surprisingly 
potent, calcium-dependant ice recrystallization inhibitors. Their activity was found to 
be modulated by the addition of calcium providing the first-reported case of 
‘switchable’ activity. Furthermore the addition of a sugar competing with ice for the 
binding site was actually beneficial, slightly increasing IRI activity, suggesting that 
IRI activity is more complicated than just the possession of an ‘ice recognition 
domain’. This activity was shown in three different l-type lectins suggesting that it is 
a universal property. 
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As many antifreeze proteins are known to be amphipathic a second class of peptides 
where also investigated; antimicrobial peptides. Nisin A, an antimicrobial was also 
found to have surprisingly potent activity at acidic pH, which corresponds with 
protonation of its two histidine residues. Furthermore, to enable antifreeze activity at 
physiological pH, nickel and zinc ions, which can bind histidine residues causing the 
same conformational change, were added. This also switched on IRI activity in a 
similar manner to the addition of Ca2+ to l-type lectins, further demonstrating the 
switchability of these proteins. 
 
The use of antifreeze proteins or other IRI active proteins is limited by the difficulty 
obtaining large quantities and potential immunogenic effects. Conversely, the 
development of synthetic polymers that mimic biological activity is highly appealing 
due to their scalability, tunable structures and huge monomer scope. Despite this, very 
few synthetic molecules have been identified which display IRI activity. It has been 
shown here that poly(ampholytes) inhibit ice recrystallization and that approximately 
a 1:1 ratio between positively and negatively charged side chains is optimum. This 
structure is the first reported that does not have a poly(hydroxylated) structure, and 
opens the possibility of a new class of IRI active molecules, while questioning the 
hypothesis that molecules must have a precise, hydroxyl based ice recognition face in 
order to possess IRI activity. 
 
While the identification of IRI molecules above has been relatively successful, it is 
currently limited by low throughput assays associated with this property. The 
application of gold nanoparticles (AuNPs) has been investigated as a potential high 
throughput method. As ice recrystallization leads to the growth of larger ice crystals 
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and hence reduced surface area, the AuNPs are forced closer together, and a colour 
change from pink to blue is observed. By using UV-Vis spectroscopy (or by eye), this 
colour change was found to be well correlated with IRI activity. As this can be 
performed in a 96 well plate, identification can be sped up dramatically. Using this 
method, serum proteins were also identified for the first time as having some IRI 
activity at higher concentrations.   
 
In addition to polymeric AFP mimics, this thesis has shown that metallohelical 
structures constructed from iron coordination complexes to resemble alpha helical 
structures, which in terms of diameter and charge, are similar to a type 1 AFPs. Thus 
providing a range of compounds which could be investigated for IRI activity. It was 
found that amphipathic metallohelices do possess IRI activity, although unfortunately, 
they could not be screened using the above gold nanoparticle assay due to the strong 
purple colour of solution when dissolved. These also have the benefit of having a 
defined molecular weight unlike polymers, which have some dispersity, allowing 
more precise structural-activity investigation to be achieved. Their similarity to a type 
1 AFP demonstrates that a structural or biomimetic approach to identifying features 
required for IRI activity and new IRI molecules is achievable.  
 
After investigating the design, synthesis and identification of IRI active molecules the 
potential applications in a clinical setting was explored. As a cryprotectant, an IRI 
active molecule would have enormous benefit, preventing highly damaging ice crystal 
growth. Building from previous work on poly(ampholytes), the polymer poly(methyl 
vinyl ether-alt-maleic anhydride) functionalized with ethanolamine to give an 
alternating positive and negative side chain structure was found to be a potent 
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cryoprotection agent in the storage of red blood cells (RBCs). This polymer is low 
cost, highly scalable and non-cytotoxic making it highly interesting for a range of 
cryopreservation challenges.  
Finally, the storage of proteins and antibodies was investigated. The polymers 
poly(vinyl alcohol) (PVA) and poly(ethylene glycol) (PEG) when mixed to together, 
were found to be highly efficient in the recovery of several proteins. PVA has 
previously been found to be IRI active, while PEG provides a stabilizing effect on the 
protein. The importance of an IRI active molecule was reinforced by the addition of 
an IRI active poly(ampholyte) to PEG providing the same recovery levels. The PEG 
and PVA mixture is also shown to be highly efficient in the protection of antibodies. 
As protein therapeutics and in particular antibodies have enormous potential in a 
clinical setting, for example the treatment of cancer and Alzheimer’s disease, the 
viable long term storage of these materials is paramount and the solution presented 
here provides a novel, viable method of achieving this. 
In uncovering a range of different IRI active molecules it is possible to rank them in 
terms of relative activity. The current best remains natural hyperactive AFPs 
followed, by other AFPs and AFGPS and PVA, all of which are extremely potent, 
working at concentrations less than 1 mg.mL-1. The antimicrobial peptide nisin and l-
type lectins are relatively equal in active concentration, while the metalohelicates 
require higher concentrations but inhibition is greater. Finally the polyampholytes 
described here are the least affective. It is important to consider possible applications 
however, and with this in mind the ampholytes are useful as cheap, biocompatible 
materials, something which may be an issue for protein based IRI active compounds. 
Furthermore, by using any IRI active compound in cryopreservation, the volume of 
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other potentially harmful additives can be reduced, meaning that providing they are 
biocompatible any IRI active compound is of benefit. 
Ultimately, it is hoped that the research presented here will lead to the rational design 
of a range of novel synthetic antifreeze protein mimics, and to a greater understanding 
of the interactions occurring at the ice water interface. In addition, it is anticipated 
that the IRI active materials will have tremendous impact on the field of regenerative 
medicine through enhanced cryopreservation of stem cells, transplantation medicine 
and the use of proteins as therapeutics.   
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Appendix 1 
Appendix 1: Supplementary Information for “Latent 
Ice Recrystallization Inhibition Activity in Non-
Antifreeze Proteins; Ca2+ Activated Plant Lectins and 
Cation-Activated Antimicrobial Peptides”. 
 
Sequential comparison of l-type lectins and type 2 antifreeze proteins 
 
The sequence from type 2 AFP (pdb code 2AFP) from Sea raven, Hemitripterus 
americanu was analyzed against the protein databank (PDB) database for similarity. It 
was found to be a member of the l-type lectins superfamily and various animal l-type 
lectins were found to display similarity, figure S1.1. 
 
Figure S1.1. Sequence alignment of type 2 AFPs and most closely related lectins. 
Similar or identical amino acid residues are highlighted. Lectins are ordered 
downward in terms of level of sequential similarity with type 2 AFP from sea raven 
shown as the top entry. 
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Plant lectins are significantly cheaper and easier to obtain in large quantities, and have 
less potential immunogenic and toxicity issues than human lectins or snake venom, 
while still displaying the same sugar binding function despite being less sequentially 
similar. Therefore, it was decided that these would be used instead of mammalian 
lectins. Comparing lithostathine, a l-type lectin found in figure S1.1 to be highly 
similar to type 2 AFP with several plant lectins there was some sequential similarity. 
Figure S1.2 gives a comparison of lithostathine, several plant lectins and type 2 Sea 
raven AFP.  
 
 
 
Figure S1.2.  Sequence alignment of lithostathine, type 2 AFP and L-type plant 
lectins.  
 
 
 
The pH dependence of ConA on IRI activity 
In order to assess the effect pH has on IRI activity, ConA was evaluated in pH 4.7 
acetate buffer (with added calcium) and compared to its activity at pH 7.4 (in HEPES 
buffer). MLGS was recorded as a percentage of the appropriate buffer control.  
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Figure S1.3. Comparison of IRI activity of ConA in acetate and HEPES buffer 
(concentration 5 mg.mL-1). Error bars represent ± SD from a minimum of 3 repeats, 
MLGS = mean largest grain size relative to HEPES and calcium chloride or Acetate 
and calcium chloride buffer control. * signifies p < 0.05 relative to ConA in HEPES 
Buffer. 
 
Changing the pH provides a significant improvement in IRI activity; it is thought that 
this is because ConA exists as a dimer at lower pH, suggesting that the quaternary 
structure also plays a role in its activity. 
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CD Spectra of lectins before and after heat denaturation 
By heating at 80 °C the protein was denatured, as seen in figure S1.4 by the change to 
a more random coil secondary structure. 
 
Figure S1.4. CD Spectra of lectins before and after denaturation by incubation at 
80 °C. (A) CD spectra of soybean agglutinin (SBA); (B) CD spectra of concanavalin 
A (ConA).  
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Figure S1.5. Circular dichroism spectra of nisin A in PBS and acetate buffer. CD 
spectra was taken at nisin concentration 500 µg.mL-1 and buffers were diluted 2 fold 
from those detailed in the methods section with deionized water. 
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It appears that there is a very minor change to the confirmation on nisin A when the 
pH is changed. As its antimicrobial activity dependents on its interaction with the cell 
membrane, it may be the case that the structure does not dramatically change in 
solution.  
MLGS of various buffers and negative controls used in this study 
To insure that the change in mean largest grain size was not a result of the change of 
buffer alone, all buffers formulations used here were also assessed for any IRI 
activity. As PBS is the standard buffer used for the “splat test” the other buffers are 
tested in comparison to this, Figure S1.6.  
 
Figure S1.6. MLGS of buffers used in this study. Error bars represent ± SD from a 
minimum of 3 repeats, MLGS = mean largest grain size relative to PBS buffer sample 
shown in the first column. Both [CaCl2] = 5mg.mL-1, Cabohydrates Gal = galactose, 
GalNac = N-acetylgalactosamine were at concentration 10 mM.   
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Appendix 2 
 
 
Appendix 2: Supplementary Information for 
“Quantitative Study on the Antifreeze Protein 
Mimetic Ice Growth Inhibition Properties of 
Poly(ampholytes) Derived from Vinyl-Based 
Polymers” 
 
SEC analysis of poly(aminoethyl methacrylate) 
Below are representative traces for the SEC of the PAEMAs. Molecular weights 
below that expected from NMR/conversion were observed, as discussed in the main 
manuscript. This was ascribed to a combination of polymer ‘sticking’ to the column 
and internal amidation by backbiting of the amine onto the ester, which is a well-
known side reaction for PAEMA upon storage in aqueous solution. 
Figure S3.1 shows the SEC trace obtained for PAEMA11k showing two peaks at 
molecular weights significantly below that expected from conversion and end-group 
analysis. Similarly, Figure S3.2 shows SEC for PAEMA35k showing a similar bimodal 
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distribution at very small molecular weights. Further evidence that these molecular 
weights are incorrect is that the polymers could be dialysed (in acidic media to 
prevent amidation) against 10 kDa MWCO dialysis tubing, without significant mass 
loss. 
 
Figure S2.1. SEC trace of PAEMA MN = 11 kg.mol-1 (by NMR).  
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Figure S2.2. SEC trace of PAEMA MN = 35 kg.mol-1 (by NMR).  
 
It was also attempted to functionalize the amine side chains, to obtain a non-reactive 
polymer. This was done by addition of Boc-anhydride, and the obtained SEC (in 
THF) trace is shown below. A rather disperse, but mono-modal peak is obtained at ~ 
20 kg.mol-1, which is in line with the NMR measurements, suggesting the polymer 
does have the anticipated chain length. The dispersity can be accounted for by the 
incomplete functionalization of the amine groups, leaving some cationic groups which 
still have strong column interactions.  
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Figure S2.3. SEC (THF) of Boc-PAEMA. MN = 33 kg.mol-1 (by NMR). 
 
 
Synthesis of carbohydrate-centered poly(ampholytes) 
The reaction scheme is shown in Figure S3.4, below, and full synthetic details are also 
included. 
 
 
Scheme S2.1. Synthesis of carbohydrate poly(ampholytes) (i) Methacrylic 
anhydride/pyridine; (ii) Boc-Cys, then TFA/DCM. 
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Figure S2.4. SEC (DMF) showing decrease in retention time upon addition of 
boc-cysteine. 
 
Synthetic procedures. 
All reactions were undertaken in a similar manner. Representative example using 
glucose core is described.  
 
Glucose pentamethacrylate 
Glucose (5.0500 g, 27.75 mmol, 1 eq), methacrylic anhydride (21.5252 g, 0.14 mol, 
5.1 eq) and pyridine (125 mL) were stirred at room temperature overnight before 
being heated to 60 °C for 3 hours. Upon cooling, dichloromethane (50 mL) was added 
and the product washed with 0.1M HCl (40x50 mL), water (2x50 mL), brine (50 mL) 
and saturated NaHCO3 (2x50 mL) before being dried with MgSO4. The solvent was 
then removed under vacuum at 40 °C to yield a clear sticky product which was 
purified from THF and water (2.9101 g, 20 % yield). 1H NMR (CDCl3, 400 MHz) δ 
(ppm): 6.45 (d, J=3.8 Hz, 0.5H, β anomer), 6.27-6.03 (m, 5H, C=H1H2), 5.87 (d, 
J=8.0 Hz, 0.5H, α anomer), 5.76-5.44 (m, 6H, 5 C=H1H2, 1 CHglucose), 5.39-5.09 (m, 
2H, CHglucose), 4.44-4.15 (m, 3H, CHglucose, CH2 glucose), 2.01-1.84 (m, 15H, CH3); 13C 
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NMR (CDCl3, 600MHz, PENDANT) δ (ppm) 166.9-164.9 (C=O), 135.7-134.8 
(R2C=CH2), 128.2-126.4 (R2C=CH2), 92.3-92.1 (β anomer), 89.8-89.7 (α anomer), 
76.1-68.2 (CHglucose), 62.8-62.0 (CH2 glucose), 18.2-18.0 (CH3); IR υ (cm-1) 1721 (s, 
C=O ester), 1637 (m, C=C), 1453 (m, CH2/CH3 bend), 1317 (m, CH3 bend), 1292 (m, 
alkyl C-H), 1140 (s, C-O stretch); ESMS (positive mode) m/z 475.1 [M(4mer)+Na]+ 
C22H28O10, m/z 543.2 [M(5mer)+Na]+ C26H32O11; GPC (DMF) Mn 432, Mw 442, 
Mw/Mn 1.02. 
 
Penta-cysteine glucose methacrylate. 
Methacrylated glucose (0.0521 g, 96 µmol, 1eq), Boc-cysteine (0.1143 g, 250 µmol, 
2.6 eq), tributyl phosphine (drop, catalytic) and benzylamine (drop, catalytic) were 
dissolved in DCM (3ml) and stirred at 45 °C for 72 hours. DCM (10 mL) was then 
added and the product washed with water (2x20 mL) and brine (20 mL) before the 
solvent was removed under vacuum. The product (Gluco-Cys5) was then purified in 
THF and water. IR υ (cm-1) 2960 (m, O-H), 2927 (m, C-H stretch), 1720 (s, C=O 
ester), 1637 (m, C=C), 1454 (m, CH2/CH3 bend), 1318 (m, CH3 bend), 1160 (s, C-O 
stretch), 751 (m, C-S); GPC (DMF) Mn 946 Da, Mw 1190 Da, Mw/Mn 1.26. The 
product was then dissolved in DCM, and TFA (4 drops) added to remove the boc 
protecting group. The product was then dialysed and the water removed by freeze-
drying to yield a sticky solid (0.0072 g, 7 % yield) 
 
Cellobiose core 
GPC (DMF) Mn = 2126 Da, Mw = 2153 Da, Mw/Mn 1.01.  
Stachyose core  
GPC (DMF) Mn = 2467 Da, Mw = 2575 Da, Mw/Mn 1.04. 
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Ice recrystallization assay 
Some example micrographs are shown below. The COOH degree of functionalization 
is indicated, with 50 % clearly have smaller grains compared to the others. 
Micrographs are for P7, P11, P16 respectively at 15 mg.mL-1. 
 
 
Figure S2.5. Example ice recrystallization assay micrographs for (left to right) 
P7, P11, P16 at 15 mg.mL-1, after 30 minutes annealing at -8 °C.  
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Appendix 3 
Appendix 3: Supplementary Information for “Gold 
Nanoparticle Aggregation as a Probe of Antifreeze 
(Glyco) Protein-Inspired Ice Recrystallization 
Inhibition and Identification of New IRI Active 
Macromolecules” 
	
Synthesis and characterisation of Poly(vinyl alcohol), PVA. 
 
The synthesis of PVA used in this study, was conducted as described in Congdon et 
al[1]. The method is explained below and shown in Scheme S3.1. Table S3.1 provides 
characterization details of the polymers selected for this study 
 
Scheme S3.1. Schematic of the synthesis of PVA using RAFT polymerisation.  
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Table S3.1. Details of polymers used in this study. 
 
Entry [M]/ 
[CTA](a) 
Conv(b) 
% 
Mn,theo  (c)  
g.mol–1 
Mn,NMR (d) 
g.mol–1 
Mn,SEC 
g.mol-1 
Đ   (e) 
 
DPN (b) PVA(g) 
PVAc10 10 83.2 860 900 870 1.18 10 PVA10 
PVAc30 50 60.0 4300 2580 2700 1.45 30 PVA30 
PVAc56 100 54.7 8600 4700 5100 1.23 56 PVA56 
PVAc154 200 73.8 17200 12700 13800 1.45 154 PVA154 
PVAc246 300 80.1 25800 20660 21700 1.39 246 PVA246 
  
(a) Monomer to RAFT agent ratio; (b) Determined by 1H NMR spectroscopy; (c) 
Theoretical Mn determined from monomer to RAFT agent ratio; (d) Determined by 1H 
NMR; (e) Determined by SEC in THF using PMMA standards; (f) Number-average 
degree of polymerization; (g) Corresponding PVA prepared by hydrolysis of the 
respective PVAc polymer. 
 
 
Synthesis of methyl(ethoxycarbonothioyl)sulfanyl acetate (MADIX 2) 
 
Ethanol (70 mL) was added to a round bottom flask equipped with a stir bar. 
Potassium hydroxide (11.45 g, 0.2 mol) was added and left to dissolve for 1 h. Carbon 
disulphide (12.1 mL, 0.2 mol) was added dropwise, forming a yellow solution, which 
was left for 5 h. Methyl bromoacetate (6.5 mL, 0.06 mol) was added dropwise and the 
solution left to stir overnight. The solution was filtered and washed with cold ethanol 
and concentrated in vacuo. The crude product was partitioned in DCM and sat. brine 
solution and the organic fraction concentrated in vacuo. The residue was washed 
through a column of basic alumina using pure ethyl acetate as the eluent. The 
fractions were concentrated in vacuo and then dried under vacuum. Yield 5.25 g 46 
%. 1H NMR (CDCl3): δ = 1.42 (2H, t, J=7.2, CH3CH2), 3.76 (3H, s, CH3O), 3.92 (2H, 
d, J=7, SCH2), 4.64 (3H, q, J=7.2, CH3CH2). 13C NMR (CDCl3): δ = 14.0 (CH2–CH3), 
37.7 (CH2), 61.0(CO2CH3), 70.4 (CH2–CH3), 167.7 (C=O), 212.4 (C=S). 
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Polymerisation of vinyl acetate using MADIX 2 
As a representative example, MADIX 2 (0.21 g, 0.99 mmol), vinyl acetate (4.67 g, 
2.64 mmol), and ACVA (4,4′-azobis(4-cyanovaleric acid); 0.013 g) were added to a 
stoppered vial. The solution was thoroughly degassed under a flow of N2 for 20 min, 
and the reaction mixture was then allowed to polymerize at 68 °C for typically 15 h. 
The yellow solutions were then cooled to room temperature. Poly(vinyl acetate) was 
then recovered as a yellow sticky solid after precipitation into hexane. The hexane 
was then decanted and the poly(vinyl acetate) was redissolved in THF, which was 
then concentrated in vacuo and thoroughly dried under vacuum at 40 °C for 24 h, 
forming a white solid. Representative characterization data for PVAc56: 1H NMR (400 
MHz, CDCl3) δ 4.61 (−CHO–CH2, br, 1H), 1.74 (−CO–CH3, br, 3H), 1.53 (−CH2–, 
br, 2H); MnSEC(THF) = 5100 Da, Mw/Mn = 1.23. 
 
Hydrolysis of poly(vinyl acetate) to poly(vinyl alcohol) 
As a representative example, poly(vinyl acetate) (1.5 g, 3300 Da, Mn/Mw = 1.22) was 
dissolved in a methanol (20 mL) and hydrazine hydrate solution (15 mL, 80 % in 
water) in a round-bottom flask. The reaction mixture was stirred at 30 °C for 2 h. The 
reaction mixture was then dialyzed using distilled water and poly(vinyl alcohol) was 
recovered as a spongy white solid by freeze-drying the dialysis solution. 
Deacetylation was determined by 1H NMR. Representative characterization data for 
PVA56: 1H NMR (400 MHz, CDCl3) δ 4.00 (−CHOH–, br, 1H), 1.68–1.60 (−CH2–, 
br, 2H). 
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Figure S3.1. SEC traces of PVA of various molecular weights showing clear 
differences in size and low polydispersities.  
 
Determining extent of aggregation 
The change in absorbance at 520 nm was identified as the simplest measurement of 
aggregation in this study. To account for scattering of aggregated samples, we 
conveniently measured the difference between the actual absorbance at 520 nm and 
that of a baseline define between 450 and 680 nm as show in Figure S3.2.  
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Figure S3.2. Measurement of absorbance used here. 
 
Variable volume gold particle aggregation experiments 
An advantage of the AuNP method is that samples can be tested at a range of different 
volumes. The rationale for this was that larger volumes would take longer to 
freeze/thaw, which should increase the amount of ice recrystallization inducing more 
aggregation and enabling optimization so that there are clear differences between IRI 
active and non-active compounds. Furthermore, the standard ‘splat’ assay only uses 
10 µL of liquid, which is far from the volumes employed in applications such as 
cryopreservation, and therefore larger volumes may provide a more predictive test for 
the additives ultimate application. To this end samples of 50, 100, 200, 500, 1000 and 
2000 µL where prepared in 96 and 24 well plates and subjected to the same 
freeze/thaw cycle as detailed within the paper. The sample depth (which is crucial for 
freezing rate) verses the volume of the samples is plotted in Figure S3.3. 
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Figure S3.3. Effect of well depth. (A) Depth of well compared to volume of sample, 
a 24 well plate is substituted for a 96 well plate for samples volumes greater than 200 
µL; (B) Absorbance dependence on the well depth. 
 
From Figure S3.3, samples with lower well depth provide a generally lower 
absorbance probably due to the decreased distance for the light to pass through. At the 
highest depth, 6.24 mm there is very little absorbance at 520 nm compared to 
background scatter, possibly due to the increased thawing time and increased ice 
recrystallization. The depth-dependence also suggests that this assay is probing ice 
recrystallization and not ice shaping, which was previously suggested. Overall the 
clearest difference between IRI active and no active compounds is found at a well 
depth of 3.118 mm, which corresponds to 100 µL in a 96 well plate. It is therefore 
recommended that 50 µL of sample to 50 µL of AuNPs making an overall volume of 
100 µL be used to investigate the IRI activity of compounds. 
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Comparison of absorbance change to mean largest grain size for poly(Amino 
ethyl methacrylate)-co-succinic anhydride 
Since PAEMA-co-SA has also been shown to exhibit IRI activity the absorbance has 
been plotted here against mean largest grain size (MLGS) (as a percentage of PBS 
buffer negative control), Figure S3.4.  
 
 
Figure S3.4. Comparison of PAEMA-co-SA polymers mean largest grain size 
(MLGS) and absorbance at 20 mg.mL-1. MLGS = mean largest grain size relative 
to a PBS control, expressed as %.  Error bars represent ± SD from a minimum of 3 
repeats. 
 
Plotting the MLGS absorbance change against each other on the same graph shows a 
linear correlation and reinforces the premise that the AuNP method is probing the 
same phenomenon as the “splat test” namely ice recrystallization inhibition. 
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Concentration dependence of AuNPs with PVA 
To assess how the concentration of AuNPs affects the assay, a serial dilution was 
performed in the presence of 5mg.mL-1 PVA, figure S3.5.  
Figure S3.5. Spectra of AuNPs frozen in the presence of 5mg.mL-1 PVA. Values 
given in the key are concentration in µg.mL-1. 
 
From Figure S3.5 it can be seen there is a reduction in absorbance across the whole 
spectra as AuNP concentration decreases. However the peak at around 550 nm 
remains at all concentrations showing that PVA prevents the aggregation of AuNPs. 
Furthermore if no PVA is added, this 550 nm peak disappears at all concentrations of 
AuNPs. To maximize the difference between 520 nm and 650 nm a minimum AuNP 
concentration of 80 µg.mL-1 is optimal to avoid wastage and still function in the assay. 
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Appendix 4 
Appendix 4: Supplementary Information for 
“Antifreeze Protein Mimetic, Supramolecular 
Metallohelices with Potent Ice Recrystallization 
Inhibition Activity”. 
 
Synthesis 
The compounds 5-(chloromethyl)-2,2'-bipyridine,[1] [2]hydroxypicolinaldehyde,[3] 
phenylglycinol,[4]  1-phenyl-2-(prop-2-ynyloxy)ethanamine[5] and pyrazine-2-
carboxaldehyde[6] were synthesised by known methods, and are described briefly 
below. 
 
5-methoxypicolinaldehyde 
 
5-hydroxypicolinaldehyde (2.0 g, 1 eq.), methyl iodide (2.3 g, 1 mL, 1 eq.), and 
potassium carbonate (2.69 g, 1.2 eq.) were dissolved in acetonitrile (50 mL) and 
heated at reflux (85 °C) for 18 h, allowed to cool to ambient temperature and filtered 
through a silica plug. Solvents were removed under reduced pressure and the crude 
material was dissolved in dichloromethane (20 mL), filtered and solvents were 
removed under reduced pressure to give the desired compound as white solid. 
Yield = 1.2 g, 72 %. 
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1H NMR (300 MHz, 298 K, CDCl3) δH 9.92 (1H, s, CHO), 8.36 (1H, d, 4JHH = 3.0 
Hz), 7.90 (1H, d, 3JHH = 8.5 Hz), 7.24 (1H, dd, 3JHH = 8.5 Hz, 4JHH =  2.5 Hz, Py), 3.89 
(3H, s, OCH3).  
13C{1H} NMR (75 MHz, 298 K, CDCl3) δC 192.1 (CHO), 159.1, 146.4, 138.7, 123.5, 
120.0 (Py), 56.0 (OCH3).  
MS (ESI) m/z 138 [M+H]+ , 160 [M+Na]+.  
IR v cm-1 3099 w, 3052 w, 3033 w, 2984 w, 2947 w, 2831 w, 1692 s, 1572 s, 1489 m, 
1452 m, 1380 w, 1308 m, 1261 m, 1222 m, 1117 m, 1007 s, 898 m, 852 s, 750 m, 734 
m.  
Elemental analysis found (calculated for C7H7NO2) % C 61.00 (61.31), H 4.98 (5.14), 
N 10.00 (10.21). 
 
(S)-1-phenyl-2-(prop-2-ynyloxy)ethanamine 
 
(S)-1-phenyl-2-(prop-2-ynyloxy)ethanamine was synthesised using the procedure 
described for 5-methoxypicolinaldehyde, substituting iodomethane for 3-bromoprop-
1-yne (80% in toluene) and (R)-phenylglycinol for (S)-phenylglycinol. Distilled under 
high vacuum at 110 °C. 
Yield 1.03 g, 81 %. 
1H NMR (400 MHz, 298 K, CDCl3) δH 7.45-7.20 (5H, m, Ph), 4.26-4.16 (3H, m, CH, 
CH2), 3.68 (1H, dd, 3JHH = 9.0 Hz, 4JHH = 4.0 Hz), 3.47 (1H, t, 3JHH = 9.0 Hz, CH2), 
2.43 (1H, t, 4JHH = 2.5 Hz, CH), 1.70 (2H, s, NH2). 
13C{1H} NMR (101 MHz, 298 K, CDCl3) δC 142.1, 128.3,  127.3, 126.7 (Ph), 79.4 
(C), 74.4 (CH), 60.2, 58.3 (CH2), 55.2 (CH). 
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MS (ESI) m/z 159 [M-NH2]+, 176 [M+H]+ 
IR υ cm-1 3286 w, 2855 w, 1087 s, 861 m, 759 s, 699 s. 
Elemental analysis found (calculated for C11H13NO) % C 74.92 (75.40), H 7.56 
(7.48), N 7.92 (7.99). 
Optical rotation +65.74 ° (3.10 g/ 100 mL)  
 
(R)-1-phenyl-2-(prop-2-ynyloxy)ethanamine  
 
(R)-1-phenyl-2-(prop-2-ynyloxy)ethanamine was synthesised using the procedure 
described for 5-methoxypicolinaldehyde, substituting iodomethane for 3-bromoprop-
1-yne (80 % in toluene). Distilled under high vacuum at 110 °C. 
Yield 0.37 g, 28 %. 
1H NMR (400 MHz, 298 K, CDCl3) δH 7.43-7.22 (5H, m, Ph), 4.25-4.17 (3H, m, CH, 
CH2), 3.68 (1H, dd, 3JHH = 9.0 Hz, 4JHH = 4.0 Hz), 3.47 (1H, t, 3JHH = 9.0 Hz, CH2), 
2.43 (1H, t, 4JHH = 2.5 Hz, CH), 1.68 (2H, s, NH2). 
13C{1H} NMR (101 MHz, 298 K, CDCl3) δC 142.7, 128.5, 127.5, 126.8 (Ph), 79.6 
(C), 74.6 (CH), 60.4, 58.4 (CH2), 55.4 (CH). 
MS (ESI) m/z 159 [M-NH2]+, 176 [M+H]+ 
IR υ cm-1 3285 w, 2855 w, 1088 s, 859 m, 759 s, 699 s. 
Elemental analysis found (calculated for C11H13NO) % C 74.82 (75.40), H 7.60 
(7.48), N 7.81 (7.99). 
Optical rotation -81.60 ° (3.12 g/ 100 mL) [Lit. -32.11 ° (6.08 g/100 mL)] 
 
5-(benzyloxy)picolinaldehyde 
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5-hydroxypicolinaldehyde (2.0 g, 1 eq.), benzyl bromide (0.73 g, 0.5 ml, 1.05 eq.), 
and potassium carbonate (2.69 g, 1.2 eq.) were dissolved in acetonitrile (50 mL) and 
heated at reflux (85 °C) for 18 h, allowed to cool to ambient temperature and filtered 
through a silica plug. Solvents were removed under reduced pressure and the crude 
material was dissolved in dichloromethane (20 mL), filtered and solvents were 
removed under reduced pressure to give the desired compound as yellow solid. 
Yield = 0.67 g, 77 %. 
1H NMR  (300 MHz, 298 K, CDCl3) δH 9.99 (1H, s, CHO), 8.52 (1H, d, 4JHH = 2.5 
Hz), 7.96 (1H, d, 3JHH = 8.5 Hz), 7.43 (6H, m, Ar), 5.21 (2H, s, CH2). 
13C{1H} NMR (75 MHz, 298 K, CDCl3) δC 192.1 (CHO), 158.2, 139.2, 135.2, 129.0, 
128.8, 127.7, 127.1, 123.5, 121.1 (Ar), 70.78 (CH2).  
MS (ESI) m/z 236 [M+Na]+. 
IR v cm-1 2836 w, 1698 s, 1571 s, 1501 w, 1477 w, 1462 w, 1452 m, 1387 m, 1370 w, 
1310 s, 1262 m, 1209 s, 1130 m, 1045 w, 1032 w, 1012 w, 996 w, 912 w, 872 w, 835 
m, 790 w, 740 s, 696 s. 
Elemental analysis found (calculated for C13H11NO2) % C 72.67 (73.23), H 5.38 
(5.20), N 6.36 (6.57).  
 
 (S)-2-(2,2'-bipyridin-5-ylmethoxy)-1-phenylethanamine 
 
S-Phenylglycinol (1.00 g, 1 eq.) was dissolved in dry tetrahydrofuran (20 mL) and 
was added dropwise to a stirred suspension of sodium hydride (0.36 g, 2 eq.) in dry 
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tetrahydrofuran (10 mL). The solution was stirred for 1 h at ambient temperature 
before a solution of 5-(bromomethyl)-2,2'-bipyridine (1.82 g, 1 eq.) in dry 
tetrahydrofuran (20 mL) was added dropwise. The solution was stirred for a further 1 
h at ambient temperature. The reaction mixture was then heated to reflux (65 ˚C) for 2 
h, allowed to cool the ambient temperature, and quenched with the addition of brine 
(40 mL). The dichloromethane extracts (4 × 60 mL) were dried over sodium sulphate 
and the solvent was removed to leave a dark yellow oil. This crude product was 
purified by Kügelrohr distillation (excess phenylglycinol removed at 120°C under 
high vacuum) to give a yellow oil that solidifies on standing. 
Yield 1.25 g, 56 %. 
1H NMR (300 MHz, CDCl3) δH 8.61-8.59 (1H, m), 8.56 (H, d, JHH 2.0 Hz), 8.33-8.29 
(2H, m), 7.76-7.67 (2H, m), 7.33-7.16 (6H, m, Ar), 4.54 (2H, s, CH2), 4.19 (1H, dd, 
3JHH = 9.0 Hz, 4JHH = 4.0 Hz, CH), 3.58 (1H, dd, 3JHH = 9.0 Hz, 4JHH = 4.0 Hz), 3.44 
(1H, t, 3JHH = 8.5 Hz, CH2). 
13C{1H} NMR (75 MHz, CDCl3) δC ppm 156.0, 155.7, 149.3, 148.6, 142.3, 137.0, 
136.4, 133.7, 128.5, 127.6, 126.9, 123.8, 121.1, 120.9 (Ar), 76.9 (CH2), 70.7 (CH2), 
55.6 (CH).  
MS (ESI) 306 [M+H]+.  
IR ν cm-1 3361 w, 3296 w, 3055 w, 3027 w, 2902 w, 2860 w, 1589 w, 1574 w, 1558 
w, 1490 w, 1459 m, 1434 w, 1414 w, 1387 w, 1349 w, 1257 m, 1098 m, 1038 w, 
1022 m, 991 w, 936 w. 
Elemental analysis found (calculated for C19H19N3O) % C 74.75 (74.73), H 6.13 
(6.27), N 13.67 (13.76).  
Optical rotation +15.41 ° (1.65 g /100 mL MeOH). 
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The R enantiomer was synthesised in an identical manner but starting from R-
Phenylglycinol. 
Yield 1.34 g, 60 %.  
Optical rotation -14.04 ° (1.64 g /100 mL MeOH). 
 
5-(2,2'-bipyridin-5-ylmethoxy)picolinaldehyde 
 
5-(hydroxy)-picolinaldehyde (2.0 g, 1.0 eq.) was dissolved in acetonitrile (50 mL). 
Potassium carbonate (2.65 g, 1.2 eq.) followed by 5-(chloromethyl)-2,2'-bipyridine 
(3.32 g, 1.0 eq.) were added and the solution was stirred at reflux (80 °C) for 16 h. 
The reaction mixture was filtered through a silica plug and the solvent was removed 
under reduced pressure. The crude product was taken up in dichloromethane (50 mL), 
filtered and the solvent was removed under reduced pressure to give the desired 5-
(2,2'-bipyridin-5-ylmethoxy) picolinaldehyde, a pale brown solid. 
Yield 3.67 g, 79 %. 
1H NMR (400 MHz, 298 K, CDCl3) δH 9.94 (1H, s, CHO), 8.69 (1H, d, 3JHH = 2.0 
Hz), 8.62 (1H, d, 3JHH = 4.5 Hz), 8.47 (1H, d, 3JHH = 2.5 Hz), 8.40 (1H, 3JHH = 8.0 
Hz), 8.34 (1H, d, 3JHH = 8.0 Hz), 7.91 (1H, d, 3JHH = 8.5 Hz), 7.84 (1H, dd, 3JHH = 8.5 
Hz, 4JHH = 2.5 Hz), 7.77 (1H, td, 3JHH = 8.0 Hz, 4JHH = 2.0 Hz), 7.34 (1H, dd, 3JHH = 
8.0 Hz, 4JHH = 3.0 Hz), 7.27 (1H, m, Py), 5.21 (2H, s, CH2). 
13C{1H} NMR  (75 MHz, 298 K, CDCl3) δC 192.1 (CHO), 149.4, 148.6, 139.0, 138.1, 
137.2, 1366, 131.9, 130.9, 124.3, 124.2, 123.5, 122.7, 121.4, 121.2 (Py), 68.1 (CH2). 
MS (ESI) m/z 292 [M+H]+, 314 [M+Na]+. 
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IR v cm-1 2811 w, 1701 s, 1567 s, 1455 m, 1204 s, 788 s, 736 s, 590 s. 
Elemental analysis found (calculated for C17H13N3O2) % C 69.82 (70.09), H 4.66 
(4.50), N 14.01 (14.42). 
 
General synthesis of HHT-[Fe2Ln]Cl4  
Anhydrous iron(II) chloride (2 eq.) was add to a stirred solution of the either the 
desired RC-chiral amine (3 eq.) and 5-(2,2'-bipyridin-5-ylmethoxy)picolinaldehyde (3 
eq.) or the desired substituted aldehyde (3 eq.) and (R)-2-(2,2'-bipyridin-5-
ylmethoxy)-1-phenylethanamine (3 eq.) in methanol (20 mL) at ambient temperature 
to give a purple solution that was then heated to reflux (65 °C) for 24 – 48 h. The 
reaction was allowed to cool to ambient temperature, filtered through a celite plug and 
the solvents were removed in vacuo to give the desired dark purple solid. Note that 
the presence of water of crystallisation in these compounds was confirmed by NMR 
and IR spectroscopy and the absence of other solvents was confirmed also by NMR. 
The hydration number was then determined by thermogravimetric analysis and the 
relevant mass loss was correlated with microanalytical data.  
 
 
 
Rc,ΛFe,HHT-[Fe2L13]Cl4.13H2O 
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Yield 0.36 g, 99 %. 
MS (ESI) m/z 357 [Fe2L3]4+ 
IR v cm-1: 3352 br s, 3035 m, 1602 m, 1561 m, 1216 m, 1344 s, 1232 s, 1011 m, 853 
m, 788 w, 753 w. 
Elemental analysis found (calculated for C75H63Cl4Fe2N15O9.13H2O) % C 48.88 
(49.88), H 4.31 (4.97), N 10.65 (11.63). 
 
Sc,ΔFe,HHT-[Fe2L13]Cl4.13H2O 
Data as for R-enantiomer 
Yield 0.33 g, 0.021 mmol, 90 % 
Elemental analysis found (calculated for C75H63Cl4Fe2N15O9.13H2O) % C 50.15 
(49.88), H 4.35 (4.97), N 10.89 (11.63). 
 
Rc,ΛFe,HHT-[Fe2L23]Cl4.11H2O 
 
Yield 0.31 g, 96 %. 
13C{1H} NMR (126 MHz, 298 K, MeOH) δC 171.1, 170.8, 170.3 (CHN), 161.1, 
160.9, 160.8, 160.5, 160.3, 160.0, 159.4, 158.7, 158.4, 157.2, 156.6, 155.1, 153.9, 
153.8, 153.7, 142.1, 141.4, 140.8, 140.7, 140.5, 140.5, 139.7, 139.75, 139.6, 136.7, 
136.6, 136.6, 133.5, 132.7, 132.5, 130.3, 130.2, 130.2, 129.9, 129.8, 129.6, 129.1, 
128.9, 128.7, 128.6, 128.5, 127.6, 126.1, 126.0, 125.3, 125.0, 124.9, 124.7 (Ar), 70.5, 
70.5, 69.6, 69.6, 69.5, 69.3 (CH/CH2), 26.4, 25.6, 25.2 (CH3). 
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MS (ESI) m/z 323 [Fe2L3]4+. 
IR v cm-1 3358 br, s, 3001 w, 1555 m, 1467 w, 1233 m, 759 w, 701 m. 
Elemental analysis found (calculated for C75H66Cl4Fe2N12O3.11H2O) % C 54.70 
(55.09), H 4.76 (5.42), N 9.67 (10.28). 
 
Sc,ΔFe,HHT-[Fe2L23]Cl4.11H2O 
Data as for R-enantiomer 
Yield 0.32 g, 96 %. 
Elemental Analysis Found (calculated for C75H66Cl4Fe2N12O3.11H2O) % C 55.02 
(55.09), H 4.99 (5.42), N 10.04 (10.28). 
 
Rc,ΛFe,HHT-[Fe2L33]Cl4.14H2O 
 
Yield 0.33 g, 94 %. 
13C{1H} NMR (126 MHz, 298 K, MeOH) δC 170.6, 170.9, 169.7 (CHN), 161.8, 
161.1, 161.0, 160.9, 160.6, 160.5, 160.4, 160.2, 160.0, 159.4, 158.6, 158.3, 157.2, 
156.6, 155.0, 154.0, 153.9, 153.8, 140.5, 139.7, 139.6, 136.7, 136.6, 133.3, 133.1, 
132.6, 132.5, 131.3, 129.8, 129.1, 129.0, 128.5, 127.4, 127.4, 125.9, 125.3, 125.0, 
124.9, 124.5, 115.6, 115.4, 115.2, 114.9 (Ar), 70.5, 70.0, 69.6, 69.5, 69.0, 68.7 
(CH/CH2), 56.0, 55.9, 55.9, (OCH3), 26.3, 25.5, 25.1 (CH3). 
MS (ESI) m/z 346 [Fe2L3]4+ 
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IR v cm-1 3359 br s, 2968 m, 1607 w, 1510 m, 1301 m, 1235 s, 1023 m, 834 m. 
Elemental analysis found (calculated for C78H72Cl4Fe2N12O6.14H2O) % C 51.97 
(52.65), H 5.33 (5.67), N 9.29 (9.45). 
 
Sc,ΔFe,HHT-[Fe2L33]Cl4.14H2O 
Data as for R-enantiomer 
Yield 0.32 g, 96 %. 
Elemental analysis found (calculated for C78H72Cl4Fe2N12O6.14H2O) % C 52.83 
(52.65), H 5.48 (5.67), N 9.43 (9.45). 
 
ΛFe,HHT-[Fe2L43]Cl4.9H2O 
 
ΛFe,HHT-[Fe2L43]Cl4 was synthesised using the procedure described for ΛFe,HHT-
[Fe2L33]Cl4, substituting (R)-1-phenylethan-1-amine for (S)-1-phenyl-2-(prop-2-
ynyloxy)ethanamine. 
Yield 0.243 g, 80 %. 
13C{1H} NMR (126 MHz, 298 K, MeOH) δC 172.0, 171.8, 171.3 (CHN), 161.1, 
160.9, 160.8, 160.5, 160.3, 160.0, 159.4, 158.8, 158.2, 157.7, 157.1, 155.0, 153.8, 
153.7, 153.5, 140.4, 139.8, 136.8, 136.6, 135.8, 135.1, 134.9, 133.8, 133.0, 132.6, 
130.5, 130.3, 130.0, 130.0, 129.7, 129.6, 129.5, 129.1, 128.8, 128.4, 127.5, 127.4, 
127.3, 127.1, 125.8, 125.3, 125.1, 125.0, 124.8, 124.7 (Ar), 77.6, 77.2, 77.0 (CH2), 
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73.5, 73.3, 72.7 (CH), 71.9, 71.7, 71.3 (CH2), 70.7, 69.6, 69.4 (CCH), 59.7, 59.5, 59.4 
(CCH). 
MS (ESI) m/z 364 [Fe2L3]4+, 449 [L+H]+. 
IR υ cm-1 3362 br s, 3024 m, 1556 m, 1434 w, 1233 m, 1082 m, 700 m. 
Elemental analysis found (calculated for C84H72Cl4Fe2N12O6.9H2O) % C 57.69 
(57.29), H 4.89 (5.15), N 9.39 (9.54). 
 
ΔFe,HHT-[Fe2L43]Cl4.9H2O 
ΔFe,HHT-[Fe2L43]Cl4 was synthesised using the procedure described for ΛFe,HHT-
[Fe2L43]Cl4, substituting (R)-1-phenyl-2-(prop-2-ynyloxy)ethanamine for (S)-1-
phenyl-2-(prop-2-ynyloxy)ethanamine.  
Yield 0.222 g, 74 %. 
MS (ESI) m/z 364 [Fe2L3]4+, 449 [L+H]+. 
IR υ cm-1 3355 br s, 3027 m, 1556 w, 1486 w, 1233 m, 1082 m, 700 m. 
Elemental analysis found (calculated for C84H72Cl4Fe2N12O6.9H2O) % C 56.68 
(57.29), H 4.85 (5.15), N 9.29 (9.54). 
 
ΛFe,HHT-[Fe2L53]Cl4 
 
ΛFe,HHT-[Fe2L53]Cl4 was synthesised using the procedure described for ΛFe,HHT-
[Fe2L33]Cl4, substituting (R)-1-phenylethan-1-amine for (R)-1-(naphthalen-1-yl)ethan-
1-amine. 
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Yield 0.267 g, 89 %. 
13C{1H} NMR (126 MHz, 298 K, MeOH) δC 172.7, 172.2, 171.7 (CHN), 161.1, 
161.9, 160.5, 160.4, 160.0, 159.7, 158.9, 157.7, 156.5, 155.4, 153.6, 153.4, 151.8, 
149.5, 148.6, 148.5, 148.4, 148.3, 147.9, 147.4, 144.7, 142.8, 142.3, 141.2, 141.0, 
140.6, 140.2, 140.0, 137.2, 137.1, 136.9, 136.6, 134.0, 133.4, 132.9, 130.6, 129.9, 
129.6, 129.0, 128.9, 127.6, 127.5, 126.9, 125.2, 125.1, 125.1, 124.9, 124.8, 124.7, 
124.4, 123.3, 122.8, 122.4 (Ar), 70.5 (CH2), 69.8 (CH), 69.6, 69.5 (CH2), 68.8, 68.7 
(CH), 27.1, 25.9, 25.0 (CH3). 
MS (ESI) m/z 467 [L+Na]+, 493 [Fe2L3][Cl]3+ 
IR υ cm-1 3364 br s, 2973 m, 1568 w, 1510 w, 1228 m, 1074 m, 702 w, 621 w. 
 
ΔFe,HHT-[Fe2L53]Cl4 
ΔFe,HHT-[Fe2L53]Cl4 was synthesised using the procedure described for ΛFe,HHT-
[Fe2L53]Cl4, substituting (R)-1-phenylethan-1-amine for (S)-1-phenylethan-1-amine.  
Yield 0.211 g, 77 %. 
MS (ESI) m/z 467 [L+Na]+, 493 [Fe2L3][Cl]3+ 
IR υ cm-1 3356 br s, 2975 m, 1567 w, 1531 m, 1229 m, 1074 m, 702 w, 621 w. 
 
Rc,∆Fe,HHT-[Fe2L6]Cl4.9H2O 
 
Yield 0.68 g, 87 %. 
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13C{1H} NMR (126 MHz, 298 K, MeOH) δC 174.7, 174.6, 174.0 (CHN), 161.0, 
160.4, 160.3, 160.0, 159.9, 159.9, 159.5, 159.3, 158.9, 158.7, 156.4, 155.7, 155.4, 
154.8, 154.4, 154.2, 141.6, 141.4, 140.5, 140.0, 139.8, 138.8, 138.6, 138.3, 135.3, 
133.8, 133.5, 132.7, 132.0, 131.4, 130.6, 130.3, 130.2, 130.1, 129.9, 129.7, 129.6, 
129.2, 129.0, 128.9, 128.7, 127.0, 125.8, 125.1, 125.1, 124.2, 123.6 (Ar), 74.5, 74.4, 
72.6 (CH), 70.9, 70.8, 70.5, 69.9 (CH2). 
MS (ESI) m/z 323 [Fe2L3]4+. 
IR v cm-1 3331 br, 3023 w, 1604 m, 1493 m, 1438 m, 1403 w, 1360 w, 1318 w, 1242 
m, 1102 m, 1073 s, 1010 w, 936 m, 866 w, 836 w. 
Elemental analysis found (calculated for C75H66Cl4Fe2N12O3·9H2O) % C 56.52 
(56.33), H 5.31 (5. 92), N 10.68 (10.51) 
 
Sc,ΛFe,HHT-[Fe2L6]Cl4.9H2O 
Data as for R-enantiomer 
Yield 0.64 g, 82 %. 
MS (ESI) m/z 323.7 [Fe2L3]4+. 
Elemental analysis found (calculated for C75H66Cl4Fe2N12O3·9H2O) % C 56.02 
(56.33), H 5.22 (5.29), N 10.34 (10.51). 
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NMR Spectra 
 
Figure S4.1. 13C{1H} (126 MHz) NMR spectrum of Rc,ΛFe,HHT-[Fe2L13][ClO4]4 
in d4-methanol at 298 K with key assignments. Residual solvent δC 49.00 (δC 52.35 
free amine). 
 
Figure S4.2. 13C{1H} (126 MHz) NMR spectrum of Rc,ΔFe,HHT-[Fe2L63][ClO4]4 
in d4-methanol at 298 K with key assignments. 
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Thermogravimetric analysis 
Thermogravimetric analysis was used to determine the amount of water of 
crystallisation present in the chloride salts of iron (II) triplex metallohelices. An 
accurately weighed 40 µl aluminium crucible was heated from 25 to 400 °C at 10 
°C.min-1 under dinitrogen in a DSC1-1600 scanning calorimeter. The mass lost was 
plotted against temperature (see below) and the % mass loss from 70-120 °C (loss of 
water) was calculated. 
 
Rc,ΛFe,HHT-[Fe2L1]Cl4
 
Sc,ΔFe,HHT-[Fe2L1]Cl4
 
Rc,ΛFe,HHT-[Fe2L2]Cl4
 
Sc,ΔFe,HHT-[Fe2L2]Cl4
 
Rc,ΛFe,HHT-[Fe2L3]Cl4
 
Sc,ΔFe,HHT-[Fe2L3]Cl4
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Rc,∆Fe,HHT-[Fe2L6]Cl4
 
Sc,ΛFe,HHT-[Fe2L6]Cl4
 
Figure S4.3. Example thermogravimetric analysis of triplex metallohelices. 
Indicating mass lost due to water of crystallisation and thermal decomposition. 
	
Circular dichroism spectroscopy 
Spectra were measured on a Jasco J-815 spectrometer, calibrated conventionally using 
0.060 % ACS a holmium filter. Measurements were collected using a 1 cm path-
length quartz cuvette. The parameters used were; bandwidth 1 nm, response time 1 
sec, wavelength scan range 200 – 750 nm, data pitch 0.2 nm, scanning speed 100 
nm.min-1 and accumulation 4.  
 
Figure S4.4. Example CD spectra of pairs of enantiomers of triplex 
metallohelices (0.03 mM in water); each enantiomer shows an equal and opposite 
spectrum to its pair. 
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Appendix 5 
 
Appendix 5: Supplementary Information for 
“Rational, yet Simple, Design and Synthesis of an 
Antifreeze-Protein Inspired Polymer for Cellular 
Cryopreservation” 
 
 
Additional data 
1H NMR spectrum of N-boc ethanolamine 
 
 
 
Figure S5.1. 1H NMR of N-boc ethanolamine (400 MHz, CDCl3). 
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Mass-spectroscopy spectrum for N-boc ethanolamine
Figure S5.2. EI Mass-spectrometry spectra of N-boc ethanolamine. 
 
1H NMR spectrum of poly(methyl vinyl ether-alt-maleic anhydride) 
 
Figure S5.3. 1H NMR of poly(methyl vinyl ether-alt-maleic anhydride).  
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Figure S5.4. 1H NMR functionalized PMVEMA with boc protected ethanol 
amine.  
 
Figure S5.5. 1H NMR functionalized polymer deprotected with TFA. 
 
Differential scanning calorimetry of HES and PMVEMA-co-EA 
In order to ascertain that the cryosolution does not vitrify differential scanning 
calorimetry (DSC) was used, Figure S5.6. As seen in Figure S5.6, there is a sharp 
peak at around –14 °C which is characteristic of crystallization. 
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Figure S5.6. DSC of HES and PMVEMA-co-EA. Cooling rate was 2 °C per 
minute, heating rate was 10 °C per minute. 
 
IRI activity of PMVEMA-co-EA dialyzed against sodium chloride  
 
Figure S5.7. Ice recrystallization inhibtion of PMVEMA-co-EA with chloride 
counter ion compared to trifluoracetate counter ion. Mean largest grain size 
(MLGS) expressed as a percentage of PBS buffer control, all samples were at 20 
mg.mL-1. Error bars represent ± SD from a minimum of 3 repeats. 
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Cryopreservation using fast thaw methodology  
Samples were frozen in liquid nitrogen, stored for 5 days then thawed at 37 °C in a 
water bath. The rapid level of thawing limits the time in which ice recrystallization 
can occur and limits damage to cells, figure S5.8 shows greater recovery for all 
samples, and a very limited improvement from adding PMVEMA-co-EA. However, 
the volumes of blood stored would likely be scaled up in commercial storage, 
meaning that differential warming rates would occur making the slow warming 
methodology more relevant for cryoprotective applications.  
 
Figure S5.8. Recovery from fast thawing of red blood cells. Standard Cryomix 
contained containing	HES	(350	mg.mL-1),	mannitol	(30	mg.mL-1)	sodium	chloride	(6.5	 mg.mL-1)	 with	 PMVEMA-co-EA	 added.	 Error bars represent ± SD from a 
minimum of 3 repeats. 
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Appendix 6 
Appendix 6: Supplementary information for “A 
Simple Polymeric Solution to the Challenge of 
Therapeutic Protein Storage”. 
 
Serial dilutions of cryoprotectants 
In order to determine the optimal concentrations of the cryoprotectant mixtures used, 
serial dilutions were made, Figure S6.1. It seems that recovery drops significantly 
when PEG concentration is reduced below 40 mg.mL-1, while there is little benefit 
over the 3 day period of increasing concentration over 50 mg.mL-1. In addition the 
PVA concentration can be reduced as low as 0.5 mg.mL-1, before recovery drops 
below a significant level. Furthermore increasing the concentration of either PEG or 
PVA from 100 mg.mL-1 and 1 mg.mL-1 used in the main manuscript results in no 
significant benefits. A serial of dilution of trehalose was also undertaken for 
comparison, figure S6.2. 
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Figure S6.1. Dilutions of PEG and PVA frozen and stored for 3 days at -20 °C. 
A.) Serial dilution of PEG, with 1 mg.mL-1 PVA; B.) Serial dilution of PVA, with 100 
mg.mL-1 PEG. ** Represents p < 0.01 relative to PBS buffer, error bars are calculated 
from minimum of 6 repeats. Recovery expressed as a percentage of fresh unfrozen β-
Gal. 
 
Figure S6.2. Serial dilution of trehalose, frozen and stored for 3 days at -20 °C. 
** Represents p < 0.01. Error bars are calculated from a minimum of 6 repeats, 
recovery is expressed as a percentage of unfrozen β-Gal. 
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The ability of trehalose to protect β-Gal under freezing drops significantly below 75 
mg.mL-1. In comparison to PEG and PVA, which still provides significant recovery at 
40 mg.mL-1 and 1 mg.mL-1 respectively, a higher concentration. This is appealing as 
all additives can have potentially negative effects on biological materials when added 
in high concentration. 
 
Aggregation induced damage caused by freezing and thawing 
As ice crystals grow by an Ostwald ripening process, whereby larger ice crystals grow 
at the expense of smaller ones, overall surface area reduces over time resulting in 
proteins being forced closer together and consequently are more likely to aggregate, 
Figure S6.3A-B. To assess whether this was occurring and whether it was having a 
detrimental effect on the protein, dynamic light scattering was used to investigate the 
size of β-Gal particles before and after freezing, figure S6.3C.  
 
It appears that PVA and PEG / PVA mix stops aggregation due to freezing and 
thawing when compared to a PBS buffer control as seem in Figure S6.3C. As PEG 
and PVA together seem to provide a greater level of protection when compared to 
PVA alone, it is surmised that the stabilizing effect of the PEG is required in addition 
to the IRI activity exhibited by the PVA, but due to the difficulty in undertaking DLS 
on protein-polymer mixtures, these results should not be viewed as conclusive proof. 
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Figure S6.3. Freeze-thaw induced aggregation of β-Gal. A.) Schematic showing 
reduction in inter-particle distance; B.) Ice crystal radius against inter-particle 
distance; C.) Dynamic light scattering plot of β-Gal. Positive control is sample of 
unfrozen protein, β-Gal was made in solution at 3 mg.mL-1, PVA at 0.8 mg.mL-1, 
PEG at 80 mg.mL-1. 
 
 
Assessment of Taq polymerase through PCR 
As a preliminary test to determine whether PEG and PVA together provide an 
efficient method of protection, PCR was used, and the resulting products imaged on a 
1 % agarose gel, Figure S6.4. 
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Figure S6.4. PCR products of Taq samples protected using various 
cryoprotectants. Positive controls are measured using commercially available Taq 
stored in glycerol. Unfrozen sample was measured using fresh dialysed Taq. Samples 
were frozen for 5 days at -20 °C. 
 
While this initial test proved inconclusive, the sample frozen in just buffer exhibited 
no activity, demonstrating that damage is caused by the freezing process and that 
QPCR would provide a good method of differentiating the level of recovery achieved 
by different protective mixtures.  
 
Freezing and thawing of glucose oxidase  
Glucose oxidase was also stored at -20 °C in order to determine whether the PEG and 
PVA mixture worked for a range of proteins, Figure S6.5. The recovery was found to 
be significantly increased when the polymer mix was added with respect to PBS 
buffer only, therefore it suggests that this mix can be used as a general cryoprotection 
solution. 
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Figure S6.5. Recovery of glucose oxidase after freezing and thawing at -20 °C for 
7 days. Recovery is expressed as a percentage of fresh, unfrozen protein, error bars 
are from a minimum of six repeats, ** represents p < 0.01 relative to PBS buffer.  
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